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Atualmente, acredita-se que a LADA é uma forma comum de 
diabetes com características intermediárias de pacientes com 
diabetes tipo 1 e tipo 2. Desta forma, os pacientes com LADA 
apresentam características genéticas, fenotípicas e imunológicas 
extremamente variadas, englobando diferentes graus de 
resistência à insulina e autoimunidade. Esta diversidade pode ser 
assim o resultado de diferentes mecanismos patológicos, que 
podem ter implicações no tratamento e, por isso, uma abordagem 
médica personalizada poderá ser necessária. 
Esta dissertação analisa os efeitos de uma série de intervenções 
para melhorar as abordagens de tratamento de pacientes com 
LADA e os seus efeitos adversos.  Sendo assim, o objetivo 
prende-se em explorar as intervenções de tratamento existentes 
e perceber como o conhecimento pode evoluir nesta área. 
Neste sentido, um total de vinte e dois estudos incluindo vinte e 
nove ensaios clínicos foram revistos, envolvendo 6562 
participantes que foram acompanhados entre três meses e dez 
anos. Após esta análise as terapias combinadas parecem ser 
uma abordagem mais eficaz para retardar a progressão da LADA. 
No entanto, a heterogeneidade nas intervenções, os critérios 
relacionados à faixa etária, os valores de IMC, a estratificação dos 
resultados e a falta de wash-out de medicamentos na baseline 
não são comparáveis, o que dificulta a generalização e constitui 
um desafio para encontrar consistência na interpretação, levando 
a um vazio entre o que é conhecido e o que pode ser feito. 
  
Por tudo isto, a existência de vários fenótipos metabólicos e 
clínicos na LADA dificulta a definição a priori de uma intervenção 
apontando assim para a necessidade de uma abordagem 
personalizada de uma terapia que considere as características e 
a apresentação clínica de cada paciente. 
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LADA is believed to be a common form of diabetes with 
characteristics of both type 1 and type 2 diabetes patients. Given 
the features of the disease, LADA patients are extremely varied in 
genetic, phenotypic and immunological characteristics 
encompassing different degrees of insulin resistance and 
autoimmunity. This diversity might be the result of different 
pathological mechanisms, which may have implications for 
treatment and hence a personalized medical method could be 
needed. 
This dissertation examines the effects of a series of interventions to 
improve the treatment approaches to LADA patients and their 
adverse effects. The objective is to explore the existing treatment 
interventions on LADA patients and to understand how knowledge 
can evolve in this field. 
 A total of twenty-two studies including twenty-nine trials were 
reviewed involving 6562 participants who were followed between 
three months up to ten years. Combination therapies appear to be 
a more effective approach to delaying LADA progression.  
Unfortunately, the heterogeneity in interventions, the criteria related 
to age range and BMI values, the stratification of outcomes, and the 
missing of drug(s) wash-out at baseline are not comparable, which 
make it difficult to generalize and challenging to find consistency in 
the interpretation, leading to an empty space between what is 
known and what could be done. 
The existence of several metabolic and clinical phenotypes in LADA 
makes it difficult to establish an a priori management intervention to 
  
the patients. This points the way towards the need of a personalized 
medicine approach to a therapy that considers the characteristics 
and clinical presentation of each patient. 
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CHAPTER I: INTRODUCTION 
 
I.1 Diabetes mellitus 
  
Diabetes mellitus (DM) is a disease characterized by a group of disorders in carbohydrate metabolism 
leading to patients presenting hyperglycemia and, in the long run, macro and microvascular 
difficulties (1). Diabetes is the fastest growing disease in the world (2) and because it is a chronic 
pathology, primary and secondary prevention are crucial. Despite being frequently divided into two 
main groups, type 1 diabetes (T1D) and type 2 diabetes (T2D), the disease appears to be 
heterogeneous. Because this heterogeneity, a third group was found, called latent autoimmune 
diabetes in adults (LADA) that shares genetic characteristics with T1D and T2D. For this reason, taking 
into account pathophysiological differences could facilitate a more precise assessment of the factors 
that influence the onset and prognosis of the disease (3). 
 
 
I.1.1 Type 1 and Type 2 Diabetes 
 
Type 1 Diabetes 
  
Type 1 diabetes is described as an autoimmune pathology (1) that is characterized by insulin 
deficiency, which is caused by the autoreactive T cells of the immune system associated with cellular 
immune responses to several β-cell autoantigens leading to the destruction of pancreatic islet β-cells 
(4,5). It is also believed that this disease can be initiated by an environmental stimulus that damages 
the cells of the islets of Langerhans. This damage is enlarged by the autoimmune features of people 
with genetic vulnerability (5).  
 
 
Type 2 Diabetes 
  
Type 2 Diabetes is the most predominant form of diabetes (1). The frequency on this disease subtype 
varies in different racial and ethnicities, genetic defects in the secretion and action of insulin as well 
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as in individuals with hypertension and dyslipidemia. Also, the risk of development increases with 
age and obesity (6). 
Despite the heterogeneity of its origin, the pathophysiological characteristics of the disease are 
similar, and the main ones are insulin resistance in skeletal muscle, liver and adipose tissue, together 
with decreased insulin secretion. This insulin resistance results in reduced peripheral glucose uptake 
and stimulates hepatic glucose production, which will lead to high blood glucose levels. 
Hyperglycemia consequently leads to a compensatory upsurge in insulin secretion which will then 
reduce β-cells and lead to a progressive loss of function, resulting in an insulin deficiency, and 
consequently in diabetes (3). 
 
 
I.2 LADA 
 
I.2.1 Definition and characteristics 
 
LADA is believed to be a common form of diabetes with characteristics of both T1D and T2D (3). This 
disease includes several acronyms such as “Slowly Progressive Insulin‐Dependent Diabetes Mellitus” 
(SPIDDM), “Type 1.5 Diabetes” and “Latent Type 1 Diabetes” (7). All of these terms refer to patients 
who were originally diagnosed with T2D due to lack of insulin dependence and ketoacidosis but 
exhibited positive autoantibodies to islets associated with T1D (such as glutamic acid decarboxylase 
(GADA) autoantibody, the protein-2 autoantibody associated with insulinoma (IA-2A), zinc-
transporting autoantibody 8 (ZnT8A) and insulin autoantibody (IAA)) (5,8). The presence of these 
autoantibodies may indicate an autoimmune attack on pancreatic β-cells with a fast loss of function 
during the follow-up of the disease (9). 
LADA can also have some of the same environmental risk factors of T2D, such as overweight (10), 
low birth weight (11), lack of physical activity  (12,13), alcohol consumption (14,15), and smoking, 
since these factors influence insulin sensitivity. These factors can suggest that insulin resistance, in 
addition to insulin deficiency due to the autoimmune destruction of β-cells, can play an important 
role in its pathogenesis (3). Given these features of the disease, the population defined as having 
LADA is extremely varied in genetic, phenotypic and immunological characteristics (16), 
encompassing different degrees of insulin resistance and autoimmunity. This diversity might be the 
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result of different pathological mechanisms, which will have implications for treatment and hence 
suggesting that a personalized medical method could be needed (17). 
Neverthless, the exact definition of LADA is still being discussed (16) and its management requires 
randomized clinical trials (18) to understand it as it is contentious whether LADA is simply a minor 
form of T1D or a mixture of T1D and T2D, or even a different disease altogether (3). 
 
 
I.2.2 T1D and LADA 
  
As mentioned above, T1D is an autoimmune disease which results from the selective destruction of 
insulin-secreting β-cells that happens mostly during childhood or adolescence, and sometimes in 
adulthood (19). 
At the genetic level, the strongest genetic influence in T1D is conferred by the human leukocyte 
antigen (HLA) complex genes (20). Some studies have demonstrated the association between HLA 
genes and LADA risk (21–23) and so, it is believed that it is plausible that HLA genes are also 
associated with LADA susceptibility (24). 
The HLA genes encode the major histocompatibility complex (MHC) proteins that controls the 
immune system (25). Additionally, slower progression in the loss of β-cells observed in LADA mirrors 
variations on the MHC genes, a reduced amount of general genetic load and reduced genetic 
penetration, suggesting a greater impact of environmental factors on patients with LADA. Also, 
genome-wide association studies suggest that LADA can be regarded as a mixture of the two main 
types of diabetes, as already mentioned (16). 
Patients with LADA are distinguished from patients with T1D because usually they are older at the 
start of the disease and show a slower progression on their need for insulin (26,27). Consequently, 
patients with LADA have a higher insulin production capacity at the time of diagnosis, when 
compared to patients with T1D, indicating that mechanisms other than autoimmune destruction of 
β-cells may affect pathogenesis (3). Some authors defend that LADA patients have higher IR values 
compared to people with T1D, what could suggest that IR may play a role in the development of 
metabolic dysregulation in adult-onset autoimmune diabetes (28) .  
The autoimmune process seems to be lighter and the progression of β-cell failure slower in LADA 
than in T1D, according to higher levels of C-peptide as an indicator of insulin secretion (3). The 
presence of islet autoantibodies in LADA and in classic T1D seems to provide strong evidence that 
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the underlying disease processes are both autoimmune. However, differences in antibodies in LADA 
and T1D suggest potentially important immunological differences. Autoantibodies like Islet Cells 
Autoantibodie (ICAs) and GADAs are common in LADA, but IA-2A are much less common in LADA 
than in T1D (29). T1D patients are often positive for two or more autoantibodies, whereas in patients 
with LADA it is common to have only one of these antibodies. 
At the same time, T1D is an autoimmune disease mediated by T cells. These cell populations seem 
to control the autoimmune process also in LADA (30). There are several types of T cells with a known 
role in these types of diabetes, such as helper T cells (Th). Type 1 helper T cells (Th1) cells contribute 
to cell-mediated immune modulation, while type 2 helper T cells (Th2) promote humoral immunity 
and these two subsets exercise reciprocal control over the other's function both in T1D and LADA. 
Thus, the Th1/Th2 balance can be a critical factor for inducing and modulating immune pathology 
(30). In addition, regulatory T cells (Treg) (such as CD3+, CD4+, CD25+, Foxp3+ cells), appear to play a 
critical role since they can suppress the proliferation and function of effector T cells (Teffs) and 
maintain immune balance. T1D patients exhibit a lower frequency of Treg (31), and this defect in the 
number and/or function of Treg is an important factor in disease progression (32–34), while at the 
same time, Treg's dysfunction is also observed in LADA (35). 
Simultaneously, similarities were found in cellular and systemic proinflammatory cytokines (36,37), 
changes in the frequency and phenotype of natural killer (NK)  cells (38,39) and the presence of β -
specific autoantibodies to cells (40,41) constituting immunological evidence that LADA shares 
immunological characteristics with T1D. 
 
 
I.2.3 T2D and LADA 
  
Type 2 diabetes and LADA are frequently confused because they display very close clinical 
characteristics. The typical LADA clinical parameters that distinguish it from T2D are the age of onset 
<50 years; acute symptoms such as polyuria, polydipsia or weight loss; Body Mass Index (BMI) 
<25Kg/m2; personal history of other autoimmune diseases; and family history of autoimmune 
disease (16,42).  
The strong genetic link between LADA and T2D was found in the transcription factor 7 type 2 
(TCF7L2) gene, which seems to be associated with both (43). 
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When the LADA metabolome was analyzed at the metabolic level, it was found to be intermediate 
of that observed in T1D and T2D, with a significant intersection between both types of diabetes, but 
more similar to T2D (44). Patients with T2D and LADA are phenotypically distinct when compared in 
large groups but, if compared individually, they share clinical and metabolic features, which makes 
diagnosis difficult. However, when evaluated for autoantibodies as a marker of autoimmune activity, 
there are marked differences in these two groups of patients (3). At the same time, patients with 
LADA have insulin resistance that is not as marked as in T2D, which may be due to differences in BMI 
(3). Actually, when comparing patients with T2D and LADA, the latter tend to show less signs of 
metabolic syndrome, like healthy lipid profiles and blood pressure, lower BMI and waist-to-hip ratio 
(45,46). The overlap of clinical characteristics between LADA and T2D makes it difficult to distinguish 
between the two if merely based on the clinical phenotype. Compared to patients with T2D, patients 
with LADA are thinner, younger at the onset of diabetes, have a greater reduction in C-peptide levels 
and are more likely to receive insulin treatment (5). Generally, LADA patients present a metabolic 
control different from T2D, notably, higher fasting glucose levels (FPG) and glycated hemoglobin 
(HbA1c) (47,48).  
In what regards immunological characteristics, estimates indicate that between 4% and 14% of 
patients initially classified as having T2D have autoantibodies, a characteristic of the adaptive 
immune response that leads to the destruction of pancreatic β-cells. On the other hand, patients 
with T2D have higher levels of pro-inflammatory cytokines and adhesion molecules (which are 
known to contribute to insulin resistance) than patients with LADA and classic T1D. Consequently, 
systemic inflammation appears to be a common feature of all these types of diabetes (49).  
 
In conclusion, it has proven so far quite difficult to find any single genetic, immunological or 
metabolic signature that distinguishes LADA from other types of diabetes when, in fact, it has not 
yet been settled whether LADA may be a hybrid between T1D and T2D or even a new disease (50). 
 
 
I.2.4 Epidemiology 
  
T2D is the most predominant form of diabetes and accounts for 90% to 95% of all diabetes cases 
worldwide (51), followed by LADA with 2% to 12% of all cases (19), and, lastly, T1D which only 
represents 4% to 10% of the total diabetes load (51). In addition to these numbers, it is known that 
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4% to 14% of patients diagnosed with T2D are positive for autoantibodies associated with T1D, which 
suggests that those may be cases of LADA and not T2D, so the real percentage of the total cases of 
LADA might be higher than the one currently reported (19,52). Even with the increasing number of 
diagnoses of LADA, its occurrence varies geographically and by ethnicities: it seems to be higher 
among Northern Europeans than in African-Americans, Latinos and Asians (16). At the same time, a 
family history of T1D and T2D can increase the risk of LADA two to four times (53). 
 
 
I.2.5 Pathophysiology of LADA 
 
The increasing evidence that LADA patients represent a heterogeneous group of patients led to 
advances in the research on the disease pathophysiology. Although LADA seems to share common 
phenotypic, genetic, and pathophysiological features with both T1D and T2D, uncertainty remains 
as to its appropriate classification (17). For this reason, it should be mentioned that the mechanisms 
of pathophysiology presented in Figure 1 | Pathophysiologic Mechanisms of Type 1 Diabetes and 
Type 2 Diabetes which may hypothetically illustrate those of Latent Autoimmune Diabetes in Adults  
is purely speculative. 
The potential mechanisms of LADA pathophysiology can be observed in patients with a normal BMI 
or who are overweight, with moderate genetic susceptibility to T1D who seems to present specific 
immunological factors, such as CD4+ and CD8+ T cells. In such cases, these factors can trigger an 
autoimmune process against the Langerhans islets, envolving Treg and Th1/Th2 cells (17). The 
pathophysiological process may start with B cells contact with CD4+ T cells, CD8+ T cells and dendritic 
cells (DCs). The presentation of antigens by B cells and DCs can lead to the activation of T cells. 
Additionally, the exposure of B cells to the autoantigens of β-cells ends in the production of 
autoantibodies (54). This process is marked by the rise of GADA65 that binds to the antigen GAD65 
probably leading to β-cell apoptosis, which results in insulin deficiency, causing disease onset (17). 
However, obese patients with genetic susceptibility to T2D seem to develop LADA. This could be 
explained by the visceral adiposity that can lead to an inflammatory process through the activity of 
macrophages and self-reactive T cells. This inflammatory process contributes to the increased 
secretion of pro-inflammatory cytokines, such as IL-6, TNF-α, IL-1β and IFN-γ (55). It can also lead to 
the presentation of extracellular antigens to the antigen-presenting cells (APCs), promoting a low-
grade autoimmune reaction (55). This response is marked by the presence of IA-2A, which appears 
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to be the most frequent autoantibody with increased BMI (56). The presence of IA-2A in patients 
with T2D may initiate a pathophysiological mechanism that results in a humoral immune response, 
which is distinct from T1D (55). This is could be derived from the chronic systemic inflammation that 
is believed to be associated with obesity. The autoimmune response appears to accelerate the loss 
of β-cell function and to compromise insulin secretion. In addition to insulin resistance that 
commonly occurs in subjects with obesity, episodes of hyperglycemia can also occur, leading to the 
onset of diabetes (17). 
Given the pathophysiological processes presented in T1D and T2D, the development of 
autoimmunity in patients with LADA may happen as a result of a specific environmental trigger that 
can promote the activation of an autoimmune process or as a result of chronic inflammatory 
responses associated with obesity (57,58). 
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Figure 1 | Pathophysiologic Mechanisms of Type 1 Diabetes and Type 2 Diabetes which may hypothetically illustrate those of Latent Autoimmune Diabetes in Adults (image constructed using 
BioRender Software) 
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I.2.6 Genetic and clinical features 
  
As previously mentioned, the etiology of LADA can be linked to genetic factors and lifestyle. So far, 
it has been argued that LADA may be not only clinically, but also genetically a hybrid form of T1D and 
T2D because of the genes involved in the pathogenic pathways are the same of the typically types 
of diabetes. This idea of an hybrid has restricted the investigation of novel genes that might be 
implicated only in the pathogenesis of LADA (17). The genetic risk loci of LADA is strongly associated 
with common disorders in T1D, however alleles with a recognized role in the predisposition to T2D 
could contribute to this type of diabetes (59).  
The possibility that different HLA genotypes associated with LADA could affect the outcome in terms 
of β-cell function is still unclear. Recent findings appear to indicate that patients who have a 
moderate- or low-risk HLA genotype, as is the case in LADA, may have a higher residual β-cell function 
(42). However, LADA is related with variants of T1D outside the HLA region, including PTPN22, INS 
and SH2B3 (60), as well as with a genetic overlap with T2D, namely in TCF7L2 (25,59,61).  
The clinical characteristics of LADA are extremely diverse, extending from diabetic ketoacidosis to 
hyperglycemia controlled only with diet or hypoglycemic agents. Consequently, patients with LADA 
who primarily do not need insulin cover a large range of phenotypes, from prevalent insulin 
resistance to prevalent insulin deficiency, sharing clinical and metabolic characteristics of T1D and 
T2D (Table 1 | Differences in Clinical, Genetic and Biochemical Features between T1D, LADA and T2D) 
(16). Overall, the characteristics of LADA tend to include an intermediate level of β-cell dysfunction 
between those in T1D and T2D (5).  
As already mentioned, the definition of LADA is extremely wide because it includes any adult who 
does not need insulin and who is positive for at least one diabetes-associated autoantibody (62). It 
is known that GADA titers could be used to distinguish different LADA subgroups. Recent studies 
suggest that the high heterogeneity observed in GADA positive patients can be partly explained by 
different autoantibody profiles, as an expression of a different degree of the autoimmune response 
(63). Patients with LADA with elevated GADA are younger, phenotypically more similar to classic T1D, 
have a higher risk of progression to insulin treatment and show lower levels of peptide C, lower body 
weight, and greater risk for diabetic ketoacidosis (DKA) (64,65). 
LADA patients with low GADA titers present no differences in respect to sex, age of diagnosis, 
baseline HbA1C levels, β-cell function reserve, and metabolic syndrome components comparing with 
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T2D. However, it has not been possible to identify any single metabolic marker that could distinguish 
between LADA from other types of diabetes (44).  
 
Table 1 | Differences in Clinical, Genetic and Biochemical Features between T1D, LADA and T2D (based on 
(16,19)) 
  T1D LADA T2D 
                  
                                       CLINICAL FEATURES  
AGE AT DIAGNOSIS Childhood / 
adolescence (rarely 
in adulthood) 
> 30 years Adulthood (rarely before) 
ONSET Acute Subclinical (rarely 
acute) 
Silent / subclinical 
FAMILY HISTORY OF 
DIABETES 
Positive or 
negative 
Positive or negative Often positive 
LONG-TERM 
COMPLICATION RATE AT 
DIAGNOSIS 
Low Low High 
RISK OF ACUTE 
COMPLICATIONS AT THE 
TIME OF DIAGNOSIS 
High Low Slight increase 
RISK OF METABOLIC 
SYNDROME 
No change Increase Severally increase 
SYMPTOMS OF 
HYPERGLYCEMIA AT 
ONSET 
Frequently acute Subclinical (rarely 
acute)  
Silent/ subclinical 
                              GENETIC FEATURES  
HLA SUSCEPTIBILITY Greatly increased Increased Slight increase 
                                 BIOCHEMICAL FEATURES  
C-PEPTIDE LEVELS IN 
DIAGNOSIS 
Not detectable  Decreased, but still 
discoverable 
Normal to increased 
AUTOIMMUNITY Pronounced 
increase 
Slight increase Absent 
KETOSIS Rare Rare Rare 
INSULIN RESISTANCE Absent (rarely 
increased) 
Slight increase Increase 
Β-CELL FUNCTION Loss of function Decreased Increase or normal 
NEED FOR INSULIN In the diagnosis > 6 months after 
diagnosis 
Absent or years after 
diagnosis 
BODY MASS INDEX Normal (or 
underweight) 
<25 Kg/m2 
(frequently <18 
Kg/m2) 
Normal (rarely 
overweight or obese) 
<25 Kg/m2 (rarely >25 
Kg/m2) 
Overweight or obesity 
>25 Kg/m2 
CARDIOVASCULAR RISK Increased Increased Increased 
LIPID PROFILE Normal Normal to 
hypertriglyceridemia 
Frequent 
hypertriglyceridemia and/or 
hypercholesterolemia 
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I.2.7 LADA Diagnosis 
  
LADA diagnosis is very challenging due to its extensive and heterogeneous clinical characteristics. 
LADA remains overlooked in the clinical setting to the point that there are no clear guidelines for 
diagnostic and there is still a high rate of diagnostic errors (5% to 10%) among patients with T2D by 
misclassifying LADA. Ideally, all individuals diagnosed with T2D should be tested for plasma C-peptide 
and autoantibodies, guaranteeing close monitoring of patients who test positive for these factors, 
though this practice would be expensive (16).  
Therefore, a fundamental question needs to be asked: what is the most appropriate strategy to 
identify diabetic patients who have an increased risk of LADA and need to be tested for diabetic 
autoantibodies (DAAs)? Studies state that in a first analysis and avoiding the performance of 
autoantibody screening tests in all newly diagnosed patients with diabetes, the levels of C-peptide 
(indicator of the remaining insulin secretion) and risk factors based on clinical parameters need to 
be analyzed (16).  However, to standardize diagnosis, the Immunology of Diabetes Society (IDS) also 
proposed, in 2005, criteria to standardize the diagnosis of LADA, namely: (1) age of disease onset 
greater than 30 years, (2) islet autoantibodies as a marker of autoimmune activity and (3) and a 
minimum period of 6 months of insulin independence (3,7,16,19,42). Despite these criteria, the age 
limit and the subjectivity of insulin use are still not consensual. In terms of clinical presentation, 
Buzzetti et al (17), suggested, in 2017, that heterogeneity may probably exist even between patients 
who test positive for different classes of autoantibodies (17)  although, at the moment, GADA was 
considered the most sensitive and specific biomarker of LADA (66). 
 
 
I.2.8 LADA Treatment  
  
The heterogeneity of LADA makes it difficult to determine a standard treatment (19) and thus, it may 
often be wrongly treated, requiring a different therapy than the one administered to patients with 
T1D and T2D and requiring more frequent monitoring of patients (67). It has been suggested the 
existence of two different LADA subtypes (LADA 1 and LADA 2) that, by having different genetic and 
pathogenic backgrounds, may need distinct therapeutic approaches (16). This can be explained due 
to the fact that the majority of subjects with LADA and high GADA titer appeared to be positive for 
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at least one or more autoantibodies, compared to those with low GADA titer. The choice of 
treatment strategy can also be challenged by insufficient data from of randomized clinical trials. 
Most individuals with LADA are usually diagnosed with T2D and therefore treated primarily for T2D 
(17), which may disturb the autoimmune process and increase β-cell loss, inducing a rapid 
progression towards insulin dependency (17) especially in patients with high GADA titer who show 
clinical features closer to T1D than T2D (47,54). As already mentioned, LADA is characterized by β-
cell failure and insulin resistance, therefore, interventions for LADA should aim to achieve good 
metabolic control, as well as to preserve the residual function of β-cells (7). The complications in 
consequence of “uncontrolled” LADA are serious and may appear in the short-term, most commonly 
by ketoacidosis episodes, and also in the long-term, which can result in metabolic problems due to 
poor control of blood glucose levels. This dysregulation can lead to cardiovascular diseases, 
metabolic syndrome, nephropathy, retinopathy and neuropathy leading to a decrease in health-
related quality of life as may increase morbidity and mortality rates in T2D adults (17). Given all these 
difficulties and complexity of interventions, several studies have tested different approaches for the 
treatment of LADA.  
Some studies suggest early treatment with insulin (70–72), however it is known that people with 
LADA usually show a slower progression towards absolute insulin dependence, raising the question 
of whether insulin therapy should be indicated as an initial treatment for these patients (73). 
Sulphonylureas (SU) have also been investigated for the treatment of LADA by appearing to 
continuously stimulate β-cell insulin secretion and therefore, leading to increased antigen expression 
of β-cells and apparently exacerbation of autoimmunity (74). Additionally, some side effects like mild 
gastroenterological disturbances have been reported (75).  
Insulin sensitizers have also been identified as having a therapeutic alternative as they may be useful 
in individuals with LADA who share more pronounced characteristics of insulin resistance. In a clinical 
setting, metformin is currently prescribed to reduce insulin resistance as the first choice of treatment 
in adult-onset who are usually overweighted and are non-insulin-requiring (76). The anti-
inflammatory activity of oral agents like thiazolidinediones as a potential effective treatment for 
patients in the non-insulin dependent stage of LADA has been tested (77). Nevertheless, some 
adverse effects have been reported upon thiazolidinediones use, such as weight gain, edema and 
congestive heart failure or even, in some cases, liver failure (75).  
Also, in recent years, studies have investigated the possibility of a therapeutic approach to delay the 
loss of β-cells in individuals with LADA, with great interest in some drugs used in the treatment of 
T2D, namely inhibitors of dipeptidyl-peptidase 4 (DPP-4) and glucagon-like peptide 1 receptor 
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agonists (GLP-1RAs). Dipeptidyl-peptidase 4 (DPP-4) inhibitors (like sitagliptin, vildagliptin, linagliptin, 
saxagliptin and alogliptin) have been extensively investigated in T2D, due to their effect influence in 
a glucose-dependent increase in insulin secretion, as well as inhibiting the release of glucagon and 
reducing the hepatic production of glucose (78), providing evidence of a protective role in β-cells 
and attenuated autoimmunity (74,79–81). Still, it is important to be aware of the associated side 
effects that include upper respiratory tract infections, headaches, and diarrhea, in particular, when 
using sitagliptin (75).  
GLP-1RA is believed to inhibit apoptosis and to promote neogenesis of β-cells (74). Pettus et al., 
stated that the available data might suggest that this class of drugs reduces β-cell apoptosis and 
promotes β-cell neogenesis in animal models (81).  
Another approach to treatment focuses on immune modulation therapy. LADA patients are believed 
to be ideal for immune modulation therapies due to the slow progression to β-cell failure (7). 
However, no immunomodulation therapy has had enough impact to permanently restore normal 
glucose homeostasis. Another therapeutic study focused on sodium glucose cotransporter 2 (SGLT2) 
inhibitors, but clinical data with LADA are rare, and therefore no conclusions can be drawn (74). 
As a consequence of the uncertainty as to what is the best therapeutic method for LADA is, the 
treatment of adults with LADA is currently guided by clinical intuition, and most patients with LADA, 
are primarily treated with therapies aimed at non-autoimmune forms of diabetes mellitus, an 
approach that can result in rapid progression to an insulin-dependent state (19). Thus, research in 
the area of LADA treatment and a personalized medical approach are urgently needed. A 
personalized therapeutic strategy for patients with LADA may indeed be necessary to preserve the 
residual function of β-cells and reduce the risk of long-term complications (16,82). 
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CHAPTER II: OBJECTIVES 
 
One of the main purposes to understand the underlying pathophysiological disorders of diabetes is 
to facilitate treatment and prevention investigation which shall ultimately facilitate high-quality 
health care for patients. 
Therefore, this systematic review and meta-analysis study aims to examine the effects of a series of 
interventions meant at improving the treatment approaches to LADA patients, particularly in light of 
the adverse effects associated to current interventions. 
Thus, by gathering and synthesizing the existing literature on this topic, this dissertation seeks to 
deepen the understanding of the treatment interventions for LADA patients and to determine how 
knowledge can evolve in this field in terms of research and practice. 
The therapies for LADA seem still not well-defined and therefore, it seems imperative to pursue some 
answers in this context in order to provide more reliable and precise data that can support the 
effective management of this disease. Hence, this systematic review aims to identify, evaluate and 
summarize the findings of all relevant individual studies on this topic and to present the available 
evidence in a compiled and more accessible fashion to readers. To achieve this goal, the results of 
several randomized clinical trials were aggregated and combined. Their results can help establish 
some consensual and solid conclusions about a possible effective intervention strategy on patients 
with LADA. 
Condensing estimates on the intervention’s outcomes can pave the way to reliable conclusions 
based on pre-specified, explicit and reproducible methods, as well as to set out what is known about 
a particular approach and also to demonstrate where the lack of knowledge lies, opening possibilities 
for future research.  
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CHAPTER III: METHODS 
 
III.1 Eligibility criteria 
 
In this review, only studies in English, Spanish or Portuguese language were eligible for the inclusion 
criteria, as well as open access articles or studies which have been completed and published. These 
studies were analyzed taking into consideration the study design, some characteristics of the 
participants, diagnostic criteria to include participants and the type of intervention for the timing of 
outcome measures. 
Randomized controlled trials, comparative studies, controlled clinical trials, clinical trials and post-
hoc studies that report controlled trials were eligible for the review. 
In the studies analyzed, participants should be more than 18 years old and have been diagnosed 
either with LADA or T2D and tested positive for islet autoantibodies. Protocols in which the patient 
was diagnosed T1D and received insulin treatment were excluded, as well as patients under 18 years 
old or T2D who did not test positive for islet autoantibodies.  
The diagnostic criteria differ between studies, therefore, the data from each study was extracted 
and synthetized (see Appendix 1| Characteristics of Included Studies). Thus, it should be noted that 
the criteria used for the classification of LADA were inconsistent across studies and may have 
influenced the results. As for interventions, studies must compare and report all the possible 
differences during the trial as preferential, state the dose and frequency of the interventions. Studies 
should aim to address the treatment of LADA or T2D with islet positive autoantibodies and, ideally, 
should have a control group for comparison. 
The duration of study follow-up for inclusion was neither established nor limited and the outcome 
measures were not established a priori, but results related to metabolic control, β-cell function 
predictors and adverse events were expected to be obtained. 
 
 
III.2 Information sources 
 
All studies were obtained by searching electronic databases and scanning reference lists from 
articles. For the construction of this systematic review the following electronic databases were 
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consulted: PubMed (PubMed Clinical Queries), Web of Science (MEDLINE, Web of Science Core 
Collection), Scopus, Science Direct and ClinicalTrial.gov. In each database adaptions of pre-defined 
and specific search terms and key words were used (Appendix 2 | Pre-defined and specific search 
terms/key words). The last search was run on 18 March 2020 and the results obtained until this date 
were thoroughly registered (Table 2 | Electronic Database Results). 
 
Table 2 | Electronic Database Results. To perform this systematic review, it was necessary to do a search in 
electronic databases, the survey was carried out between 17th and 18th March 2020 using a query of terms in 
each of the databases. 
 
Electronic 
Database 
Search 
date 
Query Results  
PubMed 18 March 
2020 
("Latent Autoimmune Diabetes" OR 
“Latent Autoimmune Diabetes in Adult” 
OR “Type 1.5 Diabetes” OR “Intermediary 
Diabetes” OR “Autoimmune Diabetes in 
Adults”) AND (therapy OR therapeutic OR 
treatment* OR intervention OR approach 
OR drug OR "alternative medicine" OR 
manag*) 
468 results  
PubMed Clinical 
Queries 
18 March 
2020 
(Therapy/Broad[filter]) AND (("Latent 
Autoimmune Diabetes" OR “Latent 
Autoimmune Diabetes in Adult” OR “Type 
1.5 Diabetes” OR “Intermediary 
Diabetes” OR “Autoimmune Diabetes in 
Adults”) AND (therapy OR therapeutic OR 
treatment* OR intervention OR approach 
OR drug OR "alternative medicine" OR 
manag*) Randomized Controlled Trials) 
25 results  
Web of Science 
(MEDLINE) 
18 March 
2020 
MeSH HEADING: (Latent Autoimmune 
Diabetes in Adults) OR ((TOPIC: 
(((((((("Latent Autoimmune Diabetes") OR 
"Latent Autoimmune Diabetes in Adult") 
OR "Diabetes Mellitus Type 1.5") OR 
"Type 1.5 Diabetes") OR LADA) OR 
"Latent Autoimmune Diabetes of Adult") 
OR "Intermediary Diabetes") OR 
"Diabetes Type 1 in Adults") OR 
"Autoimmune Diabetes in Adults") AND 
TOPIC: ((((((therap*) OR treatment*) OR 
intervention) OR approach) OR drug) OR 
"alternative medicine") OR manag*)) 
AND TOPIC: (randomized controlled trials 
OR comparative studies)) Refined 
by:  MeSH HEADINGS: ( HUMANS ) 
87 results  
Web of Science 
Core Collection 
18 March 
2020 
TOPIC: ("Latent Autoimmune Diabetes" 
OR "Latent Autoimmune Diabetes in 
Adult" OR "Diabetes Mellitus Type 1.5" 
OR "Type 1.5 Diabetes" OR LADA OR 
13 results  
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"Latent Autoimmune Diabetes of Adult" 
OR "Intermediary Diabetes" OR "Diabetes 
Type 1 in Adults" OR "Autoimmune 
Diabetes in Adults") AND TOPIC:(therap* 
OR treatment* OR intervention OR 
approach OR drug OR "alternative 
medicine" OR 
manag*]) AND TOPIC: ("randomized 
controlled trials" OR "comparative 
studies" OR "controlled clinical trials" OR 
"clinical trials") 
Scopus 18 March 
2020 
(TITLE-ABS-KEY ("Latent Autoimmune 
Diabetes"  OR  "Latent Autoimmune 
Diabetes in Adult"  OR  "Type 1.5 
Diabetes"  OR  "Intermediary Diabetes"  
OR  "Diabetes Type 1 in Adults")  AND  
TITLE-ABS-KEY (therap*  OR  treatment  
OR  approach  OR  drug  OR  "alternative 
medicine"  OR  intervention  OR  
manag*))  AND ( "randomized control* 
trial"  OR  "clinical trial"  OR  "control* 
clinical trial"  OR  "comparative stud*")  
AND  (LIMIT-TO (DOCTYPE ,  "ar"))  AND  
(LIMIT-TO (EXACTKEYWORD ,  "Human")) 
449 results  
Science Direct 17 March 
2020 
(“Latent Autoimmune Diabetes in Adult” 
OR “Type 1.5 Diabetes” OR “Intermediary 
Diabetes” OR “Diabetes Type 1 in Adults”) 
AND (therapy OR treatment OR 
intervention OR drug) 
25 results  
ClinicalTrial.gov 17 March 
2020 
["Latent Autoimmune Diabetes" OR 
“Latent Autoimmune Diabetes in Adult” 
OR “Diabetes Mellitus Type 1.5” OR “Type 
1.5 Diabetes” OR LADA OR “Latent 
Autoimmune Diabetes of Adult” OR 
“Intermediary Diabetes” OR “Diabetes 
Type 1 in Adults” OR “Autoimmune 
Diabetes in Adults”] AND [therapy OR 
therapeutic treatment* OR intervention 
OR approach OR drug OR "alternative 
medicine" OR manag*] 
10 results  
 
 
III.3 Search strategy and study selection 
 
A total of twenty-two studies involving twenty-nine trials were identified for inclusion in the review. 
The titles and abstract sections of every record retrieved were independently scanned. Full articles 
were saved for further assessment if the information suggested that the study included patients with 
latent autoimmune diabetes in adults (LADA) and evaluated an intervention. To refine the search the 
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follow key words were added to the search: “randomized controlled trials" OR "comparative studies" 
OR "controlled clinical trials" OR "clinical trials”.  
 
 
III.4 Data items 
 
From each included study in this review, information was extracted and summarized (Appendix 1 | 
Characteristics of Included Studies). Data include some study characteristics as the study design, 
ethics approval and consent from the patient, intention to treat study, and power calculation of the 
study), participants’ characteristics as gender, age, ethnicity, diagnostic criteria and co-morbidities 
or medication. Information related to intervention such as frequency and dose were recorded, as 
well as the country where the trial was conducted and if there were any treatments before the trial. 
Additionally, it was important to know if there were control or placebo groups that were tested 
versus the type of intervention (drug, dose, duration and frequency). At least the type of outcome 
measures (primary, secondary and/or additional outcomes) were searched as well as study details 
(duration of intervention, follow-up and run-in period) and risk of bias reported by the authors or 
presented in the study. 
 
 
III.5 Risk of Bias in Individual Studies 
 
To determine the eligibility of the randomized controlled trials the access to the risk of bias was 
made in a blind manner and was completed by a single person. The relevance of randomization and 
concealment of allocation, the selective reporting, blinding of patients, health care providers, data 
collectors, and outcome assessors, the incomplete outcome data and eventually other source of bias 
were evaluated.  
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III.6 Summary measures 
 
Due to the fact that in all studies outcome measurements were made on the same scale (when 
different measures were converted to a unique one), for continuous outcomes the effect measure 
is the difference in means. Therefore, this meta-analysis was performed by calculating mean 
differences (MD) using a random-effects model. MD and 95% confidence intervals for each side 
effect were computed. The primary outcome measure was the mean difference in HbA1c levels 
comparing insulin to SU or comparing insulin to SITA.  
To explore heterogeneity in the results, it was hypothesized that effect size may differ according to 
the intervention treatment of the studies and an Egger’s test was performed using R software. 
 
 
III.7 Synthesis of results 
 
Some systematic reviews include trials with more than two intervention groups or, in this case, an 
intervention and a control group so it may be necessary to combine results (e.g., groups receiving 
similar interventions), or it may be desirable to include only a subset of the data to match the 
review’s inclusion criteria. In this context, results of HbA1c were pooled in three studies that 
compared insulin versus SU (Kobayashi 1996 (70), Maruyama 2008 (83) and Thunander 2011 (72)) 
and three studies that examined insulin versus SITA (Hals 2019 (76), Wang 2019 (84), Zhao 2014 
(85)) were pooled. In some cases, the MD or SD was imputed from the mean of the known MDs or 
SDs. In other instances, standard error (SE) had to be reconstructed from other statistics such as SD.  
This meta-analysis represents a random-effect analysis due to the variation of the effects across 
studies and the lack of common treatment effect for all studies included as well as to the overweight 
given to the results of smaller trials than the fixed-effect analysis (86,87).  
To investigate the variation of the expected treatment effect, heterogeneity was measured. The 
conventional statistical approach to evaluate heterogeneity is a chi-squared test (Cochran’s Q), 
however, usually it has low power when there are few studies (88), which is the case. By contrast, 
the I2 statistic quantifies the amount of variation in results across studies and so is preferable to Q 
(88,89). Thus, the Higgins test was used to measure inconsistency (the percentage of total variation 
across studies due to heterogeneity) of the effects of interventions.  
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III.8 Risk of bias across studies 
 
For each trial the possibility of publication bias was assessed by using the following formula: 
 
 
The funnel plot of the trials mean differences for asymmetry was confirmed with Egger’s test, to see 
if the effect was or was not statiscally significant. 
 
 
III.9 Additional Analysis 
 
Once the the meta-analysis was completed, an additional analysis was performed to understand 
whether the results of the review were robust, using a sensitivity analysis. Usually, a sensitivity 
analyses can be used to explore the degree to which the main findings of a systematic review are 
affected by changes in its methods or in the data used from individual studies such as the study 
inclusion criteria or the results of risk of bias assessment. Therefore, the sensitivity analysis was 
performed on R Software, by exclusion of each study within the included studies in the meta-analysis. 
Meta-regression was also computed, however, due to the low number of studies in the sample and 
the consequent high probability for an over-interpretation of the findings, it was excluded from the 
results of additional analysis.   
S𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐸𝑟𝑟𝑜𝑟 (𝑆𝐸) =  
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 (𝑆𝐷)
√𝑛
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CHAPTER IV: RESULTS 
 
IV.1 Study selection 
 
The search for publications evaluating treatment interventions for LADA led to a total of 2.086 
results. After refining the search, 197 results were obtained, of which 40 were duplicates. Duplicates 
were identified by collating all citations into one Excel database. The titles and abstracts of 157 
citations were independently reviewed and 8 citations were added from the references of studies 
included in the results. No abstracts required translation. Of the 165 results, after exclusion, the full 
text of 55 citations was examined in more detail. In the end, 22 studies were included for the review. 
The exclusion of the studies was made following the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis) as in Figure 2 | Selection Criteria of the Included Studies.   
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2086
records identified through database 
searching
•
197
after refining the search to include only 
intervention studies (randomized, 
controlled and clinical trials or
comparative studies)
157
results after duplicates remove
165 
articles for abstract analysis
55
asseded for eligibility
22
studies included in the review
8 citations added from the references of studies 
included in the results. 
The following keywords were added to refine 
the search (“randomized controlled trials" OR 
"comparative studies" OR "controlled clinical 
trials" OR "clinical trials). 
40 studies were removed because they were 
duplicates. 
Removed 110 articles: 
• 29: no intervention given or non-
clinical intervention 
• 10: type 1 diabetes 
• 7: type 2 diabetes (differentiate 
disease manifestations) 
• 2: no human studies 
• 54: no related or not applicable) 
• 8: replication for included study 
• 2: articles written in chinese 
Removed 33 publications by not fullfilling the 
inclusion criteria: 
• Excluded because there is no 
publication available. 
• T2D not LADA 
• Antibody positive patients were 
excluded. 
• No clinical intervention 
• T1D not LADA 
• Patients were insulin dependent at 
diagnosis. 
• LADA but not an intervention study 
• T2D. No antibodies tested. 
(see Appendix 3 |Excluded Studies) 
Figure 2 | Selection Criteria of the Included Studies. The studies included in this systematic review went through a 
selection process to select those that presented relevant data, 2.086 articles were initially identified, however, after 
selection, only 22 were analyzed. 
 51 
IV.2 Study characteristics 
 
IV.2.1 Characteristics of ongoing studies 
 
Although it is believed that there is a high proportion of patients with LADA (75), so far there are 
only a few studies that have evaluated interventions and several others are still ongoing (Appendix 4 
| Characteristics of Ongoing studies). Among the latter: Agardh 2004 (NCT00456027) examining the 
administration of rhGAD65 formulated in Alhydrogel® (Diamyd®) subcutaneously compared to 
placebo, Landin-Olsson 2010 (NCT01109927) examining insulin treatment compared to conventional 
treatment (diet, oral hypoglycemic agents and insulin first when clinically needed), Martinsen 2020 
(NCT04262479) examining GAD-vaccination with vitamin D supplement, Palmer 2009 
(NCT00058981) examined DiaPep277® compared to placebo and Zhou 2015 (NCT02407899) 
examining the treatment with Saxagliptin, Vitamin D3, Insulin and Metformin. 
 
 
IV.2.2 Characteristics of Included studies 
 
A total of twenty-two publications met the inclusion criteria. The trials were organized by country: 
five studies were obtained in Japan (Kobayashi 1996 (70), Kobayashi 2002 (90), Maruyama 2003 
(91), Maruyama 2008 (83), Awata 2017 (92)), one with pilot data (Kobayashi 1996 (70)), the other 
with a three-year follow-up (Kobayashi 2002 (90)), another with a four-year follow-up (Maruyama 
2003 (91)) and, finally, one with a five-year follow-up (Maruyama 2008 (83)); seven studies in China 
(Zhang 2020 (93), Li 2009 (94), Zhou 2005 (95), Zhao 2014 (85), Wang 2019 (84)), one of these with 
3-year follow-up of one of these studies (Yang 2009 (96)); five studies in Sweden (Agardh 2005 (26), 
Agardh 2009 (27), L-Hallin 1999 (97) and Thunander 2011 (72)); one study in Norway (Hals 2019 
(76)); one study in Germany (Johansen 2014 (98)); one study in the United Kingdom (Davis 2005 
(57)); two studies in Italy (Buzzetti 2016 (99), Pozzilli 2018 (100)); and finally, one study in Cuba 
(Cabrera-Rode 2002 (71)) and one study in United States (Palmer 2018 (101)) (see Appendix 1 | 
Characteristics of Included Studies). 
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IV.2.3 Study design 
 
All publications included in this study were randomized controlled trials or post-hoc of randomized 
controlled trials (Buzzetti 2016 (99), Pozzilli 2018 (100)). There were two publications reporting short 
term follow-up (0 to 6 months: Agardh 2005 (26), Buzzetti 2016 (99)), three publications on medium 
term follow-up (7 to 12 months: L-Hallin 1999 (97), Cabrera-Rode 2002 (71), Li 2009 (94), Zang 2020, 
Zhao 2014  (85), Pozzilli 2018 (100), Wang 2019 (84)) and ten publications on long-term follow-up 
(more than 12 months: Agardh 2009 (27), Awata 2017 (92), Davis 2005 (57), Hals 2019 (76), 
Johansen 2014 (98), Kobayashi 1996 (70), Kobayashi 2002 (90), Maruyama 2003 (91), Maruyama 
2008 (83), Palmer 2018 (101), Thunander 2011 (72), Yang 2009 (96), Zhou 2005 (95)).  
 
 
IV.2.4 Participants 
 
A total of 6562 participants were included in the 22 publications (29 studies). The smallest study 
included 10 participants (Kobayashi 1996 (70)) and the largest included 2709 participants (Buzzetti 
2016 (99)). Most trials recruited adults with a diagnosis of T2D with the presence of autoantibodies 
and few selected participants with diagnosis of LADA (Yang 2009 (96), Johansen 2014 (98)). However, 
the selection criteria to define LADA varied between studies (Table 3 | Selection criteria for LADA). 
Although in these studies the patients were not labelled as LADA patients and there were no 
intervention trials specifically for LADA, the inclusion of autoantibodies examination was the reason 
to include them in the review. Only one trial reported ethnicity (Buzzeti 2016 ((99)), so it was decided 
to assume that, in the selected studies, the patients recruited were mainly of the ethnicity of the 
country where the trial was being conducted. For the majority of studies there were no selection 
criteria for disease duration of the participants at entry, but it is known tha the duration of disease 
varies between less than 3 years (Hals 2019 (76), Wang 2019 (84), Zhao 2014 (85)) and 10 years 
(Maruyama 2003 (91)). 
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Table 3 | Selection criteria for LADA. There are some basic criteria for the selection of patients with LADA, which 
should be considered, such as age, the initial diagnosis and the presence of antibodies. In parallel, there are 
other criteria that can be considered, like insulin dependence, the time elapsed since the onset of the disease, 
HbA1c levels, C-peptide levels or BMI. 
Study Age Diagnosis Antibody Comments 
Agardh 
2005 
 
30-70 
years 
T2D GADA 
Diagnosed within past 5 years and not 
requiring insulin 
Agardh 
2009 
30-70 
years 
T2D 
GADA, IA-
2A, IAA 
and ICA 
Diagnosed within past 5 years and not 
requiring insulin 
Awata 
2017 
20-79 
years 
T2D non-insulin 
dependent 
diabetes 
GADA, IA-
2A and IAA 
HbA1c level between 6.9% and 8.4%, fasting C-
peptide level of 1.0 ng/ml, no treatment with 
oral glucose-lowering drugs except metformin 
within 2 months before enrollment and no 
history of insulin or GLP-1 receptor antagonist 
treatment 
Buzzetti 
2016 
18–
77 
years 
Non-insulin 
dependent 
diabetes 
GADA 
Patients had an inadequate glycemic control 
[HbA1c 7.0–10.0% (53–86 mmol/mol), 7.5–
10.0% (58–86 mmol/mol), or 7.0–10.5% (53–91 
mmol/mol), body mass index ≤40 or ≤45 
Kg/m2, and fasting C-peptide ≥1.0 ng/ml 
Cabrera-
Rode 2002 
Not 
given 
T2D 
GADA and 
ICA 
Divided into disease durations of up to 3 years 
and >3 years 
Davis 2005 
25-65 
years 
T2D 
GADA and/ 
or ICA 
and/or IA-
2A 
Fasting plasma glucose >6.0 mmol/L on two 
subsequent occasions 
Hals 2019 
30-75 
years 
Diabetes non-
insulin dependent 
diabetes 
GADA, 
Znt8, IA-2A 
<3 years of known diabetes, without 
pharmacological treatment for diabetes 
(except metformin) and with no clinical need 
for insulin treatment, HbA1c concentration ≥1 
0% before treatment, or 5% when on 
treatment with metformin, but not exceeding 
60% at the time of randomization, Fasting 
levels of C-peptide had to be ≥0.3 nmol/L 
Johansen 
2014 
Not 
given 
T2D 
GADA 
and/or IA-
2A and/or 
IAA 
HbA1c of 6.5–10.0% (48–86 mmol/mol) on 
metformin 
Kobayashi 
1996 
None 
given 
T2D ICA 
Fasting plasma glucose >6.0 mmol/L on two 
subsequent occasions 
Kobayashi 
2002 
None 
given 
T2D non-insulin 
dependent 
ICA 
Fasting plasma glucose >6.0 mmol/L on two 
subsequent occasions 
L-Hallin 
1999 
35-75 
years 
T2D GADA 
BMI 22-32 Kg/m2, previous successful response 
to SU, fasting blood glucose >8 mmol/L and/or 
postprandial blood glucose >11 mmol/L and/or 
HbA1c >3% above normal per local standard, 
despite treatment with maximal doses of SU 
for at least 3 months 
Li 2009 
Over 
20 
years 
American Diabetes 
Association 
GADA 
Disease duration less than 5 years, fasting C 
peptide >200 pmol/l at entry 
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Standards (ADA) 
diagnostic 
Maruyama 
2003 
Not 
given 
American Diabetes 
Association 
Standards (ADA) 
diagnostic 
GADA 
Not treated with insulin for ≥6 months after 
diagnosis. Disease duration <10 years 
Maruyama 
2008 
Not 
given 
American Diabetes 
Association 
Standards (ADA) 
diagnostic 
GADA 
Patients should use SU agents to obtain good 
glycemic control and the duration of diabetes 
should be within 5 years form onset 
Palmer 
2018 
35-69 
years 
Not stated 
ICA, IAA, 
IA-2A, and 
GADA 
Not requiring insulin to achieve glycemic 
control, not receiving more than two oral 
hypoglycemic agents, not taking a 
thiazolidinedione agent, HbA1c >6% and <10%, 
fasting c-peptide ≥0.8 ng/ml 
Pozzilli 
2018 
Not 
given 
T2D GADA 
BMI of 23-45 Kg/m2, Previous therapy with 
GLP-1 agonists within 3 months prior to 
screening 
Thunander 
2011 
≥30 
years 
Diabetes 
GADA 
and/or ICA 
Non-insulin requiring 
Wang 2019 
30-70 
years 
1999 World Health 
Organization 
(WHO) Diagnostic 
Criteria for 
Diabetes Mellitus 
GADA 
Insulin independent within the first 6 months 
after the diagnosis of diabetes, fasting C- 
peptide level >200 pmol/L or a 2-h 
postprandial C-peptide >400 pmol/L, and 
duration of diabetes of ≤3 years 
Yang 2009 
Over 
25 
years 
T2D GADA 
Duration of disease less than 5 years. Fasting C-
peptide level ≥0.2 nmol/L, not treated with diet 
alone 
Zhang 2020 
18-70 
years 
1999 World Health 
Organization 
(WHO) Diagnostic 
Criteria for 
Diabetes Mellitus 
GADA 
Duration of disease <4 years, serum fasting C-
peptide ≥100 pmol/L or 2-hour postprandial C-
peptide ≥200 pmol/L, Fasting plasma glucose 
concentration of ≥7.0 mmol/l. 
Zhao 2014 
25-70 
years 
1999 World Health 
Organization 
(WHO) Diagnostic 
Criteria for 
Diabetes Mellitus 
GADA 
Insulin independent within the first 6 months 
after the diagnosis of diabetes, fasting C-
peptide level ≥200 pmol/L or a 2-hour 
postprandial C-peptide ≥400 pmol/L, and 
duration of diabetes of ≤3 years 
Zhou 2005 
Over 
25 
years 
1999 World Health 
Organization 
(WHO) Diagnostic 
Criteria for 
Diabetes Mellitus 
GADA 
Disease duration <5 years. Fasting C-peptide 
≥0.3 mmol/L. 
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IV.2.5 Interventions  
 
All trials examined interventions for LADA or antibody positive T2D. One trial examined GAD65 
immunomodulation (Diamyd®) at three different doses compared to placebo (Agardh 2005 (26) and 
Agardh 2009 (27)), one examined insulin compared to insulin and sulphonylurea (Cabrera-Rode 2002 
(71)), a pilot study and subsequent follow up examined insulin compared only to sulphonylurea 
(Kobayashi 1996 (70), Kobayashi 2002 (90), Maruyama 2003 (91), Maruyama 2008 (83)); another 
examined insulin and sulphonylurea administered together when compared to a group that 
withdrew sulphonylurea after four months (L-Hallin 1999 (97)); other study and subsequent follow-
up evaluated insulin and rosiglitazone (RSG) (Zhou 2005 (95) and Yang 2009 (96)), one examined the 
protective effects of vitamin D in LADA (Li 2009 (94)) and yet another examined insulin compared to 
conventional treatment (diet+/- OHA, metformin and/ or sulphonylurea) (Thunander 2011 (72)). 
Another study examined insulin compared to sulphonylurea compared to diet treatment (Davis 2005 
(57)), one examined metformin and insulin compared to saxagliptin, metformin and insulin 
compared to vitamin D3, saxagliptin, metformin and insulin (Zhang 2020 (93)), one examined 
sitagliptin compared to pioglitazone (Awata 2017 (92)), one examined sitagliptin compared to insulin 
(Hals 2019 (76)), two studies examined sitagliptin with insulin compared to insulin without sitagliptin 
(Zhao 2014 (85) and Wang 2019 (84)) and one compared placebo with saxagliptin in groups GADA-
positive and GADA-negative (Buzzetti 2016 (99)). 
 
 
IV.2.6 Baseline characteristics 
 
Baseline data are essential to assess the applicability of trial results to a given patient and the 
comparability of study populations for meta-analyses. Knowing the baseline characteristics of a trial 
may allow to compare possible matching patients seen in clinical practice and subsequently to 
generalize the results of a trial. For this to be possible, baseline data should adequately describe the 
population in the trial and the factors that influence the outcome, those that are likely to modify any 
benefit of treatment, and those that may predict adverse reactions, which are called potential 
“confounders”. If these “confounders” are imbalanced between the treatment groups at baseline, 
they may result in an apparent treatment effect when none exists, or may mask an effect that does 
exist, therefore, it is important to know the baseline characteristics of all studies included in this 
review (102).  
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The main baseline characteristics obtained in all trials were age, gender, C-peptide (fasting and/or 
stimulated, and/or postprandial), duration of disease and BMI. The other baseline characteristics 
measured in the studies are presented in Appendix 5 | Baseline Characteristic of Included Studies. 
 
 
IV.3 Results of individual studies 
 
IV.3.1 Outcome measures  
 
The outcomes of each study were careful analyzed. The primary and secondary outcome measures 
of the studies included in this review are presented below. However, in some studies, the outcome 
measures were unclear (Agardh 2005  (26), Agardh 2009 (27), Cabrera-rode 2002 (71), Davis 2005 
(57), L-Hallin 1999 (97), Li 2009 (94), Thunander 2011 (72), Zhou 2005 (95)). No trials reported health 
service utilization or costs or health-related quality of life. All outcome measures are summarized in 
the Appendix 6 | Outcomes of the Included Studies. 
 
 
IV.3.2 Primary outcomes 
 
The most common primary outcome measures were HbA1c levels (Atawa 2017, Buzzetti 2016 (99), 
Johansen 2014 (98), Pozzilli 2018 (100)), C-peptide levels (Kobayashi 1996 (70), Maruyama 2003 
(91), Maruyama 2008 (83), Zhang 2020 (93)), postprandial glucose (PCP) (Buzzetti 2016 (99), Yang 
2009 (96), Zhang 2020 (93), Zhao 2014 (85)) and fasting C-peptide (Johansen 2014 (98), Palmer 2018 
(101), Yang 2009 (96), Zhang 2020 (93), Zhao 2014 (85)). Other primary outcomes were stimulated 
C-peptide (SCP) (Maruyama 2003 (91), Maruyama 2008 (83), Palmer 2018 (101)), response to Oral 
Glucose Tolerance Test (OGTT) (Kobayashi 2002 (90)), Homeostasis Model Assessment of β cell 
function (HOMA2-%β) (Yang 2009 (96)), percentage of T-lymphocity and mensenger Ribunucleic 
Acid (mRNA) expression (Wang 2019 (84)), blood glucose levels (Maruyama 2003 (91), Kobayashi 
2002 (90)), fasting plasma glucose (Buzzetti 2016 (99)), GADA titer (Kobayashi 1996 (70)) and ICA 
titer (Kobayashi 1996 (70)). 
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IV.3.3 Secondary outcomes 
 
The most frequently measured secondary outcomes were HbA1c levels (Kobayashi 1996 (70), 
Kobayashi 2002 (90), Maruyama 2003 (91), Maruyama 2008 (83), Wang 2019 (84), Yang 2009 (96), 
Zhang 2020 (93), Zhao 2014 (85)) and GADA titers (Atawa 2017, Kobayashi 2002 (90), Maruyama 
2003 (91), Maruyama 2008 (83), Palmer 2018 (101), Zhang 2020 (93), Zhao 2014 (85)). Outcomes 
as postprandial blood glucose (Maruyama 2008 (83), Wang 2019 (84), Zhang 2020 (93)), BMI (Atawa 
2017, Maruyama 2003 (91), Zhao 2014 (85)),  fasting blood glucose (Pozzilli 2018 (100), Wang 2019 
(84), Zhang 2020 (93)), fasting C-peptide (Buzzetti 2016 (99)), C-peptide (Atawa 2017, Wang 2019 
(84)), postprandial C-peptide and β-cell function (Buzzetti 2016 (99)), stimulated insulin, pro insulin 
and C-peptide ratio (Hals 2019 (76)), GLP-1 (Johansen 2014 (98)), creatinine, urinary albumin and 
GAD β (Kobayashi 2002 (90)), insulin dependent state (Maruyama 2008 (83)), Homeostasis Model 
Assessment of β cell function (HOMA-β), Homeostasis Model Assessment of Insulin Resistance 
(HOMA IR) and hypoglycemia (Pozzilli 2018 (100)) and ICA, IAA, IA-2A and T-cells level (Palmer 2018 
(101)).  
 
 
IV.3.4 Additional outcomes 
 
There were additional outcomes within the analysed studies but the most reported ones were 
adverse effects (Agardh 2005  (26), Agardh 2009 (27), Buzzetti 2016 (99), Hals 2019 (76), Kobayashi 
1996 (70), Palmer 2018 (101), Yang 2009 (96), Zhao 2014 (85)), BMI (Agardh 2005 (26), Agardh 2009 
(27), Cabrera-rode 2002 (71), Davis 2005 (57), Hals 2019 (76), Kobayashi 1996 (70), L-Hallin 1999 
(97)), HbA1c levels (Agardh 2005 (26), Agardh 2009 (27), Davis 2005 (57), Hals 2019 (76), L-Hallin 
1999 (97), Thunander 2011 (72), Zhou 2005 (95)), fasting C-peptide (Agardh 2005 (26), Agardh 2009 
(27), Cabrera-rode 2002 (71), L-Hallin 1999 (97), Li 2009 (94), Zhou 2005 (95)), fasting blood glucose 
(Agardh 2005 (26), Agardh 2009 (27), Cabreda-rode 2002 (71), Hals 2019 (76), L-Hallin 1999 (97)). 
Some outcome measures were also presented, such as stimulated C-peptide (Agardh 2005 (26), 
Agardh 2009 (27)), insulin dose (Cabrera-rode 2002 (71), Zhou 2005 (95)), GADA titers (Agardh 2005 
(26), Cabrera-rode 2002 (71), Hals 2019 (76)), islet autoantibodies, serum creatinine and lipid profile 
(Agardh 2009 (27)), 2h postprandial C-peptide (Li 2009 (94)), sulphonylurea dose and ICA titers 
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(Cabrera-rode 2002 (71)), KITT and free P-insulin (L-Hallin 1999 (97)), glucagon stimulated C-peptide 
and C-peptide (Thunander 2011 (72)). 
 
 
IV.4 Effects of interventions 
 
IV.4.1 Short term interventions (0 to 6 months) 
 
Agardh 2005 
 
This study examined placebo and a low dose of GAD65 (4μg) compared to higher doses of GAD65 
(20μg, 100 μg, 500μg) per patient, over six months, every four weeks. An increase in HbA1c levels 
was evident in the placebo and 4μg dose groups (0.6 % and 0.3 %, respectively) but not in the groups 
receiving higher dose levels of Diamyd® (p=0.029). The placebo and 4μg dose groups both showed 
an increase (1.2 nmol/L and 1.3 nmol/L, respectively) in plasma glucose levels after 24 weeks but a 
decrease was observed in the 20, 100, and 500μg groups ( -0.7 nmol/L, - 0.3 nmol/L, -0.9 nmol/L 
respectively; p=0.038). The 20μg dose group showed an increase from baseline compared with 
placebo and an increase from baseline in the mean change in both fasting (0.16 ± 0.05 nmol/l; 
p=0.0081;) and stimulated log c-peptide (0.11 ± 0.04 nmol/l; p=0.0236) at 24 weeks. A decline in 
stimulated log c-peptide levels was apparent in the 4μg and 500μg dose groups (-0.13 ± 0.03 nmol/l; 
p=0.0084), which was different from the placebo (p=0.0047). Since baseline all groups indicate no 
change after one and four weeks neither in the placebo nor 4μg, 20μg, and 100μg groups. However, 
five patients in the 500μg group showed an increase in the first 4 weeks. After 24 weeks, the 500μg 
group had an increased log GADA level (0.61 ± 0.09; p=0.001). In the end, it was reported that 68% 
of patients presented adverse events, the majority experienced influenza-like symptoms, with 
nasopharyngitis. Furthermore, other adverse events were reported, judged to be probably related 
to the trial treatment, that is, vitiligo (in the placebo group), mild leukocytosis (100μg dose group), 
and a mild inflammation at the injection site on the left arm (500μg dose group). Two patients had 
abnormal clinically significant laboratory results: one patient (20μg dose group) had transient raised 
liver enzymes and another (placebo dose group) had increased blood iron levels being later 
diagnosed with hemochromatosis. 
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This study concluded that the present treatment could be considered immunologically safe with 
regard to its clinical impact on peripheral lymphocytes and can be the provision of further support 
for the clinical safety of Diamyd® treatment 
 
Buzzetti 2016 
 
This study was a post-hoc analysis of data pooled from five randomized, placebo-controlled, 24-week 
phase 3 studies where the authors evaluated GADA positive patients receiving saxagliptin (2.5, 5, 
and 10 mg/d) compared to placebo. Patients receiving saxagliptin showed reductions from baseline 
in HbA1c compared to those receiving placebo in both GADA-positive and negative groups. 
Consistent treatment effects, relative to placebo, on HbA1c were seen in GADA-negative and GADA-
positive patients (p=0.93). GADA-positive patients receiving placebo had an increase in HbA1c over 
24 weeks which was not observed in patients receiving placebo who were GADA negative. In FPG, 
greater reductions from baseline were observed in patients treated with saxagliptin compared to 
those treated with placebo. However, there was a larger treatment effect of saxagliptin on reduction 
from baseline in FPG compared to placebo in GADA-positive versus GADA-negative patients 
(p=0.008), owing to a substantial rise in FPG in patients receiving placebo that was not observed in 
those treated with saxagliptin. In PPG, patients treated with saxagliptin showed greater decreases 
from baseline than those receiving placebo, with similar effects versus placebo in GADA-negative 
and GADA-positive patients (p=0.97). In GADA-positive patients postprandial C-peptide increased 
from baseline to 24 weeks with saxagliptin treatment, whereas a lower change was noted with 
placebo (mean difference 70 ng/min/ml (95% confidence interval (CI) -91.4 to 230.5)). In fasting C-
peptide there was little or no change from baseline to week 24 across patient and treatment groups 
and no evidence of a treatment-by-subgroup interaction (p=0.27). Regarding, β-cell function namely, 
HOMA2-%β increased in GADA-positive patients receiving saxagliptin (mean difference 8.4% (95% 
(CI) 1.4% to 15.4%)) but decreased in those receiving placebo treatment (-2.7% (-14.6% to 9.3%); 
difference vs placebo (11.1% (-2.8% to 24.9%)). Adverse effects (AEs) or serious AEs, and 
hypoglycaemic events were similar across treatment groups and GADA categories. 
This study concluded that saxagliptin was generally well tolerated and effective in GADA-positive 
patients and appeared to increase β-cell function. 
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L-Hallin 1999 
 
This article was an observational study with insulin and SU given together and patients were 
randomized to insulin only or insulin with SU. At the end of phase I of treatment, FPG decreased 
(13.1 ± 2.8 mmol/l to 8.6 ± 2.2 mmol/l) after four months of combined SU and insulin treatment. 
Although at baseline, HbA1c was significantly higher in the group of patients requiring two insulin    
injections daily (9.87 ± 1.56% vs. 9.08 ± 1.36%, p=0.0052), at the end of phase I HbA1c was similar 
regardless of insulin regimen. There was substantial improvement in glycemic control during phase 
I, where HbA1c decreased from 9.65 ± 1.5S% to 7.2S ± 1.09% (p<0.0001) after four months of 
combined SU and insulin treatment. In fasting C-peptide, the concentrations were 15% lower than 
baseline values at the end of phase I. However, the ratio between C-peptide and FBG increased 
significantly, from 0.057 ± 0.035x10
-6 to 0.071 ± 0.043x10
-6 (p<0.0001). The insulin sensitivity index 
measured by KITT (Plasma Glucose Disappearance Rate) improved by more than 30%. This increase 
was related to the improvement in both HbA1c (τ=0.24, p=0.0017) and FBG (τ = 0.28, p=0.0029). 
Finally, more than 90% of the patients gained weight during the 4 months of combined therapy. The 
change in weight, median +3.0Kg was correlated both to insulin dose (τ=0.38, p<0.0001) and to 
increased HbA1c (τ=0.20, p=0.0104). 
At the end of phase II some results are different. Seventy nine percent of patients had an FBG ≥10% 
above the comparison level at the first visit at 3±4 weeks. The median increase in FBG at this visit 
was 40%. At the end of the study, 60% of patients were classified as SU responders by protocol, in 
other words, had showed an increase in FBG of ≥40% at two consecutive visits. In the group of 
withdrawal of SU HbA1c increased significantly during phase II (7.26 ± 1.00 % to 8.99 ± 1.27 %). 
However, in fasting C peptide (0.62 ± 0.35 nmol/l to 0.56 ± 0.32 nmol/l) and free P-insulin (18.9 ± 
11.3 mU/l to 17.7 ± 12.1 mU/l) there were no changes observed throughout this trial phase. 
Furthermore, in this phase the KITT decreased in of withdrawal of SU (2.44 ± 1.46 %/min to 1.74 ± 
1.15%/min). 
This study concluded that combining sulphonylurea and insulin is an effective therapy in a majority 
of patients with T2D, suggesting that patients who are GAD-antibody-positive are less likely to 
respond and that a long duration of diabetes does not exclude a beneficial effect of SU. 
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IV.4.2 Medium term interventions (7 to 12 months) 
 
Cabrera-Rode 2002 
 
This study was a randomized controlled trial that examined insulin (27.0 ± 20.7 U/day) and 
glibenclamide (25.8 ± 6.6 mg/day) compared to insulin alone (26.3 ± 30.1 U/day), during 12 months. 
Fasting blood glucose was increased in the group with combined therapy (insulin + glibenclamide) 
after one year of the study (10.0 ± 3.0 mmol/l to 11.5 ± 5.5 mmol/l). Regarding ICA titers, in the 
group treated only with insulin, 6 out of 8 patients became ICA negative, while all six individuals 
treated with the combined therapy (insulin + glibenclamide) presented persistence of ICA titres. In 
GAD antibody status, no changes were found in GADA in either group, with maintenance of positive 
outcomes in all patients. In the insulin group, GADA mean was 1.074 ± 0.48 in baseline to 0.924 ± 
0.55 after one year, while in insulin and glibenclamide group GADA mean was 1.363 ± 0.35 to 1.088 
± 0.36 after one year. In fasting C-peptide, insulin dose, SU dose and BMI did not change during the 
one-year observation period. 
This study concluded that treatment with glibenclamide, even if including use of insulin in a 
combined therapy in T2D patients maintains the positivity of ICA and possibly the progressive 
destruction of β-cells. 
 
 
Li 2009 
 
This study pursued a parallel randomized controlled trial examining insulin-only compared with 
insulin plus 1-alp hydroxyl-vitamin D3 during 12 months. Fasting C-peptide (FCP) and postprandial C-
peptide (PCP) levels remained stable in the insulin plus Vitamin D group, with FCP changing from 248 
to 261 pmol/l (p=0.469) and PCP from 587 to 614 pmol/l (p=0.717). In contrast, FCP levels decreased 
in the insulin-only group (from 368 to 179 pmol/l, p=0.006), and PCP levels showed a decline (from 
804 to 713 pmol/l, p=0.088). FCP levels were maintained or increased in 12 of 17 Vitamin D-treated 
patients but only in 4 of 18 control subjects (70.6% vs 22.2%, p<0.01). As reflected by significantly 
higher FCP and PCP levels, islet β-cell function was better preserved after treatment. 
This study concluded that adding vitamin D3 to insulin therapy preserved β-cell function better than 
insulin therapy alone in patients with LADA. 
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Pozzilli 2018 
 
This was a post-hoc, randomize trial that examined once per week the dulaglutide treatment (mainly 
1.5 mg or 0.75 mg) compared to glargine (AWARD-2 and AWARD-4), sitagliptin or placebo (AWARD-
5), during 12 months. HbA1c levels was higher in AWARD-4 compared to AWARD-2 and AWARD-5, 
and the ratio of GADA-high/GADA-low patients was higher in AWARD-4 compared to AWARD-2 and 
AWARD-5. In patients treated with dulaglutide, the HbA1c decreased at 3, 6, and 12 months. 
However, the magnitude of this reduction during treatment with dulaglutide differed per trial: 
greater reductions were observed in AWARD-4, particularly in GADA-negative populations (-1.71% 
[-1.81, -1.61] at 6 months) compared to AWARD-2 (-1.00% [-1.08, -0.92] at 6 months) and AWARD-
5 (-1.11% [-1.19, -1.04] at 6 months).  When GADA-positive patients were divided into low and high 
GADA titer groups, reductions in HbA1c during treatment with dulaglutide were numerically but not 
statistically significantly larger in GADA-low compared to GADA-high patients in the pooled sample 
and per trial. In the pooled sample, the mean change (95%CI) in HbA1c at 6 months was -1.22% (-
1.43, -1.01) in GADA-low compared to -0.89% (-1.29, -0.48) in GADA-high and, at 12 months, -1.02% 
(-1.26, -0.78) compared to -0.72% (-1.21, -0.24). Compared to sitagliptin (AWARD-5), greater 
decreases in HbA1c were observed during treatment with dulaglutide in GADA-positive and GADA-
negative patients, the mean change (95%CI) was -1.12% (-1.31, -0.93) with dulaglutide compared to 
-0.50% (-0.98, -0.01) with sitagliptin at 6 months, and -0.94% (-1.15, -0.72) compared to 0.04% (-
0.50, 0.58) at 12 months. Numerically, greater decreases in HbA1c were also observed with 
dulaglutide compared to sitagliptin in the GADA-low and GADA-high subgroups, although there were 
too few sitagliptin-treated patients to obtain reliable results in these subgroups. Reductions of 
fasting blood glucose (FBG) were observed in GADA-negative and GADA-positive patients in AWARD 
2 and -5, while in AWARD-4, where all patients already had conventional insulin treatment at 
baseline, no reductions in FBG were detected during dulaglutide-treatment in GADA-negative or 
GADA-positive patients. HOMA-β increased in GADA-positive and GADA-negative patients during 
treatment with dulaglutide (AWARD 2 and 4). Mean (SE) HOMA-β improved by 29.90 (11.17) 
(mean±SD) percentage points at 6 months and 27.52 (7.32) (mean±SD) percentage points at 12 
months in GADA-positive patients, and by 37.48 (7.00) (mean±SD) percentage points at 6 months 
and 28.94 (1.88) (mean±SD) percentage points at 12 months in GADA-negative patients. In HOMA-
IR there was little or no change at 6 or 12 months in GADA-positive and GADA-negative patients. 
Adverse effects like hypoglycemia were reported. Most hypoglycemia cases occurred in AWARD-4, 
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likely due to the use of prandial insulin in both treatment arms and the stage of the disease. In 
AWARD-2 and AWARD- 5, few GADA-positive patients reported hypoglycemia. 
This study concluded that dulaglutide was an effective anti-hyperglycemic treatment in patients with 
LADA, including patients with high and low GADA titers. 
 
 
Wang 2019 
 
This study was a randomized controlled trial comparing insulin with sitagliptin (SITA) with insulin 
without sitagliptin, during 12 months. Percentage of T-lymphocyte - the percentage of Treg to CD4+ 
T cells in the SITA group was significantly lower than that in the CONT group (2.36 ± 0.35% vs 3.92 ± 
0.50%, p=0.016) at baseline. The percentage of Th2 to CD4+ T cells was higher than that of the CONT 
group at 6 months (4.08 ± 0.58% vs 2.18 ± 0.42%, p=0.015) and 12 months (5.17 ± 0.92% vs 2.51 – 
0.33%, p=0.012). At 12 months, the percentage of Th17 to CD4+ T cells was lower in the SITA group 
than in the CONT group (0.74 ± 0.57% vs 1.20 ± 0.52%, p=0.020). Messenger ribonucleic acid 
expression - no significant difference could be found in the mRNA expression in the SITA group and 
CONT group at baseline and 6 months, neither difference can be found compared with their baseline, 
respectively. After the 1-year visit, no significant difference could be found in four transcription 
factors (T-BET, GATA3, RORC and FOXP3) between the SITA group and CONT group. However, the 
mRNA expression levels of T-BET (0.29 ± 0.16% vs 0.85 ± 0.24%, p=0.012) and RORC (0.11 ± 0.07% 
vs 0.85 ± 0.51%, p=0.009) in the SITA group were significantly lower compared to baseline in the SITA 
group. Whereas the mRNA expression levels of RORC (1.14 ± 0.84% vs 0.19 ± 0.17%, p=0.004) were 
also significantly lower than its baseline in the CONT group. Although there was a descending 
tendency in the FOXP3 expression and ascending tendency in the GATA3 expression, the differences 
were not significant. Fasting blood glucose, after the 12-month visit in the CONT group were 
significantly higher than baseline (7.54 ± 0.61 mmol/l (baseline) vs. 7.50 ± 0.63 mmol/l (CONT 
group)). However, in SITA group no differences were observed (6.68 ± 0.40 mmol/l (baseline) vs. 6.29 
± 0.29 mmol/l (SITA group)). Also, between groups, no significant difference could be found. After 
the 12-month visit, postprandial blood glucose in the CONT group were significantly higher than 
baseline (14.02 ± 1.36 mmol/l (baseline) vs. 14.90 ± 1.28 mmol/l (CONT group), p< 0.05). However, 
in SITA group no differences were observed (12.72 ± 1.07 mmol/l (baseline) vs. 11.68 ± 1.19 mmol/l 
(SITA group)). Also, between groups no significant difference could be found. In HbA1c levels, no 
significant differences were observed in GADA titers and C-peptide levels. 
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This study concluded that sitagliptin altered the phenotype of T cells and downregulated the 
expression of T-BET and RORC in LADA patients, and ameliorated glycemic control in LADA patients. 
 
 
Zhang 2020 
 
This study was a randomized trial that compared group A (1-1.7 g metformin per/day + insulin), 
group B (saxagliptin 5 mg/day + metformin + insulin) and group C (vitD3 2000 IU/day + saxagliptin 5 
mg/day + metformin + insulin), during 12 months. 
FCP showed no significant differences in group A at 6 months (p=0.992) and 12 months (p=0.197) 
compared with baseline. Incredibly, the FCP levels at 12 months in group B were significantly lower 
than those at baseline (p=0.005). In group C, the FCP levels at 12 months (p=0.320) were not 
significantly different from those at baseline. No significant differences were detected in three 
groups throughout the follow-up. C-peptide index (CPI) was also measured and the FCPI levels in 
group A were significantly reduced at 12 months compared with baseline (p=0.022), while they 
showed no significant differences in either group B or group C at 6 months and 12 months. 
Moreover, the levels of PCPI decreased continually from 95.64 ± 72.21 pmol/l to 82.75 ± 74.03 pmol/l 
at 6 months (p=0.161) and 74.20 ± 56.84 pmol/l (p=0.049) at 12 months in group A. In contrast, the 
PCPI levels in group C continued to increase from 91.31 ± 63.21 pmol/l to 116.28 ± 97.09 pmol/l 
(p=0.087) at 6 months and 118.14 ± 108.07 pmol/l (p=0.213) at 12 months. No significant differences 
in PCPI levels were found during treatment in group B. The levels of GADA titers in group C, were 
decreased significantly at 12 months compared with baseline (p=0.001). However, no changes in 
GADA titers were detected in group A or group B after 12 months of treatment (p>0.05). In fasting 
blood glucose, 2-h postprandial glucose (PPG) and HbA1c levels no significant differences were 
observed in any of the groups. 
This study concluded that adding 2000 IU per day vitamin D3 to saxagliptin might preserve β-cell 
function in patients with LADA. 
 
 
Zhao 2014 
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This article was about a randomized controlled study that examined insulin with sitagliptin (100 mg 
daily) with insulin without sitagliptin during 12 months. There were no significant differences in the 
levels of FCP and 2-hour C-peptide levels in group A at 12 months compared with baseline (p= 0.28 
- 0.88). In group B, the level of FCP continually decreased from a baseline of 389.3 ± 52.5 pmol/l to 
321.0 ± 56.1 pmol/L at 3 months (p<0.01); 300.4 ± 35.2 pmol/l at 6 months (p=0.06); 287.1 ± 30.9 
pmol/l at 9 months (p<0.05); and 279.7 ± 46.5 pmol/l at 12 months (p<0.05). The 2-hour CP levels in 
group B continually decreased from 1530.0 ± 205.4 pmol/l at baseline to 1124.6 ± 176.2 pmol/l at 3 
months (p<0.01); 1101.0 ± 121.7 pmol/l at 6 months (p<0.05); 962.6 ± 108.0 pmol/l at 9 months 
(p<0.05); and 843.0 ± 120.5 pmol/l at 12 months (p<0.01). The levels of 2-hour CP in group A were 
significantly higher than those in group B at 12 months (p<0.05). Blood glucose showed no significant 
differences between groups A and B. At 12 months, the fasting glucose levels were 6.2 ± 0.3 mmol/l 
in group A and 6.2 ± 0.7 mmol/l in group B (p=0.99) and 2-hour postprandial glucose levels (10.8 ± 
1.2 vs 13.0 ± 1.2 mmol/l, p=0.21). The 2-hour postprandial blood glucose, BMI, GADA titers (p=0.45) 
and HbA1c (6.2% ± 0.2% vs 6.2% ± 0.1%, p=1.00) showed no significant differences between groups 
A and B. Adverse effects were also measured and the incidence of drug-related adverse experiences 
including the incidence of hypoglycemia was low and similar between the two groups. 
This study concluded that LADA patients treated with sitagliptin and insulin maintained β-cell 
function by comparison with insulin alone. 
 
IV.4.3 Long term interventions (more than 12 months) 
 
Agardh 2009 
 
This study was a 5-year-follow-up of Agardh 2005 (26) on a randomized controlled trial of GAD65 
patients that examined a low dose of GAD65 (4μg) compared to higher doses of GAD65 (20μg to 
500μg) and placebo. Fasting C-peptide in the 20μg dose group increased significantly within the first 
year compared with baseline and remained elevated. Although not significant at 5 years compared 
with baseline, the increase in fasting C-peptide (0.04; 95% CI −0.12 to 0.19 log nmol/l; nmol/l; 
p=0.98). At 5 years, fasting C peptide levels showed a decline from baseline in the placebo group 
(−0.24; 95% CI −0.41 to −0.07 log nmol/l; p=0.01). In the 500μg dose group there was also a decline 
from baseline (−0.37; 95% CI −0.57 to −0.17 log nmol/l; p=0.003). In islet autoantibodies (GAD65, IA-
2A, IAA, ICAs), BMI and HbA1c (%) no important differences were detected between groups. Several 
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adverse effects were reported. There were 14 serious adverse events (SAE) in ten patients during 
the 5-year follow-up. Four of these patients were in the placebo group, one was in the 20μg dose 
group, two in the 100μg dose group and three in the 500μg dose. The adverse events consisted of 
seizures, cholecystitis, myocardial infarction and cerebellar infarction leading to death in one patient, 
and subarachnoid bleeding and insulin treatment with hospitalization due to cognitive dysfunction 
in another patient. 
This study concluded that the treatment with GAD65 was safe and did not compromise β-cell 
function. 
 
 
Awata 2017 
 
This study was an open-label, randomized, controlled trial, with GADA positive patients that were 
randomly assigned to receive either sitagliptin (50 mg) (S group) or pioglitazone (15 mg) (P group) 
during 48 months. HbA1c levels were decreased in both groups and significant reductions from 
baseline were observed at several points in the S group: at 12 months in the patients with both 24 
and 48 months of follow-up (n= 6 and n= 5, respectively) and at 36 months in those with 48 months 
follow-up.  The worst HbA1c levels in the S and P groups were 8.2% and 8.2%, respectively. However, 
the values of HbA1c did not significantly differ between the two groups during the study (7.5 ± 0.5 % 
(group S) and 7.3 ± 0.4% (group P); p=0,59). The C-peptide values throughout the follow-up periods 
were greater in the S group than in the P group, although the influence of the treatment on the 
longitudinal changes in the C-peptide values was not significant in any of the follow-up periods. In 
the six patients in the S group who were observed for at least 24 months, the ƩC-peptide values 
increased at 12 and 24 months (six patients) and decreased at 36 and 48 months (5 patients) but 
were still higher than those at baseline. Furthermore, the increases at 12months from baseline were 
significant (p=0.049) in the patients with 12 and 24 months follow-up. Among the five patients in the 
P group, only two were followed more than 36 months and their ƩC-peptide values were mostly 
unchanged from baseline. GADA titers were not significantly different between the S and P groups 
at any moment. However, the variations of the GADA titers from baseline were significantly inversely 
correlated with the change ratios of the C-peptide values from baseline in the S group (Spearman’s 
rank correlation coefficient=-0.600, p=0.003). In particular, when the variations of the GADA titers 
from baseline were negative, the C-peptide variations were mostly positive, and when the ratios of 
the GADA titers from baseline were positive, the C-peptide variations tended to show values around 
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zero. In the P group, a nonsignificant inverse correlation was observed (Spearman’s rank correlation 
coefficient=-0.478, p=0.101). In BMI, the S group did not significantly differ from that at baseline; 
the BMI in the P group showed an increasing trend from the value at enrollment, but the change was 
not significant. When compared, the BMI in both groups did not significantly differ during the study 
(23.2 ± 6.2 Kg/m2 (group S) and 23.9 ± 3.9 Kg/m2 (group P); p=0,73). 
This study concluced that with sitagliptin may be more effective in the preservation of the β-cell 
function than insulin treatment for at least 4 years. 
 
 
Davis 2005 
 
This was a randomized controlled trial comparing insulin with sulphonylurea during 10 years. There 
was a progressive rise in HbA1c in all therapies in patients with FPG values after the dietary run-in of 
6.0– 14.9 mmol/l or 15.0 mmol/l or higher (p=0.42 and p=0.33, respectively), with no interaction 
between autoantibody status and allocated therapy. BMI was also assessed, and in patients with FPG 
values between 6.0 and 14.9 mmol/l and no hyperglycemic symptoms Ab+ve patients gained more 
weight (p=0.0023). Among those with FPG values of 15.0 mmol/l or higher, or with hyperglycemic 
symptoms, Ab+ve patients gained more weight (p=0.0017). Thus, all patients increased their weight 
with treatment. 
This study concluded that autoantibody positive patients can be treated initially with SU, but are 
likely to require insulin earlier than autoantibody negative patients. 
 
 
Hals 2019 
 
This article presented results from the comparison between two groups insulin or sitagliptin (100 
mg/d) in GADA positive patients during 21 months. Glucagon-stimulated C-peptide tests (GSCTs) 
allows observed the β-cell function, and by this analysis no differences were observed in β-cell 
function between treatments during or after 21 months of intervention. The change from baseline 
at 21 months in fasting insulin and proinsulin in the insulin versus the sitagliptin arm was not 
significant (p=0.27 and p=0.62, respectively). Also, stimulated C-peptide at 21 months versus 
baseline did not differ between treatment arms (p=0.45). In addition, the change from baseline in 
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incremental C-peptide did not differ between treatments (insulin arm: −0.03 ± 0.25 nmol/l, sitagliptin 
arm: −0.06 ± 0.24 nmol/l; p=0.84). Similarly, fasting glucose stayed stable throughout the 21 months 
of intervention in both arms (p=0.37). In HbA1c a modest decrease was observed after 3 months of 
treatment in both arms (insulin arm: median −0.6% vs sitagliptin arm: median −7.9%). However, 
during the rest of the intervention, the evolution of HbA1c levels was similar between treatment 
arms. A minority of participants (13/64) changed GAD antibody titer after 21 months versus baseline, 
which did not cause any obvious difference between treatment arms. Regarding BMI, sitagliptin-
treated participants reduced their body weight compared to baseline (after 21 months: mean 
−3.4Kg). By contrast, those treated with insulin increased their body weight (mean +1.9Kg). 
Differences in weight evolution between treatments were significant (p=0.001 after 21 months). 
Some participants experienced adverse effects: in the insulin arm three experienced hypoglycemia, 
two participants experienced a single episode and one experienced several episodes of severe 
hypoglycemia. 
This study concluded that β-cell function after intervention was similar in patients with insulin- and 
sitagliptin treated LADA. However, participants with low levels of GAD antibodies did not experience 
progressive deterioration of β-cell function over a 21-month. 
 
 
Johansen 2014 
 
This study was an exploratory analysis trial in which patients were randomized to once- daily 
linagliptin (5 mg) or glimepiride (124 mg) for 2 years. In GAD65-positive patients, fasting C-peptide 
levels increased from baseline at weeks 28, 52, and 104 in patients treated with linagliptin (ΔC-
peptide +96; +143; +202 pmol/l, in weeks 28, 52, 104, respectively) but decreased in glimepiride-
treated patients (ΔC-peptide -105; -179; -29 pmol/l, in weeks 28, 52, 104, respectively) while 
between groups, differences were significant at weeks 28 and 52.  HbA1c levels decreased to a similar 
extent with glimepiride and linagliptin. Endogenous glucagon-like peptide 1 (GLP-1) increased, which 
led to a β-cell–protective effect. 
This study concluded that over a 2-year treatment with linagliptin may, at least, have attenuated the 
rate of decline in C-peptide levels in LADA patients. 
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Kobayashi 1996 
 
This article was a pilot randomized control study where one group received small doses of insulin 
(insulin group), and the other received a SU drug (glibenclamide) (SU group) during 30 months. The 
serum C-peptide response to OGTT (C-peptide) was significantly improved 6 and 12 months after 
the initiation of insulin in the insulin group (the percentage of change in c peptide went from 100% 
to 170% in those months). However, in the SU group, the serum C-peptide response to the OGTT 
decreased progressively and the the main differences were shown at 24 and 30 months (the 
percentage of change in c peptide went from 100% to 60%, from baseline to those months). The 
differences between the insulin group and the SU group in C-peptide response changes show 
significant differences at 6, 12, 24, and 30 months (p<0.05). The 2h blood glucose value during the 
OGTT tended to decrease from the baseline value in the insulin group (9.6 ± 1.4 mmol/l to 7.3 ± 1.7 
mmol/l), whereas the value increased significantly from the baseline in the SU group (9.6 ± 1.4 
mmol/l to 10.1 ± 1.4 mmol/l). ICAs disappeared in four of the five (80%) insulin group patients during 
observation. In the SU group, ICAs persisted in all patients. The duration of negative seroconversion 
of ICAs after insulin initiation was as short as 6 months in three patients and 12 months in one 
patient. In one patient, ICA status was persistently positive at the same titer. In the SU group, ICAs 
persisted in all five patients (p=0.047 vs. insulin group). ICA status was persistently positive in two 
patients and fluctuated between positive and negative in three patients. GAD antibodies 
disappeared in one patient 12 months after insulin, and the other three patients remained GAD 
antibody-positive.  In the SU group, GAD antibody status was initially positive in three of five patients. 
GAD antibody status remained unchanged. HbA1c levels remained unchanged in the insulin group 
(7.8 ± 0.4 % to 7.3 ± 0.9 %) and increased in the SU group (8.5 ± 0.6 % to 11.2 ± 1.3 %, p<0.05). No 
adverse effects or episodes of severe hypoglycemia were observed during the study. 
This study concluded that subcutaneous small doses of insulin, resulting in a high rate of negative 
conversion of ICA and an improved serum C-peptide response, may be effective in preventing 
progressive β -cell failure in ICA patients with the clinical features of Non-Insulin Dependent Diabetes 
Mellitus (NIDDM). 
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Kobayashi 2002 
 
This study was a follow-up from Kobayashi 1996 (70) where one group received subcutaneous insulin 
injection (insulin group) and the other received oral sulphonylurea (SU group), during 36 months. C 
peptide responses to OGTT (Sigma C peptide) decreased progressively in the SU group and became 
significant at 24 and 36 months (21 ng/ml to 12 ng/ml, p<0.05). In contrast, the Sigma C peptide 
values remained unchanged in the insulin group (22 ng/ml to 19 ng/ml), and these values were 
significantly different from those of the SU group at 36 months (p<0.05). Two-hour blood glucose 
values to OGTT in the SU group increased (275 mg/dl to 350 mg/dl, p<0.05) during a follow-up period 
and became significantly higher than those in the insulin group at three years (p<0.05). Titers of 
GADb remained unchanged in both the insulin and the SU groups. 
This study concluded that if administered in the early stage of SPIDDM, a small amount of insulin 
instead of SU can intervene in or modulate progressive β-cell failure in SPIDDM. 
 
 
Maruyama 2003 
 
This study was a parallel randomized controlled trial comparing insulin with sulphonylurea 
(glibenclamide) (SU group) during 4 years. The changes in C-peptide response (ƩCPR) in the SU group 
decreased progressively from 22.0 ± 10.6 to 11.3 ± 7.5 ng/ml after 48 months (p<0.001 vs. baseline). 
However, this value in the insulin group was unchanged. No patient with a low GADA titer (<10 U/ml, 
equivalent to ~ 200 IU/ml in WHO standard) progressed to IDDM in either group. Among the high 
GADA titer subjects, 9 out of 14 in the SU group (64.3%) but only 2 out of 16 in the Insulin group 
(12.5%) developed IDDM (p=0.0068). Among those with both high GADA titer (≥ 10 U/ml) and 
preserved C-peptide response (ƩCPR ≥ 10 ng/ml), SU group subjects progressed to IDDM (7/12, 
58.3%) more frequently than insulin group subjects (0/14, 0%) (p=0.0012). 
This study concluded that small doses of insulin effectively prevent β-cell failure in slowly progressive 
T1D. 
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Maruyama 2008 
 
This was a 5-year follow-up from Maruyama 2003 (91), who examined insulin alone compared to SU 
alone (SU group). The C-peptide responses to OGTT progressively decreased in the SU group while 
in the insulin group C-peptide value increased at 12 and decreased at 24 months, and the values 
remained unchanged for up to 60 months. Repeated measures ANOVA revealed a significant time-
by-treatment-assignment interaction in all patients (p=0.005) and in group A patients (p=0.04) but 
not in group C (p=0.09). No significant interaction between time, treatment, and subgroup was 
evident. The 2-h blood glucose levels were significantly increased at the completion of study in both 
groups (insulin group: 352 ± 107 mg/dl (19.5 ± 5.9 mmol/liter), p=0.004 vs. baseline; SU group: 388 
± 116 mg/dl (21.5 ± 6.4 mmol/liter), p=0.001 vs. baseline). The fasting blood glucose value at 60 
months in the SU group (184 ± 65 mg/dl (10.2 ± 3.6 mmol/liter)) significantly increased compared 
with baseline (p=0.001), whereas in the insulin group (153 ± 59 mg/dl (8.5 ± 3.3 mmol/liter)) it did 
not. The FBG value at 60 months in the insulin group was lower than in the SU group (p=0.04). The 
HbA1c levels at the end of the follow-up in both groups (insulin group, 7.2 ± 1.6%; SU group, 7.7 ± 
1.4%) did not significantly differ from those at baseline. Insulin dependent state was evaluated and 
thirteen (43%) and three (10%) patients in the SU and insulin groups, respectively, progressed to an 
insulin-dependent state. The proportion of participants who progressed to an insulin-dependent 
state, when averaged annually over follow-up, was 11 and 2% per annum in the SU and insulin 
groups, respectively. The cumulative probability of progression to an insulin-dependent state 
significantly differed between the groups (p=0.003).  
The titers of GADA at the completion of the study in the insulin group (11.7 ± 29.0 U/ml) and the SU 
group (7.0 ± 6.0 U/ml) significantly decreased compared with baseline values (p=0.001 and p<0.001, 
respectively). Titers of GADA did not significantly differ between these two groups during the study. 
The BMI of the insulin and SU groups increased significantly at the completion of the study (21.3 ± 
2.5 Kg/m2, p=0.001, and 22.8 ± 4.1 Kg/m2, p=0.002 vs. baseline, respectively). 
This study concluded that insulin intervention to preserve β-cell function is effective and safe for 
patients with SPIDDM or LADA. 
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Palmer 2018 
 
This study tested recently diagnosed antibody positive T2D patients to determine whether treatment 
with rosiglitazone (4 mg once per day) results in greater preservation of β-cell function compared to 
treatment with glyburide (2.5 mg to a maximum of 10 mg twice a day).  In this trial, the fasting C-
peptide decrease in groups of patients positive or negative for autoantibodies treated with 
rosiglitazone (rosiglitazone autoantibody positive: -0.4 ± 1.0 ng/ml; rosiglitazone autoantibody 
negative: -1.4 ± 1.6 ng/ml). However, in patients positive or negative for autoantibodies treated with 
glyburide, the levels of fasting C-peptide increase (glyburide autoantibody positive: 0.1 ± 1.2 ng/ml; 
glyburide autoantibody negative: 0.3 ± 1.1 ng/ml). Glucagon stimulated C-peptide in autoantibody 
positive group showed the same tendency of glucagon stimulated c-peptide of autoantibody 
negative group (rosiglitazone autoantibody positive: -0.6 ± 1.6 ng/ml; rosiglitazone autoantibody 
negative: -2.8 ± 2.5 ng/ml, glyburide autoantibody positive: 3.1 ± 12.1 ng/ml; glyburide autoantibody 
negative: 0.3 ± 2.2 ng/ml). Some patients also showed reactivity of T cells to islet antigens. In the 
rosiglitazone autoantibody positive group 25% of the patients showed this reactivity, whereas in the 
rosiglitazone autoantibody negative group those were 20%. In the control groups, 28.58% and 
33.33% of the patients demonstrated this effect, in the glyburide autoantibody positive and negative 
groups, respectively. This study also reported several serious adverse effects: in the rosiglitazone 
autoantibody positive group one patient died (6.67%), while in the rosiglitazone autoantibody 
negative group one patient had atrial fibrillitation (6.67%) and another cholecystitis (6.67%). In the 
glyburide autoantibody positive group, there was no serious adverse effect reported and in the 
glyburide autoantibody negative group, one patient had a heart attack (4.76%) while two had a 
stroke (9.52%). Slight adverse effects such as hypoglycemia were only noticed in the glyburide 
autoantibody positive and negative groups, in which 7.69% and 4.76%, respectively, presented this 
symptom. 
This study concluded that rosiglitazone treatment ameliorate or slow the underlying disease process 
in antibody positive T2D. 
 
 
Thunander 2011  
 
This article was a 3-year follow-up study examining insulin alone compared to OHA (metformin 
and/or SU). Among the controls, the level of HbA1c increased significantly at 36 months from 7.0 
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(±1.3) % to 7.5 (±1.5) % (p=0.006). In the intervention group, there was no significant difference 
between HbA1c at baseline, 7.3 (±1.3) %, and after 36 months, 7.2 (±0.7) % (p=0.6). The differences 
between the groups in absolute levels of HbA1c were not significant either at baseline or after 12, 24 
or 36 months. C-peptide levels were unchanged in four patients, increased by mean 0.73 (±0.5) 
nmol/l in six and declined in all others after 36 months. Mean glucagon-stimulated C-peptide 
decreased significantly in both groups during the 36 months (p<0.0001). There was a significant 
trend for the decrease in C-peptide of 0.17 nmol/l per year (p=0.03), over 36 months, without any 
significant difference between the groups. In repeated measures, ANOVA with time as covariate, 
analysed the changes in C-peptide over time with the levels at baseline considered, and no 
differences could be found regarding mean-stimulated C-peptide at any time point, although the 
Mann Whitney U test on the difference in C-peptide at baseline was significant, p=0.03. There were 
large variations in C-peptide levels between different individuals, at all-time points, within both the 
groups (p<0.0001), explaining all the variation between them. When comparing the two treatment 
groups, the results of levels of FCP were in accordance with the described results of stimulated C-
peptide.  
This study concluded that early insulin treatment in LADA patients lead to better preservation of 
level of metabolic control, and it was safe and well tolerated. 
 
 
Yang 2009 
 
This randomized controlled study compared insulin (INS) with insulin with rosiglitazone (INS+RSG), 
SU and rosiglitazone (RSG) during 36 months. There was no significant difference in FCP value 
between the SUs group and the RSG group. The FCP level in the INS + RSG group did not decrease 
until the 36th month. However, the FCP level (0.38 ± 0.29 nmol/L vs. 0.57 ± 0.46 nmol/L, p< 0.05) in 
the INS group showed apparent decrease after the 6th month. The levels of 2-h postprandial C-
peptide (PCP) were higher in the RSG group compared with those in the SUs group after the 18th 
month. The PCP levels in the INS + RSG group were sustained, whereas the PCP level in the INS group 
decreased after the 12th month (0.71 ± 0.72 nmol/l vs. 1.35 ± 0.94 nmol/l, p< 0.05). The PCP level 
after the 12th month in the INS + RSG group were higher than those in the INS group. HOMA2-% β, 
in the SUs group tended to decrease at 18 months (57.87% vs. 87.62%, p< 0.05), and lower than the 
baseline at follow-up. HOMA2-%β was lower in the SUs group than those in the RSG group in the 
24th month (52.51% vs. 82.78%, p<0.05) and in the 36th month (43.27% vs. 73.46%, p< 0.05). The 
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HbA1c level attained a desirable level in the RSG group (6.80 ± 1.80 %, p<0.05) for 3 years, but not in 
the SUs group. In INS + RSG group the HbA1c value was lower than baseline in the first 12 months 
(6.32 ± 1.27, p< 0.05). Some adverse effects were observed: INS + RSG treatment was associated 
with an increased incidence of edema requiring diuretics when compared with INS (p< 0.05). 
Hypoglycemic attacks were similar in the INS group and the INS + RSG group. 
This study concluded that rosiglitazone combined with insulin wherever or not preserved β-cell 
function in LADA patients after 3 years. 
 
 
Zhou 2005 
 
This randomized controlled study examined insulin compared to insulin with rosiglitazone (4 mg/d) 
during 18 months. During 6 months’ follow-up, there were no significant changes for ΔCP and 
postprandial C-peptide (PCP) levels in both groups. This demonstrated that no obvious β-cell 
function decline occurred under insulin with or without rosiglitazone treatment in this period. At 12 
months’ observation, both PCP and ΔCP levels in insulin + RSG group patients stayed steady, with 
PCP from 1.30 nmol/l to 1.40 nmol/l (p=0.161) and ΔCP from 0.84 nmol/l to 0.83 nmol/l (p=0.161). 
In contrast, PCP levels in insulin group decreased significantly (from 1.68 to 0.61 nmol/l, p=0.028). 
During insulin treatment, ΔCP levels showed a decreasing trend but did not reach a statistical 
significance (from 0.86 to 0.26 nmol/l, p=0.066). Furthermore, PCP (0.24 vs −0.61 nmol/l, p=0.004) 
and ΔCP (0.36 vs −0.62 nmol/l, p=0.015) differences between 12th month and baseline were higher 
in insulin + RSG group than those in the insulin group. The above results indicated that insulin plus 
rosiglitazone treatment for 12 months, but not insulin alone, could preserve β-cell function. When 
observed up to 18 months, PCP and ΔCP levels in insulin + RSG group patients still stayed steady, 
with PCP 1.27 nmol/l to 1.37 nmol/l (p=0.237) and ΔCP from 0.76 nmol/l to 0.79 nmol/l (p=0.310), 
while in the insulin group, PCP and ΔCP levels decreased more. The daily insulin doses were less in 
the insulin + RSG group compared with those in the insulin alone group (14.8 vs 26.4 U/day, p=0.032) 
and the same pattern was observed for HbA1c levels between both groups. 
This study concluded that rosiglitazone combined with insulin may preserve islet β-cell function in 
LADA patients. 
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IV.5 Synthesis of results 
 
IV.5.1 Meta-analysis 
 
Meta-analysis is the process of integration of results using statistical methods to summarize and 
arrive at evidence synthesis of individual studies (103). By combining information from all the studies 
of interest, meta-analyses can provide more accurate data on the effects of interventions than those 
derived from the individual studies included within a systematic review. 
Considering the aim of this systematic review, the results related to the preservation of β-cell 
function and insulin resistance (such as parameters of metabolic control - HbA1c, FBG, PPG; insulin 
secretion; C-peptide levels and β-cell function) were pooled for the meta-analysis. Due to the variety 
of interventions only the most measured outcomes from each study were selected. Only studies that 
shared the same intervention and control drugs and outcome measures were grouped. However, 
even if fulfilling the criteria mentioned, other studies were excluded the of the group. For example, 
Davis 2005 (57) was excluded from the analysis due to stratification based on FBG level, not being 
possible to distinguish the differences of effect between groups. Kobayashi 2002 (90) and Maruyama 
2003 (91) also presented interventions similar to the included studies in the meta-analysis, but they 
did not provide necessary results for the inclusion, namely HbA1c and, for this reason, were also 
excluded. Therefore, the meta-analysis examining insulin alone compared to SU was performed 
combining Kobayashi 1996  (70) (30 months follow-up), Maruyama 2008 (83) (60 months follow-up) 
and Thunander 2011 (72) (36 months follow-up). 
At the same time, to provide more information about the different effects of possible treatment, a 
meta-analysis was carried out evaluating insulin alone compared to SITA and combined the following 
studies: Hals 2019 (76) (21 months follow up), Wang 2019 (84) (12 months follow up) and Zhao 2014 
(85) (12 months follow up). 
 
 
IV.5.2 Insulin vs SU  
  
The heterogeneity test (I2=77%) showed that the heterogeneity between studies may be due to the 
inclusion of Kobayashi 1996 (70) which presented a large IC (95% CI -4.72, -1.68) and low weight 
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(30.8%). This can be explained maybe due to the small sample size, when compared to the results of 
the other included studies. As the overall estimated effect shows the combined difference in HbA1c 
change from baseline to study endpoint (of -1.40% (95% CI -5.05 to 2.25); p = 0.01, 107 participants, 
3 trials), it can be concluded that the effect might be statistically significant (Figure 3 | Forest Plot: 
Insulin compared to Sulphonylureas). In addition, the present heterogeneity probably due to 
Kobayashi 1996 (70) could imply uncertainty in the effect of insulin compared to SU. So, more studies 
would be needed to provide more certainty to the intervention effect.  
 
 
Figure 3 | Forest Plot: Insulin compared to Sulphonylureas. Outcome: Mean Differences in HbA1c levels from 
baseline to endpoint. 
 
 
IV.5.3 Insulin vs SITA  
 
A heterogeneity test (I2=46%) was performed to examine the treatment effect of insulin versus SITA 
regarding the difference in Hb1Ac. Such test suggested a moderate evidence of heterogeneity. The 
combined HbA1c change from baseline to study endpoints were -0.07% ((95% CI -0.75 to 0.61)), the 
overall estimated effect showed a p value of 0.16 (134 participants, 3 trials), concluding that the 
effect might not be statistically significant (Figure 4 | Forest Plot: Insulin compared to Sitagliptin). 
Hence, other randomized controlled trials are needed to evaluate the effect of insulin compared to 
SITA, given the heterogeneity and inconsistent of the results.  
 
 77 
 
 
Figure 4 | Forest Plot: Insulin compared to Sitagliptin. Outcome: Mean Differences in HbA1c levels from baseline 
to endpoint 
 
 
IV.6 Risk of bias within studies 
 
Using the Cochrane Collaboration’s tool for assessing the risk of bias were constructed a summary 
of the results (Appendix 7 | Risk of Bias of the Included Studies). Overall, the random sequence was 
not performed in one study (Thunander 2011 (72)), the allocation concealment was not done in 
seven studies  (Awata 2017 (92), Cabrera-Road 2002 (71), Davis 2005 (57), Palmer 2018 (101), 
Thunander 2011 (72), Yang 2009 (96)), the selective reporting was not present in nine studies 
(Cabrera-Road 2002 (71), Davis 2005 (57), Hals 2019 (76), Johansen 2014 (98), Kobayashi 2002 (90), 
Li 2009  (94), Maruyama 2003 (91), Palmer 2018 (101), Zhang 2020 (93)), blinding of patients and 
personnel were not performed in ten studies (Awata 2017 (92), Cabrera-Road 2002 (71), Hals 2019 
(76), Kobayashi 1996 (70), Li 2009 (94), Maruyama 2008 (83), Palmer 2018 (101), Pozzilli 2018 (100), 
Thunander 2011 (72), Yang 2009 (96)), blinding of outcome assessment were not done in sixteen 
studies (Awata 2017 (92), Cabrera-Road 2002 (71), Davis 2005 (57), Hals 2019 (76), Johansen 2014 
(98), Kobayashi 1996 (70), Kobayashi 2002 (90), Li 2009 (94), Maruyama 2003 (91), Maruyama 2008 
(83), Palmer 2018 (101), Pozzilli 2018 (100), Thunander 2011 (72), Yang 2009 (96), Zhang 2020 (93), 
Zhou 2005 (95)), the incomplete outcome data was identified in ten studies (Cabrera-Rode 2002 (71), 
Davis 2005 (57), Hals2019 (76), Johansen 2014 (98), Kobayashi 2002 (90), Maruyama 2003 (91), 
Maruyama 2008 (83), Thunander 2011 (72), Wang 2019 (84), Zhang 2020 (93)) and other source of 
bias were founded in eight studies (Agardh 2005 (26), Agardh 2009 (27), Buzzetti 2016 (99), Davis 
2005 (57), Johansen 2014 (98), L-Hallin1999 (97), Yang 2009 (96), Zhao 2014 (85)).  
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To have reproducibility in the analysis and to be able to perform more analyses and graphical 
displays, a publication of summary data from each individual study should be performed. Thereby, 
the estimated effect with a confidence interval (IC=95%) was presented in a table (Appendix 7 | Risk 
of Bias of the Included Studies) for all included studies. A forest plot shows the study characteristics, 
such as the effect estimates and confidence intervals, the number of participants group-specific 
summary data and the percentage weight. This graphical presentation of the results of each 
treatment in included studies also gives information on individual study features. 
Therefore, from the analysis of the group testing insulin versus SU the results from individual studies 
were the following: in Kobayashi 1996 (70) from 10 individuals result (-3.20 ± 0.78) MD±SD, in 
Maruyama 2008 (83) from 60 individuals result (-0.60 ± 0.60) MD±SD, in Thunander 2011 (72) from 
40 individuals result (-0.60 ± 0.55) MD±SD. In the group comparing insulin to SITA the results from 
individuals’ studies were: in Hals 2019 (76) from 64 individuals result (-0.50 ± 0.29) MD±SD, in Wang 
2019 (84) from 40 individuals result (-0.03 ± 1.00) MD±SD, in Zhao 2014 (85) from 30 individuals 
result (-0.10 ± 0.12) MD±SD. The results of the trials assessing the risk of bias are summarized in 
Appendix 8 |Summary Results of Risk of Bias Across Studies and Appendix 9 | Traffic Light Plot: Risk 
of Bias of the Included Studies. 
 
 
IV.7 Risk of bias across studies 
 
Usually, tests to evaluate the funnel plot asymmetry can only be used when there are, at least, ten 
studies included in the meta-analysis. This is explained because when there is a low number of 
studies the power of the tests is very low to verify real asymmetry. The same happens with the 
Egger’s test results (in the Insulin vs SU: -13.89 with 95% CI (-15.67 to -12.14) and a p value of 0.04; 
Insulin vs SITA: -3.41 with 95% CI (-5.18 to -1.65) and a p value of 0.16). Although there was a 
significant risk of publication bias (p>α) in the insulin versus the SITA group, it was impossible to take 
any conclusion from the funnel plots (see Appendix 10 | Funnel Plot: Insulin compared to 
Sulphonylureas and Appendix 11: Funnel Plot: Insulinu compared to Sitagliptin), as well as from the 
Egger’s test, due to the fact that less than ten studies were analyzed. 
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IV.8 Additional analysis  
 
The sensitive analysis (Appendix 12 | Forest Plot: Sensitive Analysis), showed that removing only 
Kobayashi 1996 (70) from the meta-analysis (Figure 5 | Forest Plot: Sensitivity Analysis of Insulin 
compared to Sulphonylureas), in the Insulin versus SU, caused differences in the overall effect, 
namely by not presenting results of overall effect. Thus, in this case, the results showed that there 
was no effect in the intervention group. The remaining analysis did not present any changes to the 
overall effect.  
 
 
Figure 5 | Forest Plot: Sensitivity Analysis of Insulin compared to Sulphonylureas. Outcome: Mean Differences 
in HbA1c levels from baseline to endpoint, removing Kobayashi 1996 (70).  
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CHAPTER V: DISCUSSION 
 
V.1 Main Results 
 
As previously mentioned, LADA is described by both pancreatic β-cell impairment and insulin 
resistance (104). Typically, individuals with LADA have higher levels of fasting blood glucose and 
HbA1c, which may indicate a lower prevalence of metabolic syndrome, a higher frequency of thyroid 
peroxidase autoantibodies (65), a higher frequency of risk haplotypes for HLA and a greater 
probability for insulin dependence (68,69). At the same time, these patients show less stimulated C-
peptide response, which may indicate a loss of β-cell function. Thus, it is important to consider all 
the metabolic control and insulin secretion parameters to better diagnose an individual with LADA, 
instead of assuming that T2D individual’s positivity for GADA can be classified as LADA. 
Some authors believe that this management may result in a fast progression to an insulin-dependent 
state (45,69). Nevertheless, several studies have been carried out to test different treatment 
strategies. Thus, therapy for LADA should aim to achieve good metabolic control as well as to 
preserve residual β‐cell function in order to reduce the risk of long-term complications. Although 
different recommendations are known for treatment of T1D and T2D, so far, no specific guidelines 
have been published on medical treatment for individuals with LADA. As a consequence, most 
patients with LADA are initially treated with therapies intended for non-autoimmune forms of 
diabetes mellitus due to misdiagnosis and lack of recommendations specific to the disease (17,19). 
Therefore, due to the scarce sources of investigation in this topic and the scanty clinical trials, the 
therapy of LADA patients is mostly based on the experience obtained from T1D and T2D treatments. 
This chapter covers a systematic review of twenty-two publications (29 trials) that reported 
interventions directed to LADA and assesses the implications and the limitations of such studies. 
 
 
V.1.1 Strategies for intervention in LADA 
 
The prevalence of all-cause mortality, cardiovascular disease and microvascular complications in 
LADA compared to T2D, determined the need for clinical trials specifically designed for LADA patients 
(47,48,105,106). Liu et al., suggest that some conventional oral hypoglycemic agents may accelerate 
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β-cell failure in LADA, while some may provide extra benefits (7). This and other approaches will be 
further discussed, considering the results of the studies included in this review and the existing 
general referring to LADA. Its important to notice that therapeutic strategies for LADA should 
preferentially focus on attenuation of long-term complications related to diabetes by perserving the 
residual β-cell function (17,19). Besides the preservation of β-cell function, which stop autoimmune 
destruction and promote regeneration of β-cells (73,107), the aim of LADA interventions should 
include the control of plasma levels of glucose for better clinical outcomes related to the metabolic 
response, insulin secretion and a decreased risk of complications (82,108). Measures associated with 
the development of complications such as metabolic control (HbA1c, fasting blood glucose and 
postprandial glucose) and insulin secretion levels (C-peptide levels (fasting, stimulated and 
postprandial)) were reported.  
A number of therapies are analysed below, considering the type of interventions presented in this 
review, the adverse events as consequence of possible complications and the limitations of the 
studies. 
 
 
Insulin therapy 
 
Insulin administration is believed to be the preferred treatment in patients with complete loss of β-
cells function as it has the ability to replace endogenous insulin secretion (17). However, in the case 
of patients with LADA, it remains controversial as they show a slower progression towards insulin 
dependence. This could be demonstrated by the higher C-peptide levels at the beginning of the 
disease.  
Despite the controversy in the administration of insulin to patients with LADA, consistent data from 
clinical trials refer to the importance of an early start in treatment with insulin, regardless of the 
presence of some secretion of endogenous insulin. This approach seems to preserve β-cells function, 
to improve metabolic control (37) and to decrease the severity of insulitis (109). Other studies also 
report that exogenous insulin (110,111) has the ability to promote the change of the Th1 immune 
response to Th2 and the activation of insulin-specific regulatory T cells (49,112,113). Insulin is also 
known as an important autoantigen in diabetes and it is believed that immunization with exogenous 
insulin would determine immunological modulation possibly by inducing tolerance or bystander 
suppression of autoreactive T-cells through the local release of regulatory cytokines (114). 
Therefore, reducing the function of β-cells might enhance antigen expression, leading to decreased 
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T cell potency against immunological targets, as reported by Koufakis et al. (74). So far, clinicians 
have tended to prescribe insulin therapy at an early stage in patients with LADA, regardless of C-
peptide levels and β-cell residual function. 
Buzzetti et al. (17) revealed that progression to an insulin-dependent state in patients with LADA 
differs. This can be based on clinical and biochemical characteristics (45,69), since individuals with 
high GADA titers have a higher risk of early insulin dependence, while a late onset of the appearance 
of the disease seems to be associated with a lower risk in the need for insulin therapy. Such 
dichotomies raise the question of the use of insulin therapy in LADA patients with low levels of GADA 
and who are older, who face an increased risk of suffering adverse effects related to hypoglycemia.  
Even though the evidence that insulin therapy may be protective for β-cell function (115,116), 
several studies suggested that some hypoglycemic agents could play an important role slowing down 
β-cell failure but insulin appears to be the preferential approach (70,72,83,85,95,98–100). 
In Cabrera-Rode et al. (71) and Kobayashi et al. (70), patients receiving insulin alone had improved 
markers of autoimmunity by becoming ICA negative. Metabolic control (related to FBG parameter) 
was significantly improved with insulin monotherapy at 12-months therapy (71), and, in a later study, 
it showed a decrease in PBG from the baseline values, although the Hb1Ac remained unaltered 
during the 30 months (70). Regarding C-peptide levels, in Kobayashi et al. the insulin-treated group 
had an increased SCP rate at 30 months (70), supported by Maruyama et al. that reported a 
preservation of the serum C-peptide rate over 5 years (83), suggesting that the high titer GADA 
patients with early administration of small doses of insulin were less likely to advance to the insulin-
dependent stage.  
In fact, some studies suggested that early insulin treatment may decelerate the decline in β-cell 
function, while SU seems to reveal earlier the insulin dependence in LADA patients (57,70,83,90,91). 
However, Thunander et al. concluded that the insulin intervention in LADA patients showed better 
metabolic control (HbA1c) but presented a decline of C-peptide levels compared with conventional 
therapy (diet and oral hypoglycemic agents (OHA), or metformin and/or sulphonylurea) during at 
least 3 years of follow‐up.This goes against the study above on the preservation of the β-cell function 
(72). UKPDS 70 found that LADA patients treated with SU compared with insulin alone or diet need 
insulin quicker. Also, in the NIRAD study 7, the SU group showed a faster requirement for insulin 
than those in diet and/or insulin sensitizers (57,69). The probable underlying mechanism is that 
exogenous insulin allows for β-cell function cessation and then decreases autoantigen exposure, 
while SU could lead to β-cell collapse by stimulating insulin secretion and, consequently, enhancing 
autoantigen expression (116–118).  
 86 
Cernea et al. defend that the decline of rapid insulin release occurs early in LADA, therefore, the 
replacement with fast-acting insulin might be better. In practice, it might be difficult to initiate 
multiple insulin injections therapy in these patients, especially if their metabolic control is 
deregulated. So, a long-acting insulin injection might be a good alternative (73). Notably, based on a 
study that showed that insulin failed to prevent the onset of diabetes in individuals with 
predisposition to T1D (119), Koufakis et al., argue that this might explain why insulin should not be 
considered the one and only therapy of slow-onset autoimmune diabetes management.  
Thus, it has not yet been realized whether insulin therapy is indicated as an initial approach for 
patients with LADA or if represents a good treatment approach on its own (16). 
 In this context, insulin therapy requires specific studies to prove its real benefit treating LADA 
patients. 
 
 
Sulphonylureas 
 
Sulphonylureas are a class of hypoglycemic agents that are commonly used in the treatment of 
patients with diabetes who are not insulin dependent (120). This type of treatment can promote the 
release of insulin from pancreatic cells and lead to a decrease in blood glucose levels.  
Several studies have analyzed the effect of these compounds on the treatment of patients with 
LADA. A randomized control trial (57) compared conventional treatment (diet) with treatment with 
SU and with treatment with insulin. It was concluded that patients with positive autoantibodies 
treated with SU progressed faster towards the need for insulin than patients with negative 
autoantibodies. Also, in this treatment arm, metabolic control was not achieved. These data suggest 
once again that the use of SU may accelerate the need for insulin when compared to conventional 
intervention.  
Two other studies compared treatment with SU (glibenclamide) with treatment with insulin in 
patients with LADA. The first study (70,90) reported that at the end of the trial, the SU group had 
worse metabolic control and showed a progressive deterioration of β-cell function, as measured by 
a significant reduction in C-peptide levels. That same study also reported that patients treated with 
SU become insulin dependent at the end of 24 months. Similar to the previous study, Maruyama et 
al.(83), reveal that the group that received SU therapy progressed to an insulin-dependent stage as 
well as C-peptide levels during the OGTT were more preserved in patients undergoing insulin 
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therapy. Moreover, there is evidence that metabolic control in terms of HbA1c and FBG is higher in 
treatment with insulin when compared to treatment with SU. 
Given this information, treatment with insulin appears to be preferable to treatment with 
sulphonylureas. However, another study (98) compared treatment with a DPP-4 (linagliptin) with 
treatment with sulphonylureas (glimepiride) and concluded that, despite SU appeared to have better 
metabolic control, C-peptide levels, in SU group, have decreased significantly. This may indicate 
unregulated insulin secretion and, consequently, poor preservation of β-cells as already mentioned. 
The majority of the studies investigating this therapy revealed that treatment with sulphonylureas 
may be associated with worse metabolic control than insulin treatment, with earlier progression 
towards an insulin-dependent state (59,84,86,87,93,94). Therefore, it was recommended that SU be 
avoided in favor of early insulin treatment (16). However, only Brophy et al. defend this (59) and 
seem not to take into consideration the need for a personalized medicine approach, as advised by 
the international guidelines for the treatment of diabetes mellitus in adults (121). 
However, despite the apparent initial efficacy, there appears to be a gradual reduction in insulin 
production capacity and a consequent deterioration of glycemic control.  This may be related to the 
exhaustion of β-cells (116–118) by prolonged exposure to treatment, which may trigger oxidative 
stress and apoptosis (122), as well as leading to increased β-cell antigenic expression and 
exacerbation of the autoimmune process (116–118,123). Thus, SU should be avoided as a 
preferential treatment in patients with LADA as it could accelerate cell depletion and the consequent 
need for insulin therapy (70,71,83,97). 
Although it is difficult to generalize these results because all studies had different selection criteria, 
different outcome parameters and follow-up durations, they all suggest that sulphonylureas 
progressively accelerate cell degeneration and fail to achieve good metabolic control and, therefore, 
it should not be the preferred therapy in patients with LADA (16,17). 
 
 
DPP-4 
 
Over time, dipeptidyl peptidase 4 (DPP-4) inhibitors have received increasing attention due to their 
potential benefits in immune modulation and preservation of β-cells in patients with LADA. These 
inhibitors are often used in T2D as they have been shown to preserve β-cell function and reduce 
insulitis. Likewise, DPP-4 improved glycemic control in adults with T1D (124). In animal models, these 
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inhibitors could delay or reverse T1D since they induce proliferation of β-cells (125,126), lead to a 
positive balance in T cells (127,128) and inflammatory cytokines (129), and could also positively 
impact LADA's regression. The action mechanism of these inhibitors focuses on controlling blood 
glucose, triggering pancreatic insulin secretion, suppressing pancreatic glucagon secretion and 
signaling the liver to reduce glucose production. In a study of Barnett et al., the main DPP-4 inhibitors 
showed clinically significant reductions in HbA1c and offer many advantages such as low risk of 
hypoglycemia, no effect on body weight and potential for regeneration and differentiation of 
pancreatic β-cells(130). 
Several studies were conducted in this regard and a one-year randomized controlled trial found that 
the combination of insulin and sitagliptin treatment outperformed insulin alone treatment by 
maintaining highest C-peptide levels (85). Similar results were found in Awata et al.(92), where C-
peptide levels increased in response to the OGTT in the sitagliptin group. As well as the metabolic 
control that was also achieved most effectively. Yet, another recently published study (76), showed 
that sitagliptin and insulin have a similar effect, even if no differences were seen in preserving the 
function of β-cells, they seem to have an increased effect on metabolic control. 
Other studies have reported similar benefits of saxagliptin (99) and linagliptin (98). One study 
mentioned (99) that saxagliptin appears to improve metabolic control and to be effective in 
decreasing blood glucose levels and leading to the preservation of β-cells by increasing levels of C-
peptide. In Johansen et al.(98), the same results were observed, since treatment with linagliptin 
managed to mitigate the decline in C-peptide levels. 
In every study mentioned above, DPP-4 seems to be an effective treatment to combat LADA, since 
evidence showed that these agents have positive results in both metabolic control and preservation 
of β-cell function. 
 
 
Insulin Sensitizers 
 
Insulin sensitizers have been shown to be useful in individuals with autoimmune diabetes since these 
patients also presented characteristics of metabolic syndrome and a certain degree of insulin 
resistance (73,96).  
Insulin sensitizers, such as metformin or thiazolidinediones, are useful for controlling glucose levels 
in T2D patients, especially in cases where insulin resistance is an important factor in dysregulation 
of glucose metabolism (74). In T2D mouse models, it was demonstrated that thiazolidinediones 
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improve insulin content and secretion maintainance, the structure of pancreatic islets, improve the 
protection of β-cells from oxidative stress and apoptotic stimuli, the preservation of β-cell mass and 
the promotion of their proliferation (131,132). Also, it has been shown that, in T1D, metformin 
reduces body weight, total daily insulin dose, total cholesterol and LDL levels (131).  
As it is known that individuals with LADA generally show some degree of residual β-cell function, 
treatment with insulin sensitizers should be a promising intervention since it aims to protect and 
stimulate β-cell regeneration. Beanes et al., tested metformin in NOD mouses with autoimmune 
diabetes, however it did not seem to affect the course of the disease (133). Pozzilli et al., also believe 
that this could indicate that this drug does not interfere with the pathogenic process and could lead 
to β-cell destruction (123). Moreover, there are still no studies evaluating the specific role of 
metformin in LADA in isolation. In addition, there seems to be a potential risk associated with its use, 
such as the occurrence of lactic acidosis in patients who progress to insulin dependence in studies 
of T2D patients (123).  
Thiazolidinediones (TZDs), in turn, are a more attractive therapeutic approach because, in addition 
to their effect on glucose homeostasis and lipid metabolism, there is evidence that they have 
benefits in the preservation of β-cells (122), by improving insulin content and secretion, preserving 
β-cell mass and islet structure, having anti-inflammatory effects, protecting cells from oxidative 
stress and apoptosis and even facilitating cell proliferation (132,134). Given these characteristics, 
TZDs may constitute a potential therapy for LADA. In a published study, rosiglitazone has been shown 
to inhibit the progressive functional decline of β-cells when combined with insulin, demonstrated by 
stable C-peptide levels over an 18-month follow-up period (95). Similar positive results have been 
reported in metabolic control and preservation of β-cell function in cases treated with pioglitazone 
(135). Another recent study compared the administration of rosiglitazone plus insulin, administration 
of rosiglitazone alone, and the administration of insulin alone (96). It concluded that, in the 
rosiglitazone group, the metabolic control was not achieved, whereas in the rosiglitazone plus insulin 
group HbA1c went down and, therefore, observing an improvement in metabolic control. Regarding 
the preservation of β-cells, both groups (rosiglitazone and rosiglitazone + insulin) obtained a 
significant increase in C-peptide levels, indicating a positive effect of the intervention. In contrast 
with these results, Palmer et al., compared the administration of rosiglitazone with glyburide and 
concluded that decreased C-peptide levels could indicate a lower preservation of β-cell function 
(101). 
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Although insulin sensitizers appear to have positive effects on the preservation of β-cells, there are 
still insufficient data to infer their real potential as a treatment, since there is great variability 
between studies and it is difficult to conclude with clarity what the real effect of these agents are. 
In conclusion, eventhough Cernea et al. stated that LADA patients can benefit from therapy with an 
insulin-sensitizing drug that may improve the peripheral action of insulin and protect cells from 
continuous insulin hyperstimulation (73), this cannot be confirmed due to the scarce number of trials 
performed in this area. 
 
 
GPL-1 agonist 
 
GLP-1 are a new class of pharmacological agents developed to improve metabolic control in patients 
with T2D and have also indicated positive effects on body weight and total daily dose insulin in T1D 
(136). The positive effects on blood glucose are mediated by a variety of independent β-cell 
mechanisms, such as glucagon suppression and increased tissue sensitivity to insulin (137). The most 
advanced drug in this class is exendin-4, which acts as a complete glucagon-like peptide receptor 
(GLP)-1 agonist and has glucoregulatory actions, in addition to decreasing gastric emptying and 
reducing the intake of food (137). In addition, it has been shown that exendin-4 in vitro has the ability 
to modify susceptibility to apoptotic damage, to stimulate cell proliferation and the isogenesis of 
islet cells (138). Thus, reports that associate exendin-4 with increasing cell mass, in addition to its 
glucose-reducing effects, encourage its use in the treatment of LADA. Current clinical trials also test 
the hypothesis of using these agents at the time of islet transplantation as it could be useful in 
preserving the islet mass (139). The logic behind the use of GLP-1 in LADA is based on preclinical 
data, indicating that these agents can inhibit apoptosis and promote β-cell neogenesis (140). 
However, data in humans are limited. Even so Pozzili et al.(100), analyzed data from three clinical 
trials that tested the administration of dulaglutide (a GLP-1). The authors concluded that dulaglutide 
was able to significantly reduce HbA1c levels and increase β-cells function markers in T2D patients, 
among whom there were some patients who tested positive for GAD antibodies. Thus, the efficacy 
of dulaglutide in individuals with LADA was indicated by a reduction in HbA1c and an increase in β-
cell function, without affecting the hypoglycemia rate during the observation period. Although these 
initial results seem promising, further studies are needed to assess whether these therapies translate 
into reduced progression to insulin dependence and diabetic complications (100).  
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Immune modulation therapy 
 
An intervention intended to preserve β-cell function should be pursued in patients with LADA. Recent 
immune-intervention trials have achieved promising results in terms of preserving stimulated C-
peptide levels and improving glycemic control. This fact is corroborated by Pozzilli et al., believe that 
immune modulation therapy could be an interesting intervention in LADA patients, due to the slow 
progression to β-cell failure (107).  Neverthless, a common challenge in this type of studies with 
antigen‐specific therapies is to define the optimal timing, routes, dosage, and frequency of antigen 
administration, which may even be individualized (141). 
The specific immune modulatory therapies against T1D can be categorized as anti‐inflammatory 
(such as anti‐TNF‐α antibodies), antigen‐specific therapies (as GAD, proinsulin) and immune‐cell 
directed (for example anti‐CD3 antibodies, anti‐CD20 antibodies) (142). Homann et al., defends that 
the main aim of autoantigen immunization is to promote anergy in self‐reactive T cells and induce 
regulatory lymphocytes in a bystander suppressive manner (143). 
As an autoimmune disease caused by failure to maintain tolerance to autoantigens, LADA could be 
managed through administration of autoantigen. This may be an effective way of controlling the 
autoimmune process by inducing tolerance through deviation of the Th1 phenotype of the antigen-
reactive cells towards a more favourable Th2 phenotype. 
The literature shows that the advantageous effect of an immune intervention in LADA keeping 
residual β-cell function depends on some factors such as age at diagnosis, metabolic control, and 
extension of β-cell destruction that might be influenced by HLA genotypes (144). In this context, 
Spoletini et al. suggest that patients owning a moderate- or low-risk HLA genotype, as is the case in 
LADA, may have better residual β-cell function (144), which could mean that after immune 
intervention, these LADA patients may benefit more in terms of β-cell protection. However, to 
assume that different HLA genotypes associated with LADA can affect the results in terms of β-cell 
function is still premature.  
Several immune intervention trials that focused on LADA have been carried out and have shown a 
possible efficacy in preserving SCP levels and improving metabolic control (26,145). 
Until now, the antigens that have been used as tolerogens in LADA are the following: heat shock 
protein (HSP) (146), peptide of HSP60 (DiaPep277®) (147,148), and GAD (26,27). Raz et al., showed 
that DiaPep277® could preserve C-peptide levels, as the intervention group had improved mean C-
peptide levels and required less exogenous insulin to obtain an improvement in metabolic control 
(HbA1c) than the placebo group. In this study, the intervention group had a change of the T-cell 
 92 
response to HSP60 from a proinflammatory Th1 to a predominant Th2 phenotype (147). Schloot et 
al., also studied Diapep277® in terms of β-cell function but obtained negative results (142). 
Christgau et al., considered that the 65-kDa isoform of GAD (GAD65 (Diamyd®)) is found in β-cells 
and can be an autoantigen in autoimmune diabetes (145). Falorni et al., referes that antibodies to 
GAD65 may be found in the majority of T1D patients and that GADA is the most sensitive 
autoantibody marker for LADA (149). In this context, Diamyd® were evaluated in LADA patients and 
after 24 weeks, the 20µg dose group showed an increase from baseline in the mean log FCP and log 
SCP levels (26). Regarding metabolic control, an increase in the FBG and Hb1Ac was not seen in 
placebo and 4 µg. In comparison, a decrease of these measures was reported in the groups receiving 
higher doses (20, 100, and 500µg) of GAD65. No study reported adverse effects. A phase II clinical 
study of Agardh et al.(26), stated that LADA patients treated with 20µg of Diamyd® revealed 
increased FCP and, therefore, with a probably reduced risk of starting insulin treatment after 5 years 
of follow‐up compared with placebo group (27). 
As the set of antigens, which are the primary target of the immune attack in autoimmune diabetes, 
is not yet well-defined, considerable efforts have been devoted to non-antigenic immune 
interventions. Thus, anti-CD3 (anti-CD3) monoclonal antibodies may constitute a treatment strategy. 
Although the exact action mechanisms of anti-CD3 are not yet fully understood, there are several 
interventions possibilities: induction of antigenic modulation, anergy and/or apoptosis in activated 
cells and immunological tolerance through adaptive Tregs (150). In two T1D studies, positive results 
were observed using two different anti-CD3 drugs. Both observed the preservation of β-cell function 
with the maintenance of greater endogenous insulin secretion and better metabolic control 
(151,152). This could be a possible beneficial intervention also for patients with LADA. 
From the studies presented above, it is clear that the immune modulation therapies is a recent 
approach, although it seems to be promising. In conclusion, given the heterogeneous variance in 
genetics and islet autoimmunity among LADA patients, therapeutic strategies must be personalized. 
As the mechanism of immune dysfunction in autoimmune diabetes is unreliable, there is still a need 
for investigation in specific immune therapies. 
 
 
Vitamin D 
 
Vitamin D seems to play a role in the pathogenesis of autoimmune diabetes. In animal models 
1α,25(OH)2D3 (calcitriol) was shown to modify the balance in regulatory T cells as well as alter 
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autoimmunity by affecting T cell differentiation and dendritic cell action and by promoting cytokine 
secretion (153). This way, high doses of calcitriol in NOD mice resulted in enhancement of chronic 
insulitis and in a decrease of diabetes prevalence (154). This suggests that vitamin D may have the 
potential to stop the disease progression, even when it is administered after initiation of the 
autoimmune process. Grammatiki et al., observed that, for nonspecific immune therapy, vitamin D 
may have a protective roll in both immune system and insulin sensitivity (155). The prevalence of 
both T1D and T2D associated with vitamin D deficiency have been reported by some epidemiological 
studies (156–158). Yet, the evidence to support vitamin D supplementation as an intervention to 
prevent T1D or improve metabolic control and insulin resistance in T2D appears to be insufficient 
(159–161). Zhou et al., showed that the prevalence of LADA was higher when the duration of 
sunshine is shorter (162). So, it may be hypothesized that lower concentrations of vitamin D seem 
to be associated with LADA, as observed in T1D and T2D. Although this needs to be clarified it seems 
vitamin D had a surprisingly favorable effect on β-cell preservation in LADA patients. A sustainable 
effect on metabolic control over a 2-year period has been demonstrated in one individual with LADA 
who received combined therapy with sitagliptin and vitamin D (163). In 2014, an observational study 
reported that fatty fish consumption may reduce the risk of LADA. However, it remained unclear if 
the appearing benefits could be attributed to omega‐3 fatty acids, vitamin D, or the combination of 
both (164). A study by Li et al. showed stable or increased fasting C-peptide after 1 year in the 
majority of recently onset LADA patients treated with vitamin D3 plus insulin, while this outcome in 
the insulin alone group was lower (94). Another study conducted by Zhang et al. reported increased 
levels of C-peptide in vitamin D3 plus saxagliptin (93). This could indicate a regulation in insulin 
secretion. 
In summary, it is still unclear whether vitamin D deficiency could be associated with LADA. Additional 
large‐scaled, randomized controlled trials for LADA are needed to clarify the role of vitamin D in the 
preservation of β-cell function. 
 
 
Combined Treatment 
 
As mentioned earlier, neither insulin nor other hypoglycemic agents alone seem sufficient to control 
metabolic parameters and to protect β-cells function. In this context, combined therapies to delay 
disease progression in patients with LADA may be a potential approach. Some authors suggested an 
effect of DPP-4 inhibitors and vitamin D on autoimmune diabetes (163,165). Based on Buzzetti et al. 
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and Pozzilli et al., DPP-4 inhibitors and GLP-1RAs might be used in LADA as an add-on therapy to 
other antiglycemic medication to sustain failure β-cell function (114,116). This was done by using a 
combination between the DPP-4 and an insulin sensitizer and the addition of an insulin sensitizer 
and a SU to the dulaglutide and glargine treatments, respectively. Also, other types of combinations 
were studied such as SU with insulin  and are reported in Cabrera-Rode et al. (71) and L-Hallin et al. 
(56). The first group of investigators compared the effect of insulin treatment with the combined 
treatment of sulphonylureas (glibenclamide) with insulin and assessed metabolic control as well as 
insulin secretion. After one year of treatment, they concluded that the group that received insulin 
obtained greater metabolic control than the sulphonylureas plus insulin group. Regarding insulin 
secretion, no differences were found between groups (71). The other study evaluated the effect of 
the combined treatment of sulphonylureas (glibenclamide) and supported the hypothesis that 
individuals with positive autoantibodies should not receive this therapy as they are less likely to 
respond to it (97). 
Other interventions based on the combination of drugs compared administration of rosiglitazone 
plus insulin with administration of insulin alone (95). They concluded that, at the end of 12 months, 
patients in the rosiglitazone plus insulin group had better metabolic control with HbA1c showing 
lower values. However, after 18 months, this control was not achieved. Regarding the function of β-
cells, the insulin group had a significant decrease in C-peptide levels revealing poor preservation of 
the function of these cells while in the rosiglitazone plus insulin group those levels were maintained. 
Thus, although rosiglitazone plus insulin did not significantly improve metabolic control when 
compared to the insulin group, it appears to have a beneficial effect maintaining C-peptide levels. 
Another recent study compared the administration of rosiglitazone plus insulin, rosiglitazone alone 
as well as administration of insulin alone (96). A significant increase in C-peptide levels was observed, 
indicating a positive effect on preservation of β-cells function. These findings may lead to a better 
understanding about the beneficial effects of a combination therapy for LADA. Although not stated 
in the two articles, the eligibility criteria and intervention protocol of the studies appears to assume 
a combination therapy (whether with insulin or with oral antihyperglycemic medications) 
(26,72,76,84,85,98,101). 
In summary, the combined treatment appears to have positive effects delaying the disease 
progression. However, although scarce, the majority of the studies reflect the possibility of a therapy 
that can result from two or more drugs combined. 
It can be concluded that small doses of insulin given early after diagnosis appeared to be beneficial 
maintaining β-cell function. Also, as shown by meta-analysis, there is evidence suggesting that insulin 
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is preferable for metabolic control (thoug considerable heterogeneity was presented). So, despite 
the potential to suppress autoimmunity, insulin could increase the risk of hypoglycemia and weight 
gain.  
Sulphonylureas seemed to provide no differences in metabolic control compared with insulin alone. 
Contrarilly, SU may lead to earlier insulin dependence. Therefore, the majority of authors 
recommended that sulphonylureas should not be used as first-line therapy as there is no significant 
evidence that SU could be preferable to other forms of treatment of LADA. DPP-4 inhibitors although 
demonstrated immunoregulatory properties and a potential role in preserving β-cell viability and 
function, and showed minimal effects on glycemic control.  
Although insulin sensitizers like metformin or thiazolidinediones appear to have positive effects on 
the preservation of β-cells, the data to infer their real potential as a treatment is insufficient.  
GLP-1 receptor agonists seem to have optimal effects on HbA1c levels and β-cell function, although 
they presented gastrointestinal side effects and few studies covered this topic to be able generalize 
its promising effect.  
Regarding the autoimmune pathogenesis, using immune modulation therapies may be beneficial, 
but clinical studies should clearly demonstrate their potential in LADA and investigate specific 
immune therapies before further therapy plans could incorporate them in the effort to stop the 
disease progression.  
Considering the studies mentioned above that included Vitamin D in the treatment, although it 
seems to play a role in the pathogenesis of autoimmune diabetes, the results are very scarce and its 
association with LADA remains unclear.  
 
 
V.2 Limitations 
 
V.2.1 Limitations related to study and review 
 
A number of issues occurred during the systematic research: query construction and search in each 
electronic database, no access to some articles and its outcomes (see Appendix 3 | Excluded Studies), 
no availability of published results, heterogeneity of interventions and approaches and limited trials 
directed for LADA. 
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The studies in this review reported the results of randomized controlled trials. However, the 
randomization was performed differently across studies and, for that reason, may lead to a 
discrepancy in results and probably some bias in individual study or within studies (Appendix 7 | Risk 
of Bias of the Included Studies). 
Also, only four trials (Agardh 2009 (27), Davis 2005 (57), Palmer 2018 (101) and Thunander 2011 
(72)) reported the intention-to-treat principle and others were not clear on this aspect which could 
lead to overestimation of treatment effect in these trials. Additionally, the power of each study was 
not stated, with the exception of Hals 2019 (76) and Maruyama 2008 (83). This calculation could 
indicate the quality and the risk of bias and improve generalization if future studies recorded 
clinically relevant outcomes. The power of the studie is indeed a factor that should be considered. 
Moreover, the differences in selection criteria for LADA (shown in Table 3 | Selection criteria for 
LADA), the stratification of patients before randomization taking into considerations some 
parameters and analytic levels (like FBG, GADA titers and BMI) and the different or lack of description 
of treatment regimes, presented a problem in the interpretation of results.  
 
 
V.2.2 Limitations related to inclusion criteria 
 
The current definition of LADA is vague and ambiguous since, as the American Diabetes Association 
stated, it includes any adult who does not require insulin and who is positive for at least one diabetic 
autoantibody, regardless of titer or number (166). So, there is no consistent criteria established to 
classify someone as an individual with LADA. The majority of studies were aimed at  T2D patients 
who were retrospectively identified as being antibody positive (Agardh 2005 (26), Agardh 2009 (27), 
Awata 2017 (92), Cabrera-Rode 2002 (71), Davis 2005 (57), Johansen 2014 (98), Kobayashi 1996 (70), 
Kobayashi 2002 (90), L-Hallin 1999 (97), Pozzilli 2018 (100), Yang 2009 (96)) or diabetic patients 
diagnosed by 1999 WHO Diabetes Criteria (167) (Wang 2019 (84), Zhang 2020  (93), Zhao 2014 (85), 
Zhou 2005 (95)) or diabetic patients diagnosed by the American Diabetes Association Standards 
(ADA) (168) (Li 2009 (94), Maruyama 2003 (91), Maruyama 2008 (83)), diabetes non-insulin 
dependent (Buzzetti 2016 (99), Hals 2019 (76)), not LADA patients. 
In the studies reviewed, the inclusion criteria for LADA diagnosis seemed quite arbitrary. Starting 
with the age limit for LADA diagnosis which varies among studies (169). In different studies, the 
minimum cut-off age for LADA diagnosis can vary between 18 and 79 years-old. A study from China 
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(69) set up the age limit at 15 years-old, which could lead to question whether LADA is or should be 
exclusively considered an “adulthood diabetes”. Thus, Rolandsson et al. defend that the “whole 
picture” of diabetes and other phenotypical and laboratory features of each individual patient should 
be captured (169).  
The presence of diabetes autoantibodies, which are detected in the majority of people with LADA 
(123), has also made it difficult to define whether a patient is classified with LADA or T2D. Koufakis 
et al. stated that a reasonable criterion for characterizing diabetes as autoimmune could be 
debatable if this only take into consideration the presence of a single class of autoantibodies, 
principally at low titers, as happened in Buzzetti 2016  (99), Maruyama 2008 (83) and Zhou 2005 
(95). Based on Tanaka et al., GADA titers are considered low when ≥180 WHO U/ml and high when 
<180 WHO U/ml (170). However, Oikawa et al. consider low GADA titers values <10U/ml and high 
GADA titer values >10U/ml when measured using a radioimmunoassay (RIA) test (171).  
Leslie et al. suggested that the high heterogeneity in GADA positive patients and expression of a 
different degree of the autoimmune response could be explained by the heterogeneity in 
autoantibody profiles (63). The study also defends that specific autoantibody profiles among LADA 
patients may be correlate with significant differences in demographic and/or clinical characteristics 
(68). In Buzzetti et al., patients who presented a high titer had a more severe autoimmune response 
compared to patients with LADA who had a low GADA titer. Patients with high GADA titers tipically 
present higher levels of HbA1c, a lower BMI, total cholesterol, triglycerides and a lower prevalence 
of the metabolic syndrome (65). This statement is not corroborated by the results of Pozzilli 2018 
(100), where the values of HbA1c decreased significantly in all groups as well as the lipidic 
parameters, whether for high or low GADA titer groups. in many studies (Agardh 2005 (26), Agardh 
2009 (27), Awata 2017 (92), Cabrera-Rode 2002 (71), Davis 2005 (57), Johansen 2014 (98), Kobayashi 
1996 (70), Kobayashi 2002 (90), L-Hallin 1999 (97), Pozzilli 2018 (100), Yang 2009 (96)), patients with 
T2D who are positive for GADA are identified as individuals with LADA. This can lead to conflicting 
results since the metabolic and clinical phenotypes between both types of diabetes are substantially 
different. Unfortunately, until now there are no specific recommendations on islet antibodies testing 
for adult-onset diabetes. Hence, as evidenced by Fourlanos et al., normal or low-weight individuals, 
generally assessed on the basis of BMI, are considered as potentially having LADA and could be 
tested by running immunological assays. Contrarily, overweight and obese adults may not be 
investigated by being presumed to have T2D, which could finish in misdiagnosis (17,172). However, 
some studies showed that LADA can also be diagnosed in individuals with T2D who are overweight 
or obese  (68,173,174). These statements may lead to think if it is reasonable to stratify patients 
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based on BMI, as is the case in Buzzetti 2016  (99), L-Hallin 1999 (97) and Pozzilli 2018 (100). 
Another problem found in the trials that reinforces the inconclusive results may be the possibility of 
false positive results. This may be due to random assay variation since quantification of 
autoantibodies was made whether by radioimmunoprecipitation assay, enzyme-linked 
immunosorbent assay (ELISA) (Hals 2019 (76)), radiobinding assay (Kobayashi 1996 (70), Kobayashi 
2002 (90)) and radioligand assay (Wang 2019 (84), depending on the study. In order to clarify the 
concern about the use of autoantibodies to assist clinical decisions, Daka et al. (170) used three 
different radio-binding assays to detect GADA. This study showed that GADA positivity differed 
significantly between the three techniques making it difficult to generalize the results of the studies 
included in this review. Yet, the possibility of whether GADA may help decide when to start insulin 
remains obscure. Some authors demonstrated that islet autoantibodies may reflect the intensity of 
the autoimmune response and predict future insulin deficiency (65,175,176). In fact, two of the 
studies analyzed (Davis 2005 (57), Yang 2009 (96)) showed that insulin administration was 
performed based on autoantibodies status. Besides, non-concordant data are available regarding 
the association between GADA titer and the period that elapses from diagnosis until the need for 
insulin (173,177–179). In this regard, the United Kingdom Prospective Diabetes Study (UKPDS) 
suggested that GADA has a strong power to predict progression to insulin treatment only among 
subjects >55 years old at diagnosis (179). However, this information cannot be identified in any of 
the studies in this review due the fact that the age range is large and the data is not stratified for 
each patient, which makes it impossible to take conclusions.  Nevertheless, conflicting results have 
been reported. Some studies demonstrated that a high titer of GADA autoantibodies was associated 
with a shorter insulin free period (173,178), whereas other studies did not support this hypothesis 
(177,179). Again, this hypothesis cannot be confirmed or disapproved based on the results of the 
included studies leading, once more, to inconclusive effects. Nevertheless, almost two-thirds of 
people requiring insulin are GADA-negative (179). Considering this variability, it has been proposed 
that C-peptide testing might be more useful in the clinical practice compared to GADA measurement 
which can represent an advance considering the limitations described above (16,51,169). 
 
From the analysis above, it can be concluded that the heterogeinity of approaches for diagnosis or 
classification of the disease, and for the eligibility criteria of patients within studies make it difficult 
to generalize results. Also, it should be noted that the variance in diagnosis criteria could lead to 
uncertainty in respect of the most appropriate intervention for LADA. 
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V.2.3 Limitations related to outcomes 
 
The distinct measurement of the same outcome constituted another challenge for interpreting 
comparing, and generalizing results. For example, the C-peptide levels were quantified differently 
among studies, varying from an integrated serum C-peptide response (Maruyama 2003 (91)), 
glucagon-stimulated C-peptide (Thunander 2011 (72)) and glucose stimulated delta C-peptide (Yang 
2009 (96)). Also, the possibility to apply the outcome measures in clinic practice should be taken into 
consideration.  Some studies presented analytic results (such as HOMA2-%β (Yang 2009 (96)), 
HOMA-β and HOMA-IR (Pozzilli 2018 (100)), of T-lymphocyte levels (Palmer 2018 (101), Wang 2019 
(84)) and mRNA expression (Wang 2019 (84)) and GLP-1 (Johansen 2014 (98))  and serum C-peptide 
response (Maruyama 2003 (91)) that are difficult to understand by clinicians and are perhaps only 
relevant to research studies.  
The meta-analysis shows the combined data across studies and it allows estimating treatment effects 
with more precision than is possible in a single study. However, the outcomes available were not 
sufficient or comparable to allow this. The analysis made it possible to notice a considerable 
heterogeneity though it is difficult to presume the reasons behind it. A common that data extraction 
errors could be the cause for substantial heterogeneity in results with continuous outcomes. As a 
consequence, the meta-analysis from studies of variable validity can result in false positive 
conclusions, such as erroneously concluding that an intervention is effective or even that there is no 
effect. For this reason, it was not possible to take consistent conclusions in order to avoid under or 
overestimated effects. 
 
 
V.2.4 Limitations related to publication bias  
 
Although the publications about LADA seem to be increasing, there are very few studies examining 
interventions for LADA and even less trials reporting a conclusive treatment intervention. According 
to the literature, smaller trials are, in general, analyzed with less methodological rigor than larger 
studies, which can lead to either an overestimation or underestimation of effect sizes. In fact, a huge 
variety in selection criteria for LADA was observed in the included studies, and some lacked numbers 
of patients and showed poor quality reporting their findings. Some of the studies did not report 
information on randomization methods (Awata 2017 (92), Cabrera-Rode 2002 (71), Davis 2005 (57), 
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Palmer 2018 (101), Thunander 2011 (72), Yang 2009 (96)) as well as the selective reporting that were 
omitted (Cabrera-Rode 2002 (71), Davis 2005 (57), Hals 2019 (76), Johansen 2014 (98), Kobayashi 
2002 (90), Li 2009 (94), Maruyama 2003 (91), Palmer 2018 (101), Zhang 2020 (93)), blinding of the 
analysis (Awata 2017 (92), Cabrera-Rode 2002 (71), Davis 2005 (57), Hals 2019 (76), Johnasen  2014, 
Kobayashi 1996 (70),  Kobayashi 2002 (90), Li 2009 (94), Maruyama 2003 (91), Maruyama 2008 (83), 
Palmer 2018 (101), Pozzilli 2018 (100), Thunander 2011 (72), Yang 2009 (96), Zhou 2005 (95), Zhang 
2020 (93)). Some studies even reported other potential sources of bias such as funding entities with 
interest in the results of the study (Agardh 2005 (26), Agardh 2009 (27), Buzzetti 2016 (99), Davis 
2005 (57), Johansen 2014 (98), L-Hallin 1999 (97), Yang 2009  (96), Zhao 2014 (85), Zhou 2005 (95)). 
The challenge in the assessment of the quality of the studies was due to the incomplete reporting 
that did not consider combined therapies and could lead to overestimation of the results. The 
effectiveness of the treatment as evaluated through the combination of drugs but the conclusions 
were only directed towards the intervention drug (Agardh 2005 (26), Cabrera-Rode 2002 (71), Hals 
2019 (76), L-hallin 1999 (97), Johansen 2014 (98), Palmer 2018 (101), Thunander 2011 (72), Wang 
2019 (84), Yang 2009 (96), Zhao 2014 (85), Zhou 2005 (95)). Additionally, in certain studies the wash-
out of substances were either not done or not reported and that may have compromised the results, 
leading to uncertain results about the true intervention effect. 
 
In summary, the early identification of LADA and a personalized therapeutic management of the 
disease appear to be indispensable in order to retard the autoimmunity process and to retain β-cell 
function. Unfortunately, the heterogeneity in interventions, the limitations in study design, the 
arbitrary inclusion criteria related to age range and BMI values, the different stratification of 
outcomes, the lack of drug(s) wash-out reporting at baseline make it difficult to generalize, to find 
consistency in disease interpretation and quite challenging to find an effective treatment for LADA. 
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CHAPTER VI: CONCLUSIONS 
 
VI.1 Main conclusions 
 
VI.1.1 Implications for practice 
 
The main conclusion from this study is that the most appropriate therapeutic approach should 
maintain metabolic control and protect or increase the β-cell function. This is of prime importance 
since the maintenance of some endogenous insulin production may be associated with improved 
metabolic control, better long-term disease outcome, and delayed complications associated with 
diabetes. 
Knowing the best strategy to diagnose diabetic patients who have characteristics or who may be at 
risk for LADA is still an issue. The test for autoantibodies is still the most frequent approach, though 
until now it is impossible to know who needs it or not. Unfortunately, analyzing every autoantibody 
profile might not always be achievable due to its high costs and challenges interpreting the results 
with consistency. Currently, this condition is not clearly defined, which makes it even more of a 
challenge to develop guidelines for LADA treatment. 
This systematic review covered a number of therapeutic interventions that may be further explored 
in light of their apparent capacity to prevent β-cell failure and to avoid progression to an insulin-
depending state. The challenge is to find which drug (or combination of drugs) could be more 
effective to reach such goals. 
The existence of several metabolic and clinical phenotypes in adult-onset autoimmune diabetes 
makes it difficult to establish an a priori management for intervention on LADA patients leading to 
the need for a personalized medical approach to therapy that considers the characteristics and 
disease presentation of each patient. The beneficial effects of the combination of therapies for LADA 
remain uncertain and are neglected across studies. Nevertheless, this review has not found any 
evidence to choose or reject any possible intervention, leading to a markable need for new trials, 
which should ideally facilitate a clinical approach that considers each patient’s characteristics and 
symptoms. 
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VI.1.2 Implications for research  
 
The data available in the literature are scarce and have several limitations, such as the small number 
of participants, the wide heterogeneity in both study design and in outcomes. Besides that, most of 
the studies were designed to investigate characteristic outcomes, such as changes in HbA1C levels, 
BMI, and insulin requirement. This focus could lead to overlooked data particularly on glycemic 
variability, oxidative stress, and IR markers that are known to have an important role in the 
development and progression of diabetes complications. The researchers’ consideration of 
individuals with LADA as a homogenous group is an issue, as they are assuming that the overall effect 
in various interventions will be the same for each. Instead, it is evident that specific LADA subgroups 
might have many responses to different therapies, depending on the individual pathophysiological 
and phenotypical features. So far, biochemical, molecular or genetic markers are not available. These 
would help to distinguish subgroups of patients with different characteristics of LADA. Thus, it 
remains an area of intervention for possible future studies.  
More randomized trials and prospective studies are needed before the above-mentioned drugs and 
potentially others can be used in clinical practice targeted to LADA patients. Further investigation 
should clarify whether complementary therapies are capable of retarding the progression to insulin 
dependence and of attenuating the consequent micro and macrovascular complications. 
The results of this systematic review and the literature review reveal that high-quality studies are 
needed to investigate the missing aspects of this autoimmune disease and also to delineate the most 
accurate strategy for its treatment. 
 
 
VI.2 Future Perspectives 
 
As mentioned throughout this review, there is still no established treatment for LADA due to the 
heterogeneity of the disease and its management. Thus, it seems urgent to find an effective 
treatment that attenuates the diabetic complications and protects the pancreatic β-cells function. 
The possibilities in the search for treatment seem limitless, but better results could be obtained by 
targeting treatment in three areas: immunosuppression (interruption of the autoimmune process), 
immunomodulation (alteration of the immunomodulatory response) and regeneration of islet cells 
(replacement of destroyed or compromised β-cells).  
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Some examples of promising research initiatives in these three areas are described below.  
 
 
VI.2.1 Cell Therapy: Regulatoy T cells 
 
According to the literature, LADA is a disease mediated by immune cells that cause insulin 
dependence due to the death or impairment of pancreatic β-cells, though slower than the pancreatic 
β-cell destruction in T1D (180). Some studies in T1D have already been developed taking into 
consideration cell therapy using regulatory T cells.  
Marek-Trzonkowska et al. administered CD4+ CD25highCD127- regulatory T cells in children with T1D 
and showed that this cell population can preserve the function of β-cells (181). In light of such 
discovery, a similar approach might represent an opportunity of an immunosupression, 
immunomodulation and regeneration of islet cells treatment for LADA. So, it becomes essential to 
understand which type of T cells is most prevalent in these patients. Several populations of T cells 
contribute to the immunopathology identified in LADA. Among them are helper T cells type 1 (Th1), 
which are considered the most critical agents in many specific autoimmune diseases, and helper T 
cells type 2 (Th2), which are considered protective in terms of autoimmunity. An imbalance in these 
populations can lead to immunopathology. However, this simple paradigm of Th1/Th2 imbalance is 
not enough to explain the immunopathology of different autoimmune diseases, such as autoimmune 
diabetes. Consequently, regulatory T cells (Tregs), which suppress the proliferation and secretion of 
cytokines by CD8+ and CD4+ T cells, appear to be critical suppressors in autoimmunity (182). In 
conclusion, this study evidences the need to explore further. 
A recent study focused on the heterogeneity of Tregs found differences in the phenotype and 
frequency of circulating peripheral CD4+ CD25+ T cells in patients with LADA compared to healthy 
individuals (183). The initial analysis of peripheral T cells showed a significantly lower frequency and 
a lower number of total CD4+ CD25+ T cells in patients with LADA. They divided the CD4+ CD25+ 
population into fractions of CD4+ CD25hi and CD4+ CD25int, based on the expression of CD25+. The 
study speculates that CD4+ CD25int T cells may represent, at least in part, an early stage of 
differentiation of peripheral Tregs. Therefore, a significant decrease in these cells reflects a relative 
impairment of peripheral tolerance and contributes to the chronic autoimmune process that leads 
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to impairment of β-cells in LADA patients (183). For this reason, studying administration of the CD4+ 
CD25int T cell subpopulation may be a promising approach. However, it is still essential to identify a 
study model for this purpose.  
In 2020 a spontaneous mouse model of LADA, the so-called LADA IDDM (LEW.1AR1 - iddm) rat (183), 
was identified, which mimics the characteristics of LADA. In this animal model, LADA IDDM 
(LEW.1AR1 - iddm) rat, the pre-diabetic phase with infiltration of immune cells in the islets occurred 
between 3 and 7 days before the onset of diabetes. However, in the mice that presented the LADA 
phenotype, the infiltration of immune cells to the islets began between 75 and 115 days, allowing to 
conclude that this model could become promising for LADA studies (184).  
In conclusion, the administration of CD4+ CD25int T cells in LADA IDDM animal model might lead to 
the interruption of the autoimmune process and the consequent preservation of β-cells, allowing, in 
the future, to conduct clinical trials on LADA patients. 
 
 
VI.2.2 DPP-4 inhibitors and vitamin D 
 
Another potential approach as an immunomodulation and regenration of islet cells therapy for LADA 
appears to be combined therapy with DPP-4 inhibitors and vitamin D, as both apparently have 
immunomodulating properties. 
DPP-4 inhibitors (sitagliptin, vildagliptin, linagliptin, saxagliptin and alogliptin) have been widely used 
for the treatment of T2D as they have a satisfactory effect protecting the function of β-cells (185–
189). Due to their anti-inflammatory effect and immunomodulatory, these inhibitors were tested for 
T1D and LADA (93). In T1D, administration of these inhibitors, despite improving HbA1c levels and 
reducing daily insulin requirements, did not show any effects on the preservation of β-cells 
(124,190,191). However, in LADA, positive effects were observed in β-cells (85,99).  
Vitamin D can be metabolized in the liver and converted to its active form 1,25-dihydroxyvitamin D3 
in the kidneys and in some immune cells that express the vitamin D receptor (VDR), such as 
monocytes, macrophages, dendritic cells (DCs), T and B lymphocytes (192). These immune cells seem 
to have an important role maintaining immune system homeostasis (193). Furthermore, by checking 
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vitamin D levels in patients with LADA, it was found that they were lower than expected (163), which 
may be associated with the dysregulation of T cells. As already mentioned, LADA is an autoimmune 
disease mediated by T cells (30), and it was observed a Treg's dysfunction, namely in the number 
and/or function of these cells in these patients (35). As vitamin D can be activated by the cells of the 
immune system, like T cells, if they are disregulated due to the autoimmune process in patients with 
LADA, it is expected that vitamin D levels may decrease, as these cells do not have the ability to 
activate it efficiently. Thus, the main function of vitamin D appears to be immunoregulation, which 
may constitute a potential approach to autoimmune diseases such as LADA. 
The immunomodulatory effects of DPP-4 inhibitors, as well as those of vitamin D, seem remarkable. 
However, the benefits of these drugs in the LADA treatment still require more investigation. As no 
immunomodulatory therapy alone seems to promote remission of the disease, a combination 
therapy may be the answer. Such combination may prove important due to the involvement of 
several immunological pathways that, if blocked, can lead to increased activation of other pathways 
(194). The combination of DPP-4 inhibitors and vitamin D seems to satisfy these requirements, since 
the two drugs have effects on the immune system and β-cells (128,195).  
To date, there are few studies associating vitamin D and DPP-4 inhibitors in LADA. Only one case 
(163) reported  the use of vitamin D and sitagliptin and another using vitamin D3 and saxagliptin 
therapy (93). Both reached the same conclusions and mentioned that this combined therapy could 
maintain the function of pancreatic β-cells in patients with LADA. However, both have very small 
samples and neither has the power to study the mechanism of the effect of vitamin D on LADA.  
In light of such promising results, it would be extremely important to verify these findings in larger 
populations as well as for longer periods. Concerning the best inhibitor for the study, sitagliptin 
appears to be more promising, as it presents fewer adverse effects compared to to saxagliptin 
(196,197), which seems to lead to cardiac failure. In parallel, it is necessary to define whether 
treatment with vitamin D would be more effective with the 25-OH vitamin D3 form or with the 
activated form 1.25 (OH)2D3.  
Concluding, would be relevant new randomized trials that combine the treatment of sitagliptin with 
the two forms of vitamin D, as well as the mechanism of the effect of vitamin D on LADA through, in 
a first approach, cellular models of administration of the compound in β-cells in vitro. 
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VI.2.3 SGLT2 inhibitors 
 
Another immunomodulation therapy directed to LADA can be the use of SGLT2 inhibitors. The 
mechanism of action of SGLT2 inhibitors is slightly different from those discussed so far, as they act 
independently of the function of β-cells. In addition to its glycemic effects and to the modification of 
HbA1c levels by the effect of osmotic diuresis of the drug, the extra glycemic benefits of SGLT2 appear 
to include weight loss, lower blood pressure and improvement of cardiovascular function (198). 
SGLT2 inhibitors are usually recommended as a second-line therapy in the treatment of T2D or as a 
first-line agent when metformin is not well-tolerated (199). The insulin-independent hypoglycemic 
mechanism indicates that SGLT2 can be effective in patients at any stage of diabetes and it can be 
particularly effective in those with severe insulin resistance and receiving high-dose insulin therapy 
(200).  
SGLT2 inhibitors are structurally similar to glucose, and thus competitively inhibit glucose, leading to 
increased levels of glucose in the urine (201,202).  
A clinical study in patients with T2D reported that canagliflozin (a class of SGLT2 inhibitors) plus 
insulin therapy reduced the HbA1c levels and led to a significant decrease in the FBG levels. Clinical 
studies on other types of SGLT2 inhibitors, such as dapagliflozin and empagliflozin, also reported a 
reduction in HbA1c and FBG levels (203–206). In mouse models with T2D, chlorizin achieved effects 
similar to those described above, improving insulin resistance and restoring β-cell function (207). 
Likewise, in SGLT2 knockout mouse models, glucose tolerance and increased β-cell function have 
been demonstrated (207). In addition, muscle glucose uptake increased, suggesting that fat storage 
was reduced and peripheral insulin resistance was improved (208). When glucose and insulin 
tolerance tests were performed with obese mice, empagliflozin improved glucose intolerance and 
insulin resistance in fasting and feeding states (209).  
In T1D, results from animal and human studies in the short term suggested similar results with 
empagliflozin as complementary insulin therapy to improve glycemic control (210–213). Compared 
to placebo, remogliflozin has also been associated with substantial improvements in the glucose 
profile over 10 hours in individuals with T1D (211). Although these results seem promising, clinical 
data on LADA are scarce (214,215) and, therefore, it is not possible to draw conclusions about the 
therapeutic effects of SGLT2 inhibitors. So clinical trials that relate this class of inhibitors in groups 
of patients with LADA are necessary. 
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Although these inhibitors present potential benefits, cases of DKA have been noted. In addition, by 
increasing parathyroid hormone (PTH) and fibroblasts growth factor 23 (FGF23) levels, SGLT2 
inhibitors seem to promote phosphaturia, which could have opposite effects on vitamin D 
metabolism. Evidence also demonstrates that SGLT2 inhibitors decrease mean levels of 1.25 
dihydroxyvitamin D (216) which, in addition to the low levels of vitamin D presented by patients with 
LADA, can confer a potential challenge in this treatment.  
In conclusion, studies evaluating the combination of administration of SGLT2 and vitamin D may also 
constitute a potential therapy. 
 
 
Summing up the recent studies in these three areas, cell therapy seems to have the greatest benefits 
since it manages to combine three important therapeutic areas: immunosuppression, 
immunomodulation and regeneration of islet cells. However, immunomodulation therapies using 
vitamin D and SGLT2 inhibitors seem to stand out by focusing on the manipulation of the immune 
system to control the autoimmune process, wich could become a revolutionary approach for LADA 
treatment. 
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CHAPTER VIII: APPENDIX  
 
 
Appendix 1 | Characteristics of Included Studies. For the analysis of the included studies, data of each study 
were organized according to their characteristics. The main characteristics evaluated were the methods used 
for the study design and randomization, the participants, namely, number and sex of participants, as well as 
inclusion, exclusion and diagnosis criteria, the interventions performed and their intervention period, the 
outcomes evaluated, and the main objective of each study. 
 
Agardh 2005 
 
 
 
Methods Study Design: randomized, double blind, placebo - controlled, group 
comparison, dose-escalation study 
Ethics Approval Obtained: yes 
Patient Consent Obtained: yes 
Analysis by Intention to Treat: no, exploratory trial 
Power Calculation: no 
Participants Total of participants: 47 patients 
Sex (Female% / Male%): Placebo: F: 7.7% (1/13), M: 92% (12/13), Group 1 (4μg): 
F: 22% (2/9), M: 77% (7/9), Group 2 (20μg): F: 25% (2/8), M: 75% (6/8), Group 3 
(100μg): F: 33% (3/9), M: 66% (6/9), Group 4 (500μg): F: 0% (0/8), M: 100% (8/8) 
Age (Median Years (Range)): Placebo: 56 years, Group 1 (4μg): 58 years, Group 
2 (20μg): 57 years, Group 3 (100μg): 57 years, Group 4 (500μg): 53 years. 
Ethnic Groups (%): not specified 
Duration of the disease: Not given 
Inclusion Criteria: “(1) Male or female aged 30-70 years (2) diagnosed with type 
2 diabetes within the previous 5 years (3) presence of GADA (4) only requiring 
diabetes treatment with diet, oral hypoglycemic agents, or both (5) females of 
non-childbearing potential (6) absence of associated serious diseases or 
conditions which, in the opinion of the investigator would exclude the patient 
from the trial (7) patients who had given written informed consent at the 
screening visit” 
Exclusion Criteria: not specified 
Diagnostic Criteria: Diagnosed with type 2 diabetes within the previous 5 years, 
presence of GADA, only requiring treatment with diet, oral hypoglycemic agents 
or both 
Co-Morbidities: not given 
Co-Medications: not given 
Groups: Placebo: 13, Group 1 (4μg): 9, Group 2 (20μg): 8, Group 3 (100μg): 9, 
Group 4 (500μg): 8 
Loss To Follow-Up: 0% (0/47) participants 
Interventions Country/ Location: Sweden 
Intervention (Route, Total Dose/Day, Frequency): dose comparison of 
subcutaneous GAD (Diamyd®) injections at 4μg, 20 μg, 100μg or 500μg doses 
Control (Route, Total Dose/Day, Frequency): placebo (Alhydrogel) 
Treatment Before Study: All intervention patients received 4μg for 8 weeks. If 
there were no safety concerns, then the higher dose (20μg or 100μg or 500μg) 
was initiated 
Outcomes  Primary Outcome(s): not stated 
Secondary Outcome(s): not stated 
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Additional Outcomes:  HbA1c (%), fasting blood glucose (mmol/l), Log GADA 
(U/ml), fasting and stimulated C-peptide (nmol/l), BMI (Kg/m2), adverse events 
Study Details  Duration Of Intervention: 24 weeks 
Duration Of Follow-Up: 24 weeks 
Run-In Period: 8 weeks in the intervention group (4μg for 8 weeks before higher 
dose initiated) 
Publication Details Language Of Publication: English 
Commercial Funding: yes 
Stated Aim For Study Quote: “To investigate the clinical safety of subcutaneously administered 
Diamyd® and to assess its impact on the immune system and diabetic status” 
 
 
 
Agardh 2009 
 
 
 
Methods Study Design: randomized, double-blind, placebo-controlled, group comparison, 
dose-escalation study 
Ethics Approval Obtained: yes 
Patient Consent Obtained: yes 
Analysis by Intention to Treat: unclear - “the study was carried out according to 
the intention-to-treat principle” 
Power Calculation: no 
Participants Total of participants:  47 patients 
Sex (Female% / Male%): Placebo: F: 7.7% (1/13), M: 92% (12/13), Group 1 (4μg): 
F: 22% (2/9), M: 77% (7/9), Group 2 (20μg): F: 25% (2/8), M: 75% (6/8), Group 3 
(100μg): F: 33% (3/9), M: 66% (6/9), Group 4 (500μg): F: 0% (0/8), M: 100% (8/8) 
Age (Median Years (Range)): Placebo: 56 years (37-66) Group 1 (4μg): 58 years 
(39- 69), Group 2 (20μg): 57 years (48-67), Group 3 (100μg):57 years (30-69), 
Group 4 (500μg): 53 years (39-62) 
Ethnic Groups (%): not specified 
Duration of disease: “diagnosed with type 2 diabetes within the previous 5 
years” 
Inclusion Criteria: “(1) Male or female aged 30-70 years (2) diagnosed with type 
2 diabetes within the previous 5 years (3) presence of GADA (4) only requiring 
diabetes treatment with diet, oral hypoglycemic agents, or both (5) females of 
non-childbearing potential (6) absence of associated serious diseases or 
conditions which, in the opinion of the investigator would exclude the patient 
from the trial (7) patients who had given written informed consent at the 
screening visit” 
Exclusion Criteria: not specified 
Diagnostic Criteria: Diagnosed with type 2 diabetes within the previous 5 years, 
presence of GADA, only requiring treatment with diet, oral hypoglycemic agents 
or both 
Co-Morbidities: not given 
Co-Medications: not given 
Groups: Placebo: 13, Group 1 (4μg): 9, Group 2 (20μg): 8, Group 3 (100μg): 9, 
Group 4 (500μg): 8 
Loss To Follow-Up: 15% (7/47) participants 
Interventions Country/ Location: Sweden 
Intervention (Route, Total Dose/Day, Frequency): dose comparison of 
subcutaneous GAD (Diamyd®) injections at 4μg, 20μg, 100μg or 500μg doses 
Control (Route, Total Dose/Day, Frequency): placebo (Alhydrogel) 
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Treatment Before Study: All intervention patients received 4μg for 8 weeks. If 
there were no safety concerns then the higher dose (20μg or 100μg or 500μg) 
was initiated 
Outcomes Primary Outcome(s): not stated  
Secondary Outcome(s): not stated  
Additional Outcomes: GAD65, 2. IA-2A, IAA, ICAs, BMI, serum creatinine, lipid 
profile, HbA1c (%), Fasting blood glucose (mmol/l), fasting and stimulated C-
peptide (nmol/l), Adverse events  
Study Details  Duration Of Intervention: 5 years 
Duration Of Follow-Up: 5 years 
Run-In Period: 8 weeks in the intervention group (4μg for 8 weeks before higher 
dose initiated) taken from previous publication 
Publication Details Language Of Publication: English 
Commercial Funding: yes 
Stated Aim For Study Quote: “To evaluate long-term clinical safety and dose level effects on β-cell 
function” 
 
 
 
Awata 2017 
 
 
 
Methods Study Design: open-label, prospective, randomized, controlled trial 
Ethics Approval Obtained: yes 
Patient Consent Obtained:  yes 
Analysis by Intention to Treat:  no, exploratory trial 
Power Calculation: no 
Participants Total of participants: 14 participants 
Sex (Female% / Male%):  S group (sitagliptin): F: 67% (4/6), M: 33% (2/6); P group 
(pioglitazone): F: 60% (3/5), M: 40% (2/5) 
Age (Median Years (Range)):  S group (sitagliptin): 56 years; P group 
(pioglitazone): 57 years 
Ethnic Groups (%): not given 
Duration of disease: Sitagliptin group: 4.3 ± 2.9 years (mean ± SD); Pioglitazone 
group: 3.8 ± 4.1 years (mean ± SD) 
Inclusion Criteria: (1) diabetes diagnosis and HbA1c level between 6.9% and 
8.4%, (2) GADA-positive, (3) fasting serum C-peptide level C1.0 ng/ ml, (4) age 
20–79 years of age, (5) no treatment with oral glucose-lowering drugs except 
metformin within 2 months before enrollment and (6) no history of insulin or 
GLP-1 receptor antagonist treatment. 
Exclusion Criteria: (1) women who were pregnant or planning on becoming 
pregnant, (2) renal dysfunction with serum creatinine C1.5 mg/dl for males and 
C1.3 mg/dl for females, or creatinine clearance B50 ml/min, and (3) patients who 
were deemed unsuitable for participation by their attending physician because 
of associated disease, complications or any other reasons. 
Diagnostic Criteria:  non-insulin-requiring diabetic patients with GADA  
Co-Morbidities: not given 
Co-Medications: patients could be taking metformin 
Groups: S group (sitagliptin): 7 participants and P group (pioglitazone): 7 
participants 
Loss To Follow-Up: 21% (3/14) participants 
Interventions Country/ Location: Japan 
Intervention (Route, Total Dose/Day, Frequency): S group (sitagliptin 50 mg) 
Control (Route, Total Dose/Day, Frequency):  P group (pioglitazone 15 mg) 
Treatment Before Study: not given 
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Outcomes Primary Outcome(s):  HbA1c values 
Secondary Outcome(s): C-peptide levels, BMI and islet autoantibodies 
Additional Outcomes: not given 
Study Details  Duration Of Intervention: 48 months 
Duration Of Follow-Up: 12 months of follow-up 
Run-In Period: not given 
Publication Details Language Of Publication: English 
Commercial Funding: yes 
Stated Aim For Study Quote: “assess the long-term efficacy of sitagliptin for SPIDDM/LADA” 
 
 
 
Buzzetti 2016 
 
 
 
Methods Study Design: post-hoc of randomized, placebo- controlled, 24-week phase III 
studies 
Ethics Approval Obtained: unclear 
Patient Consent Obtained: unclear 
Analysis by Intention to Treat:  not stated 
Power Calculation: not given 
Participants Total of participants:  2709 participants 
Sex (Female% / Male%):  GADA-negative group: Placebo: F: 52% (378/727), M: 
48% (348/727); Saxagliptin: F: 51% (948/ 1849), M: 49% (901/1849); GADA-
positive group: Placebo: F: 43% (15/35), M: 57% (20/35), Saxagliptin: F: 59% 
(58/98), M: 41% (40/98) 
Age (Median Years): GADA-negative group: Placebo: 55 (10.5) years, Saxagliptin: 
55 (10.1) years, GADA-positive: Placebo: 54 (11.2) years, Saxagliptin: 53 (9.9) 
years 
Ethnic Groups (%):   GADA-negative group: White: Placebo: 66% (483/727), 
Saxagliptin: 69% (1276/1849);  Black/African American: Placebo: 4% (29/727), 
Saxagliptin: 5% (84/ 1849), Asian: Placebo: 18% (126/727), Saxagliptin: 16% 
(303/1849); Other: Placebo: 12% (87/727), Saxagliptin: 10% (186/1849);  GADA-
positive group:  White: Placebo: 66% (23/727), Saxagliptin: 69% (68/1849);  
Black/African American: Placebo: 6% (2/727), Saxagliptin: 7% (7/ 1849), Asian: 
Placebo: 17% (6/727), Saxagliptin: 13% (13/1849); Other: Placebo: 11% (4/727), 
Saxagliptin: 10% (10/1849) 
Duration of disease:  GADA-negative group: (Placebo: 5.4 ± 5.5 years (mean ± 
SD); Saxagliptin group: 5.1 ± 5.3 years (mean ± SD)); GADA-positive group: 
(Placebo: 5.7 ± 4.8 years (mean ± SD); Saxagliptin group: 4.1 ± 4.2 years (mean  
SD)) 
Inclusion Criteria: (1) 18–77 years of age, (2) type 2 diabetes, (3) inadequate 
glycemic control [ HbA1c 7.0–10.0% (53–86 mmol/mol), 7.5–10.0% (58–86 
mmol/mol), or 7.0–10.5% (53–91mmol/mol), (4) body mass index ≤40 or ≤45 
Kg/m2, and (5) fasting C peptide ≥1.0 ng/m 
Exclusion Criteria: (1) class III or IV congestive heart failure and/or known left 
ventricular ejection fraction <40%, (2) history of liver disease, serum creatinine 
≥1.5 mg/dl for men or ≥1.4 mg/dl for women, and (3) the use of potent CYP3A4 
inhibitors or inducers. 
Diagnostic Criteria: not mentioned 
Co-Morbidities: not given 
Co-Medications: not given 
Groups: GADA-negative group (Placebo vs Saxagliptin) and GADA-positive group 
(Placebo vs Saxagliptin) 
Loss To Follow-Up: 0% (0/2709) participants 
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Interventions Country/ Location: Italy 
Intervention (Route, Total Dose/Day, Frequency):  several doses of saxagliptin 
(2.5, 5, and 10 mg/d) 
Control (Route, Total Dose/Day, Frequency):   Placebo or placebo plus a stable 
dose of metformin (1,500-2,500 mg) or glyburide 10 mg  
Treatment Before Study: not given 
Outcomes Primary Outcome(s) (as stated in the publication): HbA1c, GADA levels, fasting 
plasma glucose (FPG) and postprandial plasma glucose (PPG) 
HbA1c, fasting plasma glucose and postprandial plasma glucose, HOMA2-%β and 
postprandial C-peptide 
Secondary Outcome(s) (as stated in the publication): Fasting and Postprandial C-
peptide, HOMA2-%β 
Additional Outcomes:  Adverse events  
Study Details  Duration Of Intervention:  24 weeks 
Duration Of Follow-Up:  24 weeks 
Run-In Period: not given 
Publication Details Language Of Publication: English 
Commercial Funding: yes 
Stated Aim For Study Quote: “To assess the efficacy and tolerability of saxagliptin and C-peptide 
secretion in patients with diagnosed type 2 diabetes classified as glutamic acid 
decarboxylase antibody (GADA)-positive or GADA-negative.” 
 
 
 
Cabrera-Rode 2002 
 
 
 
Methods Study Design: randomized controlled trial 
Ethics Approval Obtained: not stated 
Patient Consent Obtained: yes 
Analysis by Intention to Treat: not stated. No loss to follow-up 
Power Calculation: no 
Participants Total of participants: 14 participants 
Sex (Female% / Male%): Insulin+SU: F: 66% (4/6), M: 33% (2/6). Insulin: F: 38% 
(3/ 8), M: 62% (5/8) 
Age (Median Years): Insulin+SU: 53 years, Insulin: 53 years 
Ethnic Groups (%): not specified 
Duration of disease:  Insulin + SU: 1.5 ± 1.8 years (mean ± SD); Insulin: 2.0 ± 2.6 
years (mean ± SD) 
Inclusion Criteria: Type 2 diabetic patients with ICA (>20 JDF U) and GADA65A 
(on at least two consecutive tests) previously treated with glibenclamide and 
insulin (for at least 1 month) without history of ketonuria and diabetic 
ketoacidosis 
Exclusion Criteria: not specified 
Diagnostic Criteria: Diagnosed with type 2 diabetes with ICA and GADA 
Co-Morbidities: not given 
Co-Medications: not given 
Groups: Insulin + SU: 6 participants, Insulin: 8 participants 
Loss To Follow-Up: 0% (0/14) participants 
Interventions Country/ Location: Cuba 
Intervention (Route, Total Dose/Day, Frequency): insulin therapy 
Control (Route, Total Dose/Day, Frequency): insulin therapy plus sulphonylurea 
(glibenclamide) 
Treatment Before Study: Previously treated with glibenclamide and insulin (for 
at least 1 month) 
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Outcomes Primary Outcome(s): not stated  
Secondary Outcome(s): not state 
Additional Outcomes: fasting blood glucose (mmol/l), fasting C- peptide (pmol/l), 
BMI (Kg/m2), insulin dose (U/day), SU (glibenclamide, mg/ day), ICA titres and 
GAD antibody status 
Study Details  Duration Of Intervention: 12 months 
Duration Of Follow-Up: 12 months 
Run-In Period: Treatment with glibenclamide and insulin for at least 1 month 
Publication Details Language Of Publication: English 
Commercial Funding: no 
Stated Aim For Study Quote: “To evaluate whether the exclusion of glibenclamide in the treatment of 
ICA positive type 2 diabetic patients may diminish the levels of ICA and anti-
GAD65 autoantibodies as well as improve fasting glucose and insulin secretion.” 
 
 
 
Davis 2005 
 
 
 
Methods Study Design:  randomized controlled trial 
Ethics Approval Obtained: yes 
Patient Consent Obtained: yes 
Analysis by Intention to Treat: yes 
Power Calculation: no 
Participants Total of participants: 536 participants 
Sex (Female% / Male%): unable to distinguish by treatment groups. Of total 
antibody positive group 56% (n=293/536) were male 
Age (Median Years): unable to distinguish by treatment groups. Of total antibody 
positive group, average age 48.2 (SD: 10.8) 
Ethnic Groups (%): unable to distinguish by treatment groups. Of total antibody 
positive group; WC (initials not explained in text so assumed white Caucasian): 
93%, AC (initials not explained in text but assumed African/Carabean): 2%, IA 
(initials not explained in text but assumed Indian/Asian): 5%, other 0% 
Duration of the disease: Newly diagnosed. Average disease duration not stated 
Inclusion Criteria: aged 25-65 years with type 2 diabetes and fasting plasma 
glucose above 6.0 mmol/L on two subsequent occasions 
Exclusion Criteria: Exclusion criteria (1) severe vascular disease, (2) accelerated 
hypertension (3) proliferative retinopathy (4) renal failure (5) other life-
threatening disease (6) illness requiring systemic steroids (7) occupation 
precluding insulin treatment (8) unable to speak English (9) ketonuria greater 
than 3 mmol// suggestive of type 1 diabetes 
Diagnostic Criteria: Type 2 diabetes newly diagnosed by general practitioner and 
fasting plasma glucose higher than 6.0 mmol/L on two subsequent occasions 
Co-Morbidities: not given 
Co-Medications: not given 
Groups: Group FPG 60.-14.9 mmol/l: insulin: 95 participants, SU: 140, 
Conventional: 100 Group FPG>15 mmol/l: insulin: 65 participants, SU: 88 
participants. 
Loss To Follow-Up: not given 
Interventions Country/ Location: UK 
Intervention (Route, Total Dose/Day, Frequency): Baseline: FPG: 6.0-14.9 
mmol/l: Insulin OR SU. Baseline: FPG>15 mmol/l: Insulin 
Control (Route, Total Dose/Day, Frequency): Baseline FPG 6.0-14 mmol/l. 
Conventional care. Baseline FPG>15 mmol/l: SU 
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Treatment Before Study: All patients entered a 3-4-month dietary run-in period, 
during which they were advised to take a diet containing 50% carbohydrate, with 
low saturated fat, high fiber 
Outcomes Primary Outcome(s): not stated 
Secondary Outcome(s): not stated 
Additional Outcomes: Recorded annually: HbA1c, weight 
Study Details  Duration Of Intervention: 10 years 
Duration Of Follow-Up: 10 years 
Run-In Period: 3-4 months 
Publication Details Language Of Publication: English 
Commercial Funding: yes 
Stated Aim For Study Quote: “to examine objectively the effect of autoantibody status on glycemic 
response to therapy and to assess the association between autoantibody status 
and cardiovascular risk.” 
 
 
 
Hals 2019 
 
 
 
Methods Study Design:  randomized controlled trial 
Ethics Approval Obtained: yes 
Patient Consent Obtained: yes 
Analysis by Intention to Treat: no, exploratory trial 
Power Calculation: yes (80% at a P value of <.05) 
Participants Total of participants: 64 participants 
Sex (Female% / Male%):  Insulin group: F: 47% (15/32), M: 53% (17/32).  
Sitagliptin group: F: 44% (14/32), M: 56% (18/32) 
Age (Median Years):  Insulin Group: 53 years (46-58), Sitagliptin Group: 53 years 
(43-61) 
Ethnic Groups (%): not given 
Duration of disease: <3 years of known diabetes 
Inclusion Criteria: Men and women, aged 30 to 75 years, positive for GAD 
antibodies with <3 years of known diabetes, without pharmacological treatment 
for diabetes (except metformin) and with no clinical need for insulin treatment 
were eligible for the study. Glycated hemoglobin (HbA1c) concentration had to 
be at least 10% above the upper limit of normal (ULN) before treatment, or 5% 
above the ULN when on treatment with metformin, but not exceeding 60% 
above the ULN at the time of randomization. Fasting levels of C-peptide had to 
be ≥0.3 nmol/L. 
Exclusion Criteria: kidney failure (creatinine >150μmol/l), proliferative 
retinopathy with or without sequelae, myocardial infarction (within the last 6 
months), unstable angina pectoris and other serious chronic diseases (such as 
glucocorticoid-treated asthma). We also excluded fertile women who planned to 
become pregnant during the study period. 
Diagnostic Criteria:  diagnosed with diabetes <3 years, without clinical need for 
insulin treatment and GAD antibody positivity 
Co-Morbidities: not given 
Co-Medications: not given  
Groups: Insulin group: 32 participants, sitagliptin group: 32 participants  
Loss To Follow-Up: not given 
Interventions Country/ Location: Norway and Sweden 
Intervention (Route, Total Dose/Day, Frequency: Sitagliptin given orally 100 
mg/d. Both treatments were adjusted by algorithms based on HbA1c and fasting 
glucose. 
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Control (Route, Total Dose/Day, Frequency): Insulin group: injected 
subcutaneously 
Treatment Before Study: “Recruited participants-initiated metformin tablets, if 
they were not already receiving metformin.” 
Outcomes Primary Outcome(s): β-cell function, evaluated using glucagon-stimulated C-
peptide tests (GSCTs) performed at baseline (ie, at randomization) and after 3, 9 
and 21 months. 
Secondary Outcome(s):  effects on insulin, proinsulin, and proinsulin to C- 
peptide ratios 
Additional Outcomes: HbA1c, fasting glucose, GAD antibody titre, body weight 
and adverse effects 
Study Details  Duration Of Intervention: 21 months 
Duration Of Follow-Up: 21 months 
Run-In Period:  3-month 
Publication Details Language Of Publication: English 
Commercial Funding: yes 
Stated Aim For Study Quote: “To compare outcomes of glucagon-stimulated C-peptide tests (GSCTs) 
in people with latent autoimmune diabetes in adults (LADA) after a 21-month 
intervention with either insulin or the dipeptidyl peptidase-4 inhibitor 
sitagliptin.” 
 
 
 
Johansen 2014 
 
 
 
Methods Study Design: randomized trial 
Ethics Approval Obtained: not stated 
Patient Consent Obtained: not stated 
Analysis by Intention to Treat: no, exploratory analysis 
Power Calculation: no 
Participants Total of participants: 118 participants 
Sex (Female% / Male%):  Not given 
Age (Median Years): Linagliptin: mean age 59–62 years, Glimepiride: mean age 
63–68 years 
Ethnic Groups (%):  not stated 
Inclusion Criteria: one or more autoantibodies against GAD 65-kDa isoform 
(GAD65), islet cell cytoplasm, tyrosine phosphatase IA-2 (IA-2A), or insulin (IAA) 
are positive 
Exclusion Criteria: no stated 
Duration of disease: not given 
Diagnostic Criteria:  patients diagnosed with type 2 diabetes and HbA1c of 6.5– 
10.0% (48–86 mmol/mol) on metformin, classified as having LADA if positive for 
one or more autoantibody (GAD65, IA-2A and IAA). 
Co-Morbidities: not given 
Co-Medications: not given 
Groups Group linagliptin and Group glimepiride (number of patients per group 
were not stated) 
Loss To Follow-Up: not given 
Interventions Country/ Location: Germany 
Intervention (Route, Total Dose/Day, Frequency): Group linagliptin: 5 mg/day for 
2 years  
Control (Route, Total Dose/Day, Frequency): Group glimepiride: 1-4 mg/day for 
2 years 
Treatment Before Study: not given 
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Outcomes Primary Outcome(s): C-peptide measurements at weeks 28, 52, and 104, and 
HbA1c levels 
Secondary Outcome(s): Endogenous glucagon-like peptide 1 (GLP-1) 
Additional Outcomes:  not given  
Study Details  Duration Of Intervention: 2 years 
Duration Of Follow-Up: 2 years 
Run-In Period: not given 
Publication Details Language Of Publication:  English 
Commercial Funding: yes 
Stated Aim For Study Quote: “adds to the currently sparse evidence on the effects of oral glucose-
lowering drugs LADA patients”. In this case linagliptin vs glimepiride.” 
 
 
 
Kobayashi 1996 
 
 
 
Methods Study Design:  parallel randomized controlled trial 
Ethics Approval Obtained: unclear 
Patient Consent Obtained: yes 
Analysis by Intention to Treat: not stated 
Power Calculation: no 
Participants Total of participants: 10 participants 
Sex (Female% / Male%):  Insulin: F: 30% (2/5), M: 60% (3/5), SU F: 30% (2/5): M: 
60% (3/5) 
Age (Median Years):  Insulin: 51 years (8), SU 48 years (11) 
Ethnic Groups (%): not stated 
Duration of disease: insulin group: 0.7 ± 1.1 years (mean ± SD), SU group: 1.5 ± 
2.1 years (mean ± SD) 
Inclusion Criteria: (1) disease diagnosed according to the National Diabetes Data 
Group (2) ICA positive (3) patients were not related to each other. 
Exclusion Criteria: (1) history of ketonuria, diabetic ketoacidosis or marked 
hypoglycemia initially requiring insulin. 
Diagnostic Criteria:  Type 2 diabetes newly diagnosed by general practitioner and 
fasting plasma glucose higher than 6.0 mmol/L on two subsequent occasions. 
Co-Morbidities: not given 
Co-Medications: not given 
Groups: Insulin: 5 participants, SU: 5 participants. 
Loss To Follow-Up: 0% (0/10) participants 
Interventions Country/ Location: Japan 
Intervention (Route, Total Dose/Day, Frequency):  small doses of subcutaneous 
insulin 
Control (Route, Total Dose/Day, Frequency): sulphonylurea (glibenclamide) 
Treatment Before Study: Diet therapy before study entry. Consume a diet 
containing 30 kcal per Kg ideal body weight per day with 55%-60% carbohydrate. 
Outcomes Primary Outcome(s) (as stated in the publication):  C-peptide, Blood glucose, ICA 
titres, GADA levels 
Secondary Outcome(s) (as stated in the publication):   HbA1c 
Additional Outcomes: BMI e adverse effects 
Study Details  Duration Of Intervention: 30 months 
Duration Of Follow-Up: 30 months 
Run-In Period:  not given 
Publication Details Language Of Publication: English 
Commercial Funding: no 
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Stated Aim For Study Quote: “conduct a prospective pilot study on the effects of small doses of insulin 
in patients with presumed NIDDM who were ICA and thus at high risk for 
progression to insulin dependence” 
 
 
 
Kobayashi 2002 
 
 
 
Methods Study Design: randomized controlled trial 
Ethics Approval Obtained: unclear 
Patient Consent Obtained: yes 
Analysis by Intention to Treat: no, exploratory trial 
Power Calculation: no 
Participants Total of participants: 55 participants 
Sex (Female% / Male%):  Insulin group: F: 30% (2/5), M: 60% (3/5), SU group: F: 
30% (2/5), M: 60% (3/5) 
Age (Median Years):  Insulin group: 51 years, SU group: 48 years 
Ethnic Groups (%): not stated 
Duration of disease: not given 
Inclusion Criteria: (1) GADA were positive in two samples taken within two 
months; (2) diabetes was in a non-insulin-dependent stage when screened for 
GADA but required sulphonylurea treatment; (3) the duration of the diabetes 
was less than five years. 
Exclusion Criteria: (1) history of ketosis, ketoacidosis, or hyperglycemia requiring 
insulin treatment; (2) renal and hepatic dysfunction affecting C peptide 
clearance and glucose tolerance. 
Diagnostic Criteria: Type 2 diabetes newly diagnosed by general practitioner and 
fasting plasma glucose higher than 6.0 mmol/L on two subsequent occasions 
Co-Morbidities: not given 
Co-Medications: not given 
Groups: Insulin group: 25 participants, SU group: 30 participants 
Loss To Follow-Up: 9% (5/55) participants 
Interventions Country/ Location: Japan 
Intervention (Route, Total Dose/Day, Frequency):  small doses of subcutaneous 
insulin injection 
Control (Route, Total Dose/Day, Frequency): oral sulphonylurea (glibenclamide) 
Treatment Before Study: not given 
Outcomes Primary Outcome(s): serum C peptide response and level of blood glucose during 
75-g OGTT.  
Secondary Outcome(s): Titers of GADA, levels of FBG, HbA1c, serum creatinine, 
and urinary microalbumin 
Additional Outcomes:  not stated 
Study Details  Duration Of Intervention:  36 months 
Duration Of Follow-Up: 36 months 
Run-In Period:  not given 
Publication Details Language Of Publication: English 
Commercial Funding: yes 
Stated Aim For Study Quote: “conduct a prospective pilot study on the effects of small doses of insulin 
in patients with presumed NIDDM who were ICA and thus at high risk for 
progression to insulin dependence” 
 
 
 
L-Hallin 1999  
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Methods Study Design:  parallel randomized controlled trial 
Ethics Approval Obtained: yes 
Patient Consent Obtained: yes 
Analysis by Intention to Treat: no, not stated 
Power Calculation: no 
Participants Total of participants: 15 participants 
Sex (Female% / Male%):  Placebo (insulin+placebo): F: 58% (7/12), M: 48% 
(5/12), SU (insulin+SU): F: 0% (0/3), M: 100% (3/3) 
Age (Median Years):  Placebo (insulin+placebo): 56.4 years, SU (insulin+ SU): 60 
years 
Ethnic Groups (%): not specified 
Duration of the disease: Placebo (insulin+placebo): 9.9 ± 6.2 years (mean ± SD); 
group SU (insulin+SU): 8.8 ± 4.9 years (mean ± SD) but not reported for antibody 
positive patients only 
Inclusion Criteria: (1) type 2 diabetic patients (the findings from the study's 15 
GAD positive patients were of relevance to this review) (2) 35-75 years old (3) 
BMI 22-32 Kg/m2 (4) previous successful response to sulphonylurea (5) fasting 
blood glucose>8 mmol/l and/or a postprandial blood glucose>11mmol/l and/or 
an HbA1c>3% above normal per local standard, despite treatment with maximal 
doses of SU for at least 3 months 
Exclusion Criteria: (1) renal disease (2) liver dysfunction (3) concurrent acute 
disease 
Diagnostic Criteria: Type 2 diabetes GAD antibodies. 
Co-Morbidities: Not given 
Co-Medications:  Not given 
Groups: Placebo (insulin+placebo): 12 participants, SU (insulin + SU): 3 
participants 
Loss To Follow-Up: 13% (2/15) participants 
Interventions Country/ Location: Sweden 
Intervention (Route, Total Dose/Day, Frequency): Sulphonylurea (glibenclamide) 
and premix insulin for 8 months 
Control (Route, Total Dose/Day, Frequency): Sulphonylurea (glibenclamide) and 
premix insulin for 4 months, then premix insulin alone for 4 months 
Treatment Before Study:  Run-in period for 1-2 weeks, SU treatment was 
standardized to 10.5mg glibenclamide daily. Then 4 months on premixed insulin 
in combination with open glibenclamide. 
Outcomes Primary Outcome(s) (as stated in the publication): not stated  
Secondary Outcome(s) (as stated in the publication):  not stated  
Additional Outcomes:  Fasting blood glucose (mmol/l), HbA1c (%), Fasting C-
peptide (nmol/l), Free P-insulin (mU/l), KITT (%/min), Weight (Kg) 
Study Details  Duration Of Intervention: 8 months 
Duration Of Follow-Up: 8 months 
Run-In Period: 4 months 
Publication Details Language Of Publication: English 
Commercial Funding: yes 
Stated Aim For Study Quote: “Identifying responders to combined glibenclamide and insulin 
treatment and predictors of such response, in patients no longer able to achieve 
acceptable metabolic control.” 
 
 
 
Li 2009 
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Methods Study Design:  parallel randomized controlled trial 
Ethics Approval Obtained: yes 
Patient Consent Obtained: yes 
Analysis by Intention to Treat: no, not stated 
Power Calculation: no 
Participants Total of participants: 35 participants 
Sex (Female% / Male%): Insulin: F: 27% (5/18), M: 72% (13/18), Insulin+Vit D: F: 
17.6% (3/17), M: 82.4% (14/17) 
Age (Median Years): Insulin: 42.8 years, Insulin+Vit D: 38.5 years  
Ethnic Groups (%): not stated 
Duration of the disease: Insulin: 0.5 (0.1–4.0) years (mean (min-max)); 
Insulin+VitD): 1.0 (0.1–4.0) years (mean (min-max)) 
Inclusion Criteria: (1) age to onset over 20 years (2) no ketosis within the first 6 
months after diagnosis (3) disease duration less than 5 years (4) autoantibodies 
to GADA positive twice within one month and (5) fasting C-peptide (FCP) > 200 
pmol/L at entry. 
Exclusion Criteria: (1) patients with liver or kidney disorders (alanine 
aminotransferase or aspartate aminotransferase > 2.5-fold of upper normal 
limit, total bilirubin > 1.5 U/ml or blood creatinine > 15 mg/dl (2) premenopausal 
women who did not use effective contraception, or any pregnant women (3) 
patients who have had any severe systemic disease such as heart failure, cancer, 
stroke, or recent surgery. 
Diagnostic Criteria: Diabetes diagnosed according to American Diabetes 
Association (ADA) standards 
Co-Morbidities: not given 
Co-Medications:  not given 
Groups: Insulin: 18 participants, Insulin+Vit D: 17 participants 
Loss To Follow-Up: 0% (0/35) participants 
Interventions Country/ Location: China 
Intervention (Route, Total Dose/Day, Frequency): both groups treated with 
mixed human Insulin (Novolin 30 R or Humulin 70/30). Vit D group was Alpha-
calcidol 0.25 ug bid for 12 months glibenclamide) and premix insulin for 8 
months 
Control (Route, Total Dose/Day, Frequency):  both groups treated with mixed 
human Insulin (Novolin 30 R or Humulin 70/30). 
Treatment Before Study: none 
Outcomes Primary Outcome(s): not stated 
Secondary Outcome(s): not stated 
Additional Outcomes:  Fasting C-peptide (FCP) and 2h postprandial C-peptide 
(PCP) 
Study Details  Duration Of Intervention: 12 months 
Duration Of Follow-Up: 12 months 
Run-In Period: none 
Publication Details Language Of Publication: English 
Commercial Funding: no 
Stated Aim For Study Quote: "to study the possible benefits of 1-α-hydroxyvitamin D3 combined with 
insulin on β-cell function in LADA" 
 
 
 
Maruyama 2003 
 
 
 
Methods Study Design:  parallel randomized controlled trial 
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Ethics Approval Obtained: unclear 
Patient Consent Obtained: unclear 
Analysis by Intention to Treat: no, not stated 
Power Calculation: no 
Participants Total of participants: 54 participants 
Sex (Female% / Male%):  Insulin group: F: 37.5% (9/24), M: 62.5% (15/24), SU 
group: F: 53% (16/30), M: 47% (14/30) 
Age (Median Years): Insulin group: 56.6 years, SU group: 50.4 years  
Ethnic Groups (%): not stated 
Duration of the disease: Insulin group: 2.4±2.9 years (mean ± SD); SU group: 2.7 
± 3.8 years (mean ± SD) 
Inclusion Criteria:(1) diagnosis of diabetes according to ADA criteria (2) not 
treated with insulin at least 6 months after diagnosis of diabetes (3) positive 
GADA in 2 samples taken within 2 months (4) disease duration < 10 years (5) 
patients were unrelated 
Exclusion Criteria: (1) history of ketonuria, diabetic ketoacidosis, marked 
hyperglycemia requiring insulin, (2) renal or hepatic dysfunction affecting C-
peptide clearance and glucose tolerance 
Diagnostic Criteria: Diabetes diagnosed according to American Diabetes 
Association (ADA) standards 
Co-Morbidities: not given 
Co-Medications: not given 
Groups: Insulin group: 24 participants, SU group: 30 participants 
Loss To Follow-Up: unclear (54 reported at baseline but 56 reported at 48 
month) 
Interventions Country/ Location: Japan 
Intervention (Route, Total Dose/Day, Frequency):  subcutaneous insulin therapy 
Control (Route, Total Dose/Day, Frequency): sulphonylurea (glibenclamide) 
Treatment Before Study: none 
Outcomes Primary Outcome(s):  Stimulated C-peptide and change in C-peptide response 
(ng/ml), blood glucose level 
Secondary Outcome(s):   HbA1c (%), GADA (U/ml), BMI 
Additional Outcomes: not given 
Study Details  Duration Of Intervention: 4 years 
Duration Of Follow-Up: 4 years (with 3-monthly assessments) 
Run-In Period: none 
Publication Details Language Of Publication: English 
Commercial Funding: not reported 
Stated Aim For Study Quote: "to clarify the efficacy of small dose of insulin for progressive β-cell 
failure." 
 
 
 
Maruyama 2008 
 
 
 
Methods 
 
 
Study Design:  parallel randomized controlled trial 
Ethics Approval Obtained: yes 
Patient Consent Obtained: yes 
Analysis by Intention to Treat: no, not stated 
Power Calculation: 90% 
Participants Total of participants: 60 participants 
Sex (Female% / Male%): Insulin group: F: 43% (13/30), M: 57% (17/30), SU group: 
F: 46% (14/30), M: 53% (16/30) 
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Age (Median Years):  Insulin group: 54 years, SU group: 51 years 
Ethnic Groups (%):  not stated 
Duration of the disease: Insulin group:  1.7 ± 1.9 years (mean ± SD); SU group: 
1.9 ± 1.7 years (mean ± SD) 
Inclusion Criteria: (1) diagnosis of diabetes according to ADA criteria (2) not 
treated with insulin at least 6 months after diagnosis of diabetes (3) positive 
GADA in 2 samples taken within 2 months (4) disease duration < 10 years (5) 
patients were unrelated 
Exclusion Criteria: (1) history of ketonuria, diabetic ketoacidosis, marked 
hyperglycemia requiring insulin, (2) renal or hepatic dysfunction affecting C-
peptide clearance and glucose tolerance, 
Diagnostic Criteria:  Diabetes diagnosed according to American Diabetes 
Association (ADA) standards 
Co-Morbidities: Not given 
Co-Medications: Not given 
Groups:  Insulin group: 30 participants, SU group: 30 participants 
Loss To Follow-Up: 0% (0/60) participants 
Interventions Country/ Location:  Japan 
Intervention (Route, Total Dose/Day, Frequency):   subcutaneous insulin therapy 
Control (Route, Total Dose/Day, Frequency): sulphonylurea (glibenclamide) 
Treatment Before Study: none 
Outcomes Primary Outcome(s): Stimulated C-peptide and change in C-peptide response 
(ng/ml) 
Secondary Outcome(s):  Blood glucose, HbA1c (%), GADA (U/ml), insulin 
dependent state and BMI 
Additional Outcomes: not given 
Study Details  Duration Of Intervention:  5 years 
Duration Of Follow-Up: 5 years (with 3-monthly assessments) 
Run-In Period: none 
Publication Details Language Of Publication: English 
Commercial Funding: not reported 
Stated Aim For Study Quote:  "to examine the ability of insulin to prevent progressive β-cell 
dysfunction in SPIDDM " 
 
 
 
Palmer 2018 
 
 
 
Methods Study Design:   parallel randomized, open label study 
Ethics Approval Obtained: not stated 
Patient Consent Obtained: not stated 
Analysis by Intention to Treat:  yes 
Power Calculation: no 
Participants Total of participants: 64 participants 
Sex (Female% / Male%):  Rosiglitazone Autoantibody Positive: F: 27% (4/15), M: 
73% (11/15); Rosiglitazone Autoantibody Negative: F: 27% (4/15), M: 73% 
(11/15); Glyburide Autoantibody Positive: F: 15% (2/13), M: 85% (11/13); 
Glyburide Autoantibody Negative:  F: 38% (8/21), M: 62% (13/21) 
Age (Median Years): Rosiglitazone Autoantibody Positive:  55.4 years, 
Rosiglitazone Autoantibody Negative:  56.4 years, Glyburide Autoantibody 
Positive:  53.7, Glyburide Autoantibody Negative:  57.5 years. 
Ethnic Groups (%): not given 
Inclusion Criteria: (1) Age at onset of diabetes - 35-69 years old; (2) No history of 
ketonuria or ketoacidosis; (3) Not requiring insulin to achieve glycemic control; 
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(4) Not receiving more than two oral hypoglycemic agents; (4) Not taking a 
thiazolidinedione agent; (5)  HbA1c in established patients (on an oral 
hypoglycemia agent for over 4 months) of greater than 6% and under 10%; (6) 
Fasting c-peptide greater than or equal to 0.8 ng/ml; (7) Women must be either 
post-menopausal or on adequate birth control (i.e. oral contraceptives, tubal 
ligation, hysterectomy, condoms, or diaphragm) or use abstinence. 
Exclusion Criteria: (1) Patients with history of chronic pancreatitis or other 
secondary causes of diabetes; (2) Patients receiving systemic corticosteroids; (3) 
Patients with severe systemic illness (e.g. recent MI, CHF or cerebral vascular 
disease); (4) Creatinine greater than 1.4 or liver enzymes greater than 2 times 
the upper limits of normal; (5) Not able to adhere to the protocol. 
Diagnostic Criteria: not stated 
Co-Morbidities: not given 
Co-Medications: not given 
Groups: Rosiglitazone Autoantibody Positive: 15 participants, Rosiglitazone 
Autoantibody Negative: 15 participants, Glyburide Autoantibody Positive: 13 
participants, Glyburide Autoantibody Negative: 21 participants 
Loss To Follow-Up: 4/64 (6%) 
Interventions Country/ Location: United States 
Intervention (Route, Total Dose/Day, Frequency): Rosiglitazone taken orally at a 
dosage of 4 mg once per day and increase to twice per day if adequate glycemic 
control was not achieved 
Control (Route, Total Dose/Day, Frequency): Glyburide taken orally, initially 2.5 
mg in the morning or dose subject received prior to starting the study. Dosage 
was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day 
if necessary to achieve desired glycemic control. 
Treatment Before Study: not given 
Outcomes Primary Outcome(s):  Fasting and Stimulated C-peptide Measured 
Secondary Outcome(s): ICA, IAA, IA-2A, and GADA and cellular immunoblotting 
measurement of T cell responses to islet antigens 
Additional Outcomes:  Serious adverse effects and adverse events 
Study Details  Duration Of Intervention: 36 months 
Duration Of Follow-Up: 3 years 
Run-In Period: not given 
Publication Details Language Of Publication: English 
Commercial Funding: no 
Stated Aim For Study Quote: “we tested recently diagnosed antibody positive type 2 diabetic patients 
to determine whether treatment with rosiglitazone results in greater 
preservation of β-cell function compared to treatment with glyburide.” 
 
 
 
Pozzilli 2018 
 
 
 
Methods Study Design: post-hoc, randomized trial 
Ethics Approval Obtained: not stated but ethics approval obtained in AWARD-2, 
-4 and -5 study  
Patient Consent Obtained: not stated but patient consent obtained in AWARD-2 
study, -4 and -5 study. 
Analysis by Intention to Treat: exploratory trial 
Power Calculation: no 
Participants Total of participants: 2466 patients 
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Sex (Female% / Male%):  AWARD-2: F: 51% (248/488), M: 49% (240/488), 
AWARD-4: F: 55% (475/870), M: 45% (395/870), AWARD-5: F: 57% (625/1108), 
M: 43% (483/1108) 
Age (Median Years): AWARD-2: 56,7 years, AWARD-4: 58,1 years, AWARD-5: 
56,1 years 
Ethnic Groups (%):  not given 
Duration of disease:  AWARD-2: GADA-negative: 9.1±6.08 years (mean  SD), 
GADA-positive: 9.3±5.56 years (mean ± SD), GADA-low*: 9.0±5.89 years (mean ±  
SD), GADA-high*: 10.5±4.36 years (mean ±  SD);  AWARD-4: GADA-negative: 
13.0±6.94years (mean ±  SD),  GADA-positive: 10.9±6.85years (mean ±  SD), 
GADA-low*: 11.2±6.79 years (mean ±  SD), GADA-high*: 10.4± 7.00 years (mean 
±  SD);  AWARD-5: GADA-negative: 7.1±5.08 years (mean ±  SD), GADA-positive: 
6.1±4.20 years (mean ±  SD), GADA-low*: 6.6±4.30 years (mean ±  SD), GADA-
high*: 4.5±3.53 years (mean ±  SD); 
Inclusion Criteria: (1) 18–75 years old patients, (2) Type 2 diabetes (≥6 months' 
duration), (3) HbA1c of ≥7.0% (≥53 mmol/mol) and ≤11.0% (≤97 mmol/mol), or  
HbA1c value of >8.0% (>63.9 mmol/mol) and ≤9.5% (≤80.3 mmol/mol) on diet and 
exercise alone, or ≥7.0% (≥53.0 mmol/mol) and ≤9.5% (≤80.3 mmol/mol) on 
monotherapy or combination therapy (metformin plus another oral 
antihyperglycaemic medication), (4) BMI ≥23 and ≤45 Kg/m2, (5) Stable weight 
for 3 months prior to screening, (6) Currently using insulin for at least 3 months 
with a conventional insulin regimen with or without oral medications. 
Exclusion Criteria: (1) Type 2 Diabetes, (2) Previous therapy with glucagon-like 
peptide 1 (GLP-1) agonists within 3 months prior to screening, (3) 1 or more 
episodes of ketoacidosis within 6 months prior to screening, (4) Have been 
treated with prescription or over the counter medication to promote weight loss 
within 3 months prior to screening (5) Estimated glomerular filtration rate (eGFR) 
less than or equal to 30 milliliters per minute per 1.73 square meters 
(ml/min/1.73 m2) at screening, (6) Taking steroids for greater than 14 days 
except for topical, eye, nasal, or inhaled, (7) History of heart failure, New York 
Heart Classification III or IV within 2 months prior to screening, (8) 
Gastrointestinal (GI) problems such as diabetic gastroparesis or bariatric surgery 
(stomach stapling) or chronically taking medications that directly affect GI 
motility, (9) Acute or chronic hepatitis or pancreatitis, (10) Self or family history 
of 2A or type 2B multiple endocrine neoplasia or medullary C-Cell hyperplasia, 
(11) Serum calcitonin greater than or equal to 20 picograms per milliliter 
(pcg/ml) at screening, (12) Organ transplant except cornea,(13) Significant active 
autoimmune disease such as Lupus or Rheumatoid Arthritis, (14) History of or 
active malignancy except skin or in situ cervical or prostate cancer within the last 
5 years,  (15) Known drug or alcohol abuse, (16) Have enrolled in another clinical 
trial within the last 30 days. 
Diagnostic Criteria:  diagnosed with T2D, with a body mass index (BMI) of 23-45 
Kg/m2 
Co-Morbidities: not given 
Co-Medications: not given 
Groups:   Dulaglutide group: 1710 patients, Glargine group: 298 patients, 
Sitagliptin group: 294 patients, Placebo group: 164 patients 
Loss To Follow-Up: 0% (0/2466) participants 
Interventions Country/ Location:  Europe, the Americas, and Asia 
Intervention (Route, Total Dose/Day, Frequency): once weekly dulaglutide 
treatment groups (mainly 1.5 mg or 0.75 mg)  
Control (Route, Total Dose/Day, Frequency): glargine, sitagliptin or placebo 
Treatment Before Study:  not stated 
Outcomes Primary Outcome(s): HbA1c, assessed in patients diagnosed with apparent T2D 
that were positive for GADA vs. GADA-negative patients treated with dulaglutide. 
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Secondary Outcome(s): FBG levels; HOMA-β and HOMA-IR; incidence and rate 
of hypoglycemia 
Additional Outcomes: not given 
Study Details  Duration Of Intervention: 12 months 
Duration Of Follow-Up: 12 months 
Run-In Period: not given 
Publication Details Language Of Publication:  English 
Commercial Funding: yes 
Stated Aim For Study Quote: “evaluate the effect of dulaglutide on glycemic control (HbA1c) in GADA-
positive LADA vs. GADA-negative T2D patients.” 
 
 
 
Thunander 2011 
 
 
 
Methods Study Design: randomized controlled trial (incomplete randomization as patients 
refusing insulin were not analyzed within the insulin arm as per ITT but were 
considered within the tablet arm) 
Ethics Approval Obtained: yes 
Patient Consent Obtained: yes 
Analysis by Intention to Treat:  reported to use intention to treat analysis but not 
evidence this was performed 
Power Calculation: no 
Participants Total of participants: 37 participants 
Sex (Female% / Male%):   Conventional treatment group: F: 42% (7/17), M: 58.8% 
(10/17), Insulin group: F: 55% (11/20), M: 45% (9/20) 
Age (Median Years): Conventional treatment group: 57.8 years, Insulin group: 
51.0 years 
Ethnic Groups (%):  not stated 
Duration of the disease:  All participants: 5.0 (1–24) months (mean (min-max)); 
Conventional treatment group: 6.0 (1.5–24) months (mean (min-max)); insulin 
group:  5.0 (1–22) months (mean (min-max)) 
Inclusion Criteria: (1) diagnosis of diabetes (2) aged >30 years (3) not insulin 
requiring at diagnosis (3) GAD antibodies or ICA antibodies. 
Exclusion Criteria: (1) mental conditions or severe physical illness. 
Diagnostic Criteria:  Diagnosed with diabetes with at least one of GADA or ICA 
Co-Morbidities: not given 
Co-Medications: not given 
Groups:  Conventional treatment group: 17 participants, Insulin: 20 participants 
Loss To Follow-Up:  Conventional treatment group: 12% (2/17) lost at 36 months, 
Insulin group: 10% (2/20) lost at 36 months. 
Interventions Country/ Location:  Sweden 
Intervention (Route, Total Dose/Day, Frequency):   subcutaneous insulin therapy 
starting with 2-6 units intermediate-acting insulin at night. 
Control (Route, Total Dose/Day, Frequency):  diet +/- oral hypoglycaemic agents 
(metformin and or SU) 
Treatment Before Study:  none 
Outcomes Primary Outcome(s): not stated  
Secondary Outcome(s): not stated 
Additional Outcomes: Collected at baseline and 12 months, 24 months and 36 
months: HbA1c, Glucagon-stimulated C-peptide and changes in C-peptide were 
measured. 
Study Details  Duration Of Intervention: 36 months 
Duration Of Follow-Up: 36 months 
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Run-In Period:  none 
Publication Details Language Of Publication:  English 
Commercial Funding: no 
Stated Aim For Study Quote:  "To investigate the effect of early insulin treatment of LADA patients, 
during three years, on residual β-cell function and metabolic control, compared 
to a group initially treated with diet and/ or hypoglycemic agents (OHA). " 
 
 
 
Wang 2019 
 
 
 
Methods Study Design: randomized control trial 
Ethics Approval Obtained: yes 
Patient Consent Obtained: yes 
Analysis by Intention to Treat:  no, exploratory trial 
Power Calculation: no 
Participants Total of participants: 40 participants 
Sex (Female% / Male%):   SITA group (insulin + sitagliptin): F: 35% (7/20), M: 65% 
(13/20), Control group (insulin without sitagliptin): F: 45% (9/20), M: 55% (11/20) 
Age (Median Years):  not given 
Ethnic Groups (%):  not stated 
Duration of disease:  duration of diabetes of ≤3 years 
Inclusion Criteria: (i) diabetes diagnosed according to the report of the World 
Health Organization in 1999; (ii) age range 30–70 years; (iii) glutamic acid 
decarboxylase anti- body (GADA)-positive; (iv) insulin independent within the 
first 6 months after the diagnosis of diabetes; (v) fasting C- peptide level >200 
pmol/l or a 2-h postprandial C-peptide >400 pmol/l; and (vi) duration of diabetes 
of ≤3 years. 
Exclusion Criteria:   (i) total insulin doses >0.8 U/Kg/day; (ii) evidence of any other 
autoimmune diseases; (iii) evidence of chronic or acute infection; (iv) a history 
of any malignancy, congestive heart failure or secondary diabetes; (v) renal 
diseases or renal dysfunction with serum creatinine of ≥1.5 mg/dl for men and 
≥1.4 mg/dl for women; (vi) women who were pregnant, had several miscarriages 
or were breast-feeding; and (vii) patients unable to abide by the treat- ment 
protocol. 
Diagnostic Criteria:  1999 World Health Organization (WHO) Diagnostic Criteria 
for Diabetes Mellitus that used as criteria fasting plasma glucose concentration 
of ≥ 7.0 mmol 
Co-Morbidities: not given 
Co-Medications: not given 
Groups: SITA group (insulin with sitagliptin): 20 participants, Control group 
(insulin without sitagliptin): 20 participants 
Loss To Follow-Up: 0% (0/40) participants 
Interventions Country/ Location: China 
Intervention (Route, Total Dose/Day, Frequency):  insulin with sitagliptin 100 
mg/day  
Control (Route, Total Dose/Day, Frequency):  insulin without sitagliptin: 
administration of premixed insulin (30% insulin aspart and 70% insulin aspart 
protamine) twice or three times daily according to the patient’s glycemic profile. 
Treatment Before Study:  diet and lifestyle modifications and insulin dose 
adjustment. 
Outcomes Primary Outcome(s): percentage of T-lymphocyte, and the messenger 
ribonucleic acid expression  
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Secondary Outcome(s): HbA1c, GADA, fasting blood glucose, C-peptide and 
postprandial blood glucose 
Additional Outcomes: not given 
Study Details  Duration Of Intervention: 12 months. 
Duration Of Follow-Up:  12 months 
Run-In Period: 3 months 
Publication Details Language Of Publication:  Englsih 
Commercial Funding: yes 
Stated Aim For Study Quote: “we tested T-lymphocyte subsets and expression of relevant 
transcription factors in LADA patients with sitagliptin intervention for up to 1-
year.” 
 
 
 
Yang 2009  
 
 
 
Methods Study Design: parallel randomized controlled trial 
Ethics Approval Obtained: yes 
Patient Consent Obtained: yes 
Analysis by Intention to Treat:  no 
Power Calculation: no 
Participants Total of participants: 54 participants 
Sex (Female% / Male%):   Insulin group: F 42% (5/12), M: 58% (7/12), Insulin plus 
rosiglitazone: F: 50% (6/12), M: 50% (6/12), SU group: F: 43% (6/14), M: 57% 
(8/14), Rosiglitazone group: F: 33% (5/15), M: 66% (10/15)  
Age (Median Years):  Insulin group: 48.5 years, Insulin plus rosiglitazone: 48.0 
years, SU group: 50.0 years, Rosiglitazone group: 50.6 years 
Ethnic Groups (%):  no stated 
Duration of disease: Insulin group: 1.35 ± 1.52 years (mean ± SD); Insulin + 
rosiglitazone group: 1.5 ± 1.52 years (mean ± SD); SU group: 1.1 ± 1.31 years 
(mean ± SD); Rosiglitazone group: 1.16 ± 1.46 years (mean ± SD); 
Inclusion Criteria: (1) No ketosis within the first 6 months after diagnosis (2) 
disease duration less than 5 years (3) FCP level of 0.2 nmol/l or more (4) diet 
alone cannot achieve glycemic control. 
Exclusion Criteria:  impaired liver, kidney or heart function or other severe 
diseases. 
Diagnostic Criteria:  type 2 diabetes diagnosed as LADA 
Co-Morbidities: not given 
Co-Medications: not given 
Groups:  Insulin group: 12 participants, Insulin + Rosiglitazone group: 12 
participants, SU group: 14 participants, Rosiglitazone group: 15 participants. 
Loss To Follow-Up: 0% (0/54) participants 
Interventions Country/ Location:  China 
Intervention (Route, Total Dose/Day, Frequency):   Patients with GADA <175 and 
FCP >0.3 nmol/l were randomized to SU. Patients with GADA<175 U/ml and FCP 
<0.3 nmol/l were assigned subcutaneous insulin with rosiglitazone 4 mg/d. 
Control (Route, Total Dose/Day, Frequency):  Patients with GADA <175 and 
FCP>0.3 nmol/l were randomized to rosiglitazone 4 mg/d. Patients with GADA 
<175 U/ml and FCP <0.3 nmol/l were assigned subcutaneous insulin therapy 
Treatment Before Study:  None 
Outcomes Primary Outcome(s):  fasting C-peptide (FCP), C-peptide after 2-h glucose load 
(PCP) and HOMA2-%β 
Secondary Outcome(s):  HbA1c 
Additional Outcomes: adverse effects 
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Study Details  Duration Of Intervention: 36 months 
Duration Of Follow-Up: 36 months 
Run-In Period: none 
Publication Details Language Of Publication: English 
Commercial Funding: no 
Stated Aim For Study Quote:  " To clarify whether LADA benefit from rosiglitazone" 
 
 
 
Zhang 2020 
 
 
 
Methods Study Design: randomized-controlled study   
Ethics Approval Obtained: yes 
Patient Consent Obtained: not given 
Analysis by Intention to Treat: not specified  
Power Calculation: no 
Participants Total of participants: 60 participants 
Sex (Female% / Male%):  Group A (metformin + insulin): F: 48% (10/21), M: 52% 
(11/21), Group B (saxagliptin 5 mg/day + metformin + insulin): F: 55% (11/20), 
M: 45% (9/20), Group C (vitD3 2000 IU/day + saxagliptin 5 mg/day + metformin 
+ insulin): F: 37% (7/19), M: 63% (12/19) 
Age (Median Years (Range)):   Group A (metformin + insulin): 45 years, Group B 
(saxagliptin 5 mg/day + metformin + insulin): 42 years, Group C (vitD3 2000 
IU/day + saxagliptin 5 mg/day + metformin + insulin): 41 years 
Ethnic Groups (%): not given 
Duration of the disease: Group A (metformin + insulin):  7.76 ± 5.51 months 
(mean ± SD); Group B (saxagliptin 5 mg/day + metformin + insulin):  9.43 ± 11.40 
months (mean ± SD); Group C (vitD3 2000 IU/day + saxagliptin 5 mg/day + 
metformin + insulin): 7.29 ± 8.69 months (mean ± SD) 
Inclusion Criteria: (1) Met the 1999 World Health Organization (WHO) Diagnostic 
Criteria for Diabetes Mellitus; (2) Aged between 18 and 70 years old; (3) Were 
GADA positive; (4) Had serum fasting C-peptide ≥ 100 pmol/L or 2-hour 
postprandial C-peptide ≥ 200 pmol/L; (5) Had a duration of diabetes < 4 years. 
Exclusion Criteria: (1) Women who were pregnant, intending to become 
pregnant during the study period, or currently lactating; (2) Gestational diabetes 
mellitus or other specific types of diabetes; (3) Allergy to saxagliptin, vitamin D3 
(vitD3) or excipient; (4) Treatment with medications including DPP-4 inhibitors, 
GLP-1 analogues, GLP-1 receptor agonists, or thiazolidinediones (TZDs) in the 8 
weeks prior to randomization; (5) Hypercalcaemia (exceeding the upper limit of 
the reference range ); (6) Treatment with systemic corticosteroid therapy(oral 
or intravenous) consecutively for more than 7 days over the past 6 months; (7) 
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 
3 times the normal upper limit, or total bilirubin (TBIL) more than 2 times the 
normal upper limit; (8) Serum creatinine levels ≥ 1.5 mg/dl for males and ≥ 1.4 
mg/dl for females or CrCl ≤ 50 ml/min; (9) Malignant tumours; (10) Mental 
disorders; (11) History of alcohol abuse or illegal drug abuse; (12) Serious 
systemic disease not suitable for the study by evaluation of the investigator; or 
(13) Inability to abide by the treatment protocol. 
Diagnostic Criteria: 1999 World Health Organization (WHO) Diagnostic Criteria 
for Diabetes Mellitus that used as criteria Fasting plasma glucose concentration 
of ≥ 7.0 mmol/l. 
Co-Morbidities: not given 
Co-Medications: not given 
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Groups: Group A (metformin + insulin): 21 participants, Group B (saxagliptin 5 
mg/day + metformin + insulin): 20 participants, Group C (vitD3 2000 IU/day + 
saxagliptin 5 mg/day + metformin + insulin): 19 participants 
Loss To Follow-Up: 0% (0/60) participants 
Interventions Country/ Location: China 
Intervention (Route, Total Dose/Day, Frequency): Group A (1-1.7 g metformin 
per/day + insulin), Group B (saxagliptin 5 mg/day + metformin + insulin) and 
Group C (vitD3 2000 IU/day + saxagliptin 5 mg/day + metformin + insulin) 
Control (Route, Total Dose/Day, Frequency): not applicable 
Treatment Before Study: not given 
Outcomes Primary Outcome(s): fasting C-peptide (FCP), 2-hour postprandial C-peptide 
(PCP), and the C-peptide index (CPI, serum C-peptide-to-plasma glucose level 
ratio, including fasting CPI (FCPI) and postprandial CPI (PCPI)) 
Secondary Outcome(s): fasting blood glucose (FBS), postprandial glucose (PBS), 
HbA1c and GADA titres 
Additional Outcomes: not given 
Study Details  Duration Of Intervention: 12 months 
Duration Of Follow-Up: 3-, 6- and 12-month intervals 
Run-In Period: not given 
Publication Details Language Of Publication: English 
Commercial Funding: yes  
Stated Aim For Study Quote: “we hypothesized that vitamin D3 plus a DPP-4 inhibitor might achieve 
better protective effects on β-cell function in LADA” 
 
 
 
Zhao 2014 
 
 
 
Methods Study Design: open-label, randomized-controlled study 
Ethics Approval Obtained: yes 
Patient Consent Obtained: yes 
Analysis by Intention to Treat: no, exploratory trial 
Power Calculation: no 
Participants Total of participants: 30 participants 
Sex (Female% / Male%): Group A (insulin + sitagliptin): F. 33% (5/15), M: 66% 
(10/15), Group B (insulin): F: 47% (7/15), M: 53% (8/15) 
Age (Median Years):   Group A: 48.0 years, Group B: 46.9 years 
Ethnic Groups (%):  not stated 
Duration of disease:  Group A (insulin + sitagliptin): 1.4 ± 0.2 years (mean ± SD); 
Group B (insulin): 1.4 ± 0.2 years (mean ± SD) 
Inclusion Criteria:  1) diabetes diagnosed according to the report of the World 
Health Organization in 1999, 2) age of 25–70 years, 3) glutamic acid 
decarboxylase (GAD) antibody (GADA) positive, 4) insulin independent within the 
first 6 months after the diagnosis of diabetes, 5) fasting C-peptide (FCP) level of 
200 pmol/L or greater or a 2-hour postprandial C-peptide (CP) ≥ 400 pmol/L or 
greater, and 6) duration of diabetes of 3 years or less. 
Exclusion Criteria: 1) evidence of any other autoimmune diseases; 2) insulin 
requirement of more than 0.8 U/kg·d; 3) evidence of chronic or acute infection; 
4) a history of any malignancy, congestive heart failure, or secondary diabetes; 
5) renal disease or renal dysfunction with serum creatinine of 1.5 mg/dl or 
greater for males and 1.4 mg/dl or greater for females; 6) women who were 
pregnant, had frequent abortion, or were breastfeeding; and 7) patients unable 
to follow the treatment protocol. 
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Diagnostic Criteria: diabetes diagnosed according to the report of the World 
Health Organization in 1999 
Co-Morbidities: not given 
Co-Medications: not given 
Groups:  Group A (insulin + sitagliptin): 15 participants, Group B (insulin): 15 
participants 
Loss To Follow-Up: 0 
Interventions Country/ Location: China 
Intervention (Route, Total Dose/Day, Frequency):   Group A: insulin with 
sitagliptin 100 mg daily  
Control (Route, Total Dose/Day, Frequency):  Group B: insulin without sitagliptin 
Treatment Before Study:  1 month of insulin therapy 
Outcomes Primary Outcome(s): fasting and 2-hour C-peptide levels, 2-hour postprandial 
blood glucose 
Secondary Outcome(s): BMI, GADA titers and HbA1c 
Additional Outcomes:  adverse events  
Study Details  Duration Of Intervention: 12 months 
Duration Of Follow-Up: 12 months 
Run-In Period: 1 month 
Publication Details Language Of Publication:  English 
Commercial Funding: no 
Stated Aim For Study Quote: “The objective of the study was to investigate the effects of the DPP-4 
inhibitor on β-cell function in patients with recent-onset latent autoimmune 
diabetes in adults (LADA).” 
 
 
 
Zhou 2005 
 
 
 
Methods Study Design: parallel randomized controlled trial 
Ethics Approval Obtained: yes 
Patient Consent Obtained: yes 
Analysis by Intention to Treat: no  
Power Calculation: no 
Participants Total of participants: 33 participants 
Sex (Female% / Male%):   Insulin group: F: 42% (5/12), M: 58% (7/12), Insulin plus 
rosiglitazone: F: 45% (5/11), M: 55% (6/11) 
Age (Median Years):   Insulin group: 51.8 years, Insulin plus rosiglitazone: 46.5 
years: 
Ethnic Groups (%):  not stated 
Duration of disease: Insulin group: 0.8 (0.3–4.0) years (mean (min-max)); Insulin 
+ rosiglitazone group: 1.8 (0.1–5.0) years (mean (min-max)) 
Inclusion Criteria: (1) diabetes diagnosed according to the report of WHO 1999 
(2) age at onset over 25 years old (3) no ketosis within the first six months of 
diagnosis (4) disease duration less than five years (5) GAD-Ab positive testing 
twice within one-month (6) FCP level of 0.3nmol/l or more. 
Exclusion Criteria:  impaired liver, kidney or heart function or other severe 
diseases. 
Diagnostic Criteria:  diabetes according to the report of WHO 1999 with GAD-Ab 
positive twice within one month 
Co-Morbidities:  Not given 
Co-Medications:  Not given 
Groups:  Insulin group: 12 participants, Insulin + Rosiglitazone group: 11 
participants 
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Loss To Follow-Up: 36% (8/22) participants 
Interventions Country/ Location:  China 
Intervention (Route, Total Dose/Day, Frequency):   Insulin + rosiglitazone. 
Premixed human insulin (Novolin 30 R or Humulin 70/30) was injected twice a 
day. Rosiglitazone 4 mg/day. Diet advice 
Control (Route, Total Dose/Day, Frequency):  Insulin. Premixed human insulin 
(Novolin 30 R or Humulin 70/30) was injected twice a day. Diet advice 
Treatment Before Study: none 
Outcomes Primary Outcome(s): not stated  
Secondary Outcome(s): not stated 
Additional Outcomes:  Insulin dose (U/day), HbA1c (%), Fasting C-peptide 
(nmol/l) and C-peptide after 2h glucose load (PCP) (nmol/l). 
Study Details  Duration Of Intervention: 18 months 
Duration Of Follow-Up: 18 months. All 23 patients followed-up for 6 months, but 
only 17 for 12 months and 14 for 18 months 
Run-In Period: none 
Publication Details Language Of Publication: English 
Commercial Funding: yes 
Stated Aim For Study Quote:  "we hypothesized that LADA patients might benefit from 
thiazolidinediones treatment." 
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Appendix 2 | Pre-defined and specific search terms/key words. To carry out this systematic review, it was 
necessary to establish terms and key words that would provide relevant data for the research of LADA 
interventions. 
 
Pre-defined and specific search terms/key words 
["Latent Autoimmune Diabetes" OR “Latent Autoimmune Diabetes in Adult” OR “Diabetes Mellitus 
Type 1.5” OR “Type 1.5 Diabetes” OR LADA OR “Latent Autoimmune Diabetes of Adult” OR 
“Intermediary Diabetes” OR “Diabetes Type 1 in Adults” OR “Autoimmune Diabetes in Adults”] AND 
[therap* OR treatment* OR intervention OR approach OR drug OR "alternative medicine" OR manag*] 
 
["Latent Autoimmune Diabetes" OR “Latent Autoimmune Diabetes in Adult” OR “Diabetes Mellitus 
Type 1.5” OR “Type 1.5 Diabetes” OR LADA OR “Latent Autoimmune Diabetes of Adult” OR 
“Intermediary Diabetes” OR “Diabetes Type 1 in Adults” OR “Autoimmune Diabetes in Adults”] AND 
[therapy OR therapeutic treatment* OR intervention OR approach OR drug OR "alternative medicine" 
OR manag*] 
 
("Latent Autoimmune Diabetes" OR "Latent Autoimmune Diabetes in Adult" OR "Diabetes Mellitus 
Type 1.5" OR "Type 1.5 Diabetes" OR LADA OR "Latent Autoimmune Diabetes of Adult" OR 
"Intermediary Diabetes" OR "Diabetes Type 1 in Adults" OR "Autoimmune Diabetes in Adults") AND 
(therap* OR treatment* OR intervention OR approach OR drug OR "alternative medicine" OR 
manag*) AND ("randomized controlled trials" OR "comparative studies" OR "controlled clinical trials" 
OR "clinical trials") 
 
 
Appendix 3 | Excluded Studies. Some studies at the time of a first analysis seemed to present relevant data for 
inclusion in the systematic review, however, when a more detailed analysis was carried out, they presented 
flaws that led to their exclusion. 
Study Reason for exclusion 
Agardh 2007 LADA but unpublished article or outcomes 
Ataie-Jafari 2013 Children with T1D 
Bekris 2007 No clinical intervention 
Brophy 2008 Study protocol with no results 
Chaillous 2000 T1D not LADA 
Elkassaby 2014 T2D not tested for antibodies 
Forst 2010 T2D not tested for antibodies 
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Garg 2010 T1D not LADA 
Griffin 2010 T1D not LADA 
Grill 2010 LADA but unpublished article or outcomes 
Jones 2016 LADA but longitudinal observational study 
Keymeulen 2005 T1D not LADA 
Krause 2014 Exploratory trial to evaluate GADA affinity 
Kumar 2010 T1D not LADA 
Landin-Olsson 2010 LADA but unpublished article or outcomes 
Lebovitz 2001 T2D not tested for antibodies 
Lei 2006 LADA but unpublished article or outcomes 
Linn 1996 Insulin dependent diabetes not LADA 
Lóriz 2007 LADA but observational study 
Palmer 2003 LADA but unpublished article or outcomes 
Raz 2001 T1D not LADA 
Raz 2007 T1D not LADA 
SA Hinke 2008 T1D and LADA but unpublished article or outcomes 
Schloot 2010 T1D not LADA 
Schnell 1997 Insulin dependent diabetes not LADA 
Uzunlulu 2019 T2D not tested for antibodies 
Vilsbøll 2003 LADA but comparative study between phenotypes 
Walter 2010 T1D not LADA 
Xu 2008 LADA but unpublished article or outcomes 
Yang 2014 T1D not LADA 
Zampetti 2014 LADA but longitudinal observational study 
Zhou 2010 LADA but unpublished article or outcomes 
Zhu 2004 LADA but unpublished article or outcomes 
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Appendix 4 | Characteristics of Ongoing studies. Currently, there are studies underway with interventions 
similar to those of the studies included in this systematic review and which may reveal promising results with 
regard to the management of LADA treatment. 
Agardh 2004 (NCT00456027) 
Trial name or official title  Safety of Diamyd® in Patients with LADA (Latent 
Autoimmune Diabetes in Adult) / A Placebo-
Controlled Study to Investigate the Impact of 
Diamyd® on the Diabetes Status of Patients With 
LADA (Latent Autoimmune Diabetes in Adult) 
Methods Randomized Controlled Trial 
Participants 160 participants: Male and female patients 
between 30-70 years of age, presence of GAD65 
antibodies, detectable C-peptide level, patients 
requiring treatment with diet and/or 
hypoglycaemic agents (OHA) 
Interventions • 20 micrograms of rhGAD65 formulated in 
Alhydrogel® (Diamyd®) administered 
subcutaneously twice 4 weeks apart compared to 
placebo 
Outcomes HbA1c, C-peptide, blood glucose and insulin 
requirement  
Starting date December 2004 
 
 
Landin-Olsson 2010 (NCT01109927) 
Trial name or official title  Early Insulin Treatment in Patients With Latent 
Autoimmune Diabetes (LADA) 
Methods Randomized Controlled Trial 
Participants 42 participants: over 18 years, positive for 
pancreatic autoantibodies 
Interventions • Insulin treatment (given as soon as possible after 
diagnosis) compared to conventional treatment 
(diet, oral hypoglycemic agents and insulin first 
when clinically needed) 
Outcomes Glucagon stimulated C-peptide (after 36 months 
after entering the study) 
Starting date February 1995 
 
 
Martinsen 2020 (NCT04262479) 
Trial name or official title  Injections of Glutamic Acid Decarboxylase (GAD) 
for LADA Type of Diabetes (GADinLADA) / A Pilot 
Study on Safety, Feasibility and Insulin-promotion 
by Intra-inguinal Lymph Node Injections of 
Glutamic Acid Decarboxylase (GAD) in Patients 
With LADA Type of Diabetes 
Methods Interventional Clinical Trial 
Participants 15 participants: Diagnosis of LADA within the last 
12 months before inclusion. LADA should be 
defined by the criteria of age ≥30 years at the 
onset of diabetes, anti-GAD positivity and no 
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clinical need for insulin treatment during the first 
6 months after the diagnosis of diabetes, fasting C-
peptid levels ≥ 0.3 nmol/l, high GADA titers (>190 
U/ml), patients must be insulin independent at 
baseline by clinical judgement and C-peptide 
criteria 
Interventions • GAD-vaccination with vitamin D suppletion 
Outcomes Occurrence of adverse events, GAD65A titer in 
serum (at 5 and 12 months), Insulin secretion (at 5 
and 12 months), HbA1c, fasting glucose, fasting C-
peptide, maximum C-peptide during Mixed Meal 
Tolerance Test. 
Starting date February 2020 
 
 
Palmer 2009 (NCT00058981) 
Trial name or official title  Safety, Tolerability, Immunological and Clinical 
Efficacy of Multiple Subcutaneous Doses of 
DiaPep277 in Latent Autoimmune Diabetes in 
Adults (LADA) / Randomized, Double-Blind, 
Placebo-Controlled, Parallel-Group Study to 
Investigate the Safety and Tolerability as Well as 
the Immunological and Clinical Efficacy of Multiple 
Subcutaneous Doses of DiaPep277 in LADA 
Subjects 
Methods Randomized Controlled Trial 
Participants 100 participants: Diabetes according to WHO 
criteria, duration 2 month to 5 years, diabetes 
controlled by diet and insulin for 2 or more weeks, 
aged 30 to 65, positive for GAD autoantibodies, 
fasting C-peptide of 0.3 nmol/l or greater at 
screening 
Interventions • DiaPep277 compared to placebo 
Outcomes Undefined 
Starting date October 2002 
 
 
Zhou 2015 (NCT02407899) 
Trial name or official title  Protective Effects of Saxagliptin (And Vitamin D3) 
on β-cell Function in Adult-onset Latent 
Autoimmune Diabetes / A Randomized Controlled, 
Open-label, Multi-center Study With 104-week 
Saxagliptin or (and) Vitamin D3 Assessing 
Protective Effects on β-Cell Function in Latent 
Autoimmune Diabetes in Adults (LADA) Treated 
With Metformin (and Insulin) 
Methods Randomized Controlled Trial 
Participants 300 participants: 1999 WHO Diagnostic Criteria for 
Diabetes Mellitus, age at diagnosis of DM ≧ 18 
years old, GADA positive, serum fasting C-peptide 
≥ 100 pmol/l or 2-hour postprandial C-peptide≥ 
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200 pmol/l, age between 18-70 years old, diabetes 
duration <4-year, outpatient or inpatient. 
Interventions • Treatment with Saxagliptin, Vitamin D3, Insulin 
and Metformin. 
Outcomes Fasting C-peptide levels at week 26, 52, 78 and 
104, C peptide at 60-min and 120-min (AUC) 
during a mixed-meal tolerance test and at week 
26, 52, 78 and 104, fasting or post-stimulus C 
peptide levels, percentage of C peptide pre-and 
post-mixed-meal tolerance test (Delta C peptide), 
HbA1c levels, response to glucose therapy, 
average daily insulin dose (U/Kg/d), GADA titers 
and BMI. 
Starting date March 2015 
 
 
Appendix 5 | Baseline Characteristic of Included Studies. When the baseline characteristics of each study 
included in this systematic review were analyzed, they presented several differences. Some studies carried out 
a detailed analysis of all the initial characteristics presented by the participants while others presented a more 
general analysis. 
Agardh 2005 
Age (Years), Sex (M/F), BMI (Kg/m2), Hba1c (%), Log GADA (U/ml) , IA-2A 
Positive (N), Plasma-Glucose (mmol/l), Pre-Sustacal , Log P C-Peptide 
(nmol/l), Pre-Sustacal , Post-Sustacal, Total T Cells (X/10
9
/l) 
Agardh 2009 
BMI (Kg/m2), HbA1c (%), FCP (nmol/l), SCP (nmol/l), GAD65, IA-2A, IAA  
ICAs, High-risk HLA DQB1*0302, S C-reactive protein (mg/l), S LDL 
(mmol/l), S HDL (mmol/l), S Triacylglycerol (mmol/l), B Hemoglobin (g/l) 
 
Atawa 2017 
Age (years), Sex (M/F), BMI (Kg/m2), Duration of diabetes (years), HbA1c 
(%), GADA (U/ml), IA-2A positive, n (%), IAA positive, n (%), Metformin 
use before entry, n (%), TAb (TPOAb and/or TGAb) positive, n (%) 
Buzzetti 2016 
Age (years), Sex (M/F), BMI (Kg/m2), Race, n (%), Duration of diabetes 
(years), HbA1c (mmol/mol), FCP (nmol/l), FPG (mg/dl), PPG (mg/dl), 
HOMA2-%β (%) 
Cabrera-Rode 2002 
Age (years), Sex (M/F), BMI (Kg/m2), Duration of diabetes (years), ICA 
titer (JDF U), Insulin (U/day), SU (mg/day) 
Davis 2005 
Weight (kg), HbA1c (%), Number at baseline, Number with cohort data 
(%), FPG (mmol/l), Systolic blood pressure (mmHg), Total cholesterol 
(mmol/l), LDL-cholesterol (mmol/l), HDL-cholesterol (mmol/l), 
Triglycerides (mmol/l) 
 
Hals 2019 
Age (years), Sex (M/F), BMI (Kg/m
2
), Hb1Ac (mmol/mol), Age at diabetes 
diagnosis (years), Time, diagnosis to randomization (months), FCP 
(nmol/l), Autoimmunity category (low/middle/high), Study medication, 
Systolic blood pressure (mmHg), Diastolic blood pressure (mmHg) 
 
Johansen 2014 HbA1c (%), FCP (nmol/l) 
Kobayashi 1996 
Age (years), Sex (M/F), BMI (Kg/m2), Duration of NIDDM (years), ICA titer 
(JDF U), Insulin (U/day), SU (mg/day) 
Kobayashi 2002 Age (years), Sex (M/F), BMI (Kg/m2), Duration of diabetes (years) 
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HbA1c (%), Titers of GADAβ, Sigma C-peptide, FBG (nmol/l), Serum 
creatinine, Urinary microalbumin 
 
L-Hallin 1999 
Age (years), BMI (Kg/m2), Weight (kg), Duration of diabetes (years), 
HbA1c (%), FCP (nmol/l), Free plasma insulin (mU/l), KITT (%/min), Waist-
hip-ratio, Systolic BP (mmHg), Diastolic BP (mmHg), FBG (mmol/l), Total 
cholesterol (mmol/l), HDL-cholesterol (mmol/l), Triglycerides (mmol/l) 
Li 2009 
Age (years), Sex (M/F), BMI (Kg/m2), Duration of diabetes (years), HbA1c 
(%), FCP (pmol/l), PCP (pmol/l), GAD-Ab titer (U/ml), Fok I FF (%), Fok I 
Ff (%), Fok I ff (%), 25(OH)D3 (ng/ml) 
 
Maruyama 2003 
Age (years), BMI (Kg/m2), Duration of diabetes (years), HbA1c (%), CPR 
(ng(ml), GADA (U/ml) 
 
Maruyama 2008 
Age (years), Sex (M/F), BMI (Kg/m2), Duration of diabetes (years), HbA1c 
(%), FCP (ng/ml), ΔC-peptide (ng/ml, GADA (U/ml), FBG (mg/dl), 2-h BG 
(mg/dl), Treatment for diabetes mellitus before entry, Gliclazide, n (%), 
Glibenclamide, n (%), Family history of type 2 diabetes, n (%), HLA, DR4, 
n (%), DR9, n (%), DR2, n (%), IAA, n (%), Dose of insulin (U/kg·d) 
Palmer 2018 
Age (years), Sex (M/F), Region of Enrollment  
 
Pozzilli 2018 
Age (years), Sex (M/F), BMI (Kg/m2), Duration of diabetes (years), HbA1c 
(%), FBG (mmol/l), HOMA-IR (%), HOMA-β (%), SBP (mmHg)†, DBP 
(mmHg)†, Total cholesterol (mmol/l), Triglycerides (mmol/l) 
Thunander 2001 
BMI (Kg/m2), HbA1c (%), Insulin dose (U/day), FBG (mmol/l), PBG 
(mmol/L), MBG (mmol/l) 
 
Wang 20199 
Age (years), Sex (men, %), BMI (Kg/m2), Duration of diabetes (months), 
HbA1c (%), SCP (nmol/l), Titre GADA (index, ref <0.08), Titre ICA (JDF-U), 
Hypertension (%) 
 
Yang 2009 
Age (years), Sex (M/F), BMI (Kg/m2), Duration of diabetes (years), HbA1c 
(%), FCP (nmol/l), PCP (nmol/l), FBS (mmol/l), PBS (mmol/l), GAD-Ab titer 
(U/ml), Daily insulin dose (U/(kg d))  
Zhang 2020 
Age (years), Sex (M/F), BMI (Kg/m2), Duration of diabetes (months), 
HbA1c (%), HbA1c (mmol/mol), GADA titre(U/ml), FBG (mmol/l), 2-h BG 
(mmol/L), FCP (pmol/l), 2-h PCP (pmol/l), FCP to glucose ratio, 2-h PCP 
to glucose ratio, ΔC-peptide (pmol/l), C-peptide AUC (pmol·h/L), Systolic 
blood pressure (mm Hg), Diastolic blood pressure (mm Hg), Insulin dose 
(units/Kg·d), Metformin dose (g/d), 25(OH)D3 (nmol/l), Total cholesterol 
(mmol/l), Triglycerides (mmol/l), HDL-cholesterol (mmol/l), LDL-
cholesterol (mmol/l) 
 
Zhao 2014 
Age (years), Sex (M/F), BMI (Kg/m2), Duration of diabetes (years), HbA1c 
(%), HbA1c (mmol/mol), FBG (mmol/l), PPG (mmol/l) FCP (pmol/l), PCP 
(pmoll), ΔC-peptide (pmol/l), GADA titer(U/ml), Systolic blood pressure 
(mmHg), Diastolic blood pressure (mm Hg), Total insulin daily dose (U), 
Insulin dose (units/Kg·d), Total cholesterol (mmol/l), Triglycerides 
(mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) 
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Zhou 2005 
Age (years), Sex (M/F), BMI (Kg/m2), Duration of diabetes (years), HbA1c 
(%), GAD-Ab titer, FCP (nmol/l), PCP (nmol/l), ΔCP (nmol/l), Insulin dose 
(U/day)  
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Appendix 6 | Outcomes of the Included Studies. In the included studies, the outcomes assessed differed from 
study to study, so for a better analysis of each, the results were divided into primary, secondary and additional 
outcomes. Furthermore, the limitations and conclusions that each study could provide were registered. 
Study 
  
Agardh 2005 Intervention Low dose of GAD65 vs Higher doses of GAD65 vs Placebo. 
 
 Primary Outcomes Unclear. 
 
 Secondary Outcomes Unclear. 
 
 Additional Outcomes HbA1c - increase in the placebo and 4μg dose groups but not in the 
dose groups receiving higher dose levels of Diamyd®. 
FPG - the placebo and 4μg dose groups both showed an increase in 
plasma glucose levels after 24 weeks, but in comparison, a decrease 
was observed in the 20, 100, and 500 μg groups. 
GADA titers - no change after 1 and 4 weeks in the placebo and the 4, 
20, and 100μg groups. After 24 weeks, the patients in the 500μg group 
had increased log GADA levels. 
FCP and SCP - the 20μg dose group showed an increase from baseline 
compared with placebo, and an increase from baseline in the mean 
change in both fasting and stimulated log c-peptide at 24 weeks. A 
decline in stimulated log c-peptide levels was apparent in the 4μg and 
500μg dose groups which was different from the placebo. 
BMI – no changes were observed in BMI between groups during 
treatment. 
Adverse effects – 68% of patients reported adverse events. 
 
 Limitations (as stated 
in the study) 
“No limitations of the study were reported.” 
 
 
 Conclusions (as 
stated in the study) 
This Phase II clinical trial is the provision of further support for the 
clinical safety of Diamyd® treatment. 
 
Agardh 2009 Intervention Low dose of GAD65 vs Higher doses of GAD65 vs Placebo. 
 
 Primary Outcomes Unclear. 
 
 Secondary Outcomes Unclear. 
 
 Additional Outcomes Islet autoantibodies (GAD65, IA-2A, IAA, ICAs) - no important 
differences were detected in these characteristics between groups. 
BMI - no important differences were detected between groups. 
HbA1c - no important differences were detected between groups. 
FCP and SCP - In 4μg, 20μg, 100μg no changes after 5 years when 
compared with placebo; in 500μg a decreased in FCP when compared 
with placebo. 
The study did not report any differences in serum creatinine, lipid 
profile and FPG. 
Adverse events - seizures, cholecystitis, myocardial infarction, and 
cerebellar infarction leading to death in one patient, and subarachnoid 
bleeding and insulin treatment with hospitalization. 
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 Limitations (as stated 
in the study) 
“Small randomized trial”. 
 
 
 Conclusions (as 
stated in the study) 
“The treatment was safe and did not compromise β-cell function.” 
 
 
Awata 2017 Intervention Sitagliptin vs Pioglitazone. 
 
 Primary Outcomes HbA1c - did not significantly differ between the two groups during the 
study. 
 
 Secondary Outcomes BMI - did not significantly differ between the two groups during the 
study. 
C-peptide - changes in the values was not significant in any of the 
follow-up periods.  
GADA titers - were not significantly different between the S and P 
groups at any time point in the present study. 
 
 Additional Outcomes No additional outcomes were observed. 
 
 Limitations (as stated 
in the study) 
“Small sample size”; “Metformin can suppress the course of LADA”; 
“use of an alpha-glucosidase inhibitor was also allowed in this trial”. 
 
 Conclusions (as 
stated in the study) 
“Treatment of SPIDDM/LADA by sitagliptin, possibly as a class effect of 
DPP-4 inhibitors, may be more effective in the preservation of the β-
cell function than insulin treatment for at least 4 years.” 
 
Buzzetti 2016 Intervention Saxagliptin vs Placebo. 
 
 Primary Outcomes HbA1c - Patients receiving saxagliptin showed reductions from 
baseline in HbA1c than those receiving placebo in both GADA-positive 
and negative groups. GADA-positive patients receiving placebo had an 
increase in HbA1c over 24 weeks and this was not observed in patients 
receiving placebo who were GADA negative. 
FPG - greater reductions from baseline in FPG were observed in 
patients treated with saxagliptin compared with those with placebo. 
PPG - Patients treated with saxagliptin showed greater decreases from 
baseline in PPG than those receiving placebo. 
 
 Secondary Outcomes PCP - increased from baseline to 24 weeks with saxagliptin treatment, 
whereas less change was noted with placebo. 
FCP - there was little or no change from baseline to week 24 in fasting 
C- peptide concentrations across patient and treatment groups and no 
evidence of a treatment-by-subgroup interaction. 
HOMA2-%β - increased in GADA-positive patients receiving saxagliptin 
but decreased in those receiving placebo treatment. 
 
 Additional Outcomes Adverse events - were similar across treatment groups and GADA 
categories. 
 
 Limitations (as stated 
in the study) 
“Limited number of patients that were GADA- positive”; “the clinical 
trials had an inclusion criterion of FCP ≥1.0 ng/ml, more advanced 
LADA patients were excluded”; “post hoc nature”; “need to pool data 
from five studies across doses”; “small sample sizes”; “24 weeks may 
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be insufficient to discern the potential long-term effect of saxagliptin 
in patients with LADA.” 
 
 Conclusions (as 
stated in the study) 
“Saxagliptin was generally well tolerated and effective in GADA-
positive patients and appeared to increase β-cell function.” 
Cabrera-Rode 
2002 
Intervention Insulin and Glibenclamide (SU) vs Insulin. 
 Primary Outcomes Unclear. 
 
 Secondary Outcomes Unclear. 
 
 Additional Outcomes FPG - was increased in the group with combined therapy (insulin + 
glibenclamide) after one year of the study. 
FCP - not find any changes during one year of observation in fasting C 
peptide. 
BMI – no changes in body weight were observed in either group. 
Insulin dose - not find any changes during one year of observation in 
insulin doses in either group. 
SU dose - no significant change in glibenclamide dose was seen in the 
insulin þ glibenclamide group. 
ICA titres – in the group treated only with insulin, 6 out of 8 patients 
became ICA negative, while all six individuals treated with the 
combined therapy (insulin + glibenclamide) presented persistence of 
ICA titres. 
GAD antibody status – no changes were found in GADA in either of 
both groups, with maintenance of positivity in all patients. 
 
 Limitations (as stated 
in the study) 
No limitations of the study were reported. 
 
 
 Conclusions (as 
stated in the study) 
“Treatment with glibenclamide, even if including use of insulin in a 
combined therapy in type 2 ICAþ diabetes (LADA), maintains the 
positivity of ICA and possibly the progressive destruction of β-cells.” 
 
Davis 2005 Intervention Insulin vs SU. 
 
 Primary Outcomes Unclear. 
 
 Secondary Outcomes Unclear. 
 
 Additional Outcomes HbA1c - there was a progressive rise in all therapies. 
BMI - all patients increased their weight with treatment. 
 
 Limitations (as stated 
in the study) 
No limitations of the study were reported. 
 
 
 Conclusions “Auto- antibody-positive patients can be treated initially with 
sulphonylurea but are likely to require insulin earlier than 
autoantibody-negative patients.” 
 
Hals 2019 Intervention Insulin vs Sitagliptin. 
 
 Primary Outcomes Glucagon-stimulated C-peptide - No differences were observed 
between treatments during or after 21 months of intervention. 
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 Secondary Outcomes Stimulated insulin - The change from baseline in insulin tended to 
differ between treatment arms; however, this trend towards a 
stronger increase in the insulin versus the sitagliptin arm was not 
significant. 
Proinsulin- No difference between treatments was seen for stimulated 
proinsulin. 
C-peptide levels - at 21 months versus baseline did not differ between 
treatment arms. 
 
 Additional Outcomes HbA1c - modest decrease after 3 months of treatment in both arms 
however during the rest of the intervention the evolution of HbA1c 
levels was similar between treatment arms. 
FPG - stable throughout the 21 months of intervention in both arms. 
GADA titer - there was no obvious difference between treatment 
arms. 
BMI - Sitagliptin-treated participants reduced their body weight 
compared to baseline, and this differences in weight evolution 
between treatments were significant. 
Adverse effects – some participants in the insulin arm experienced 
hypoglycemia. 
 
 Limitations (as stated 
in the study) 
“Heterogeneity of autoimmune activity”; “levels of GAD antibodies.” 
 
 
 Conclusions “β-cell function after intervention was similar in patients with insulin- 
and sitagliptin-treated LADA however participants with low levels of 
GAD antibodies did not experience progressive deterioration of β-cell 
function over a 21-month.” 
Johansen 2014 Intervention Linagliptin vs Glimepiride (SU). 
 
 Primary Outcomes FCP - in GAD65-positive patients levels increased from baseline at 
weeks 28, 52, and 104 in patients treated with linagliptin but 
decreased in glimepiride-treated patients and between group 
differences were significant at weeks 28 and 52. 
HbA1c - decreased to a similar extent with glimepiride and linagliptin. 
 
 Secondary Outcomes GLP-1 - elevation of endogenous glucagon-like peptide. 
 
 Additional Outcomes No additional outcomes were observed. 
 
 Limitations (as stated 
in the study) 
“Exploratory nature”; “lack of information on C-peptide after drug 
washout, small sample size, and lack of inert comparator.” 
 
 Conclusions (as 
stated in the study) 
“Over a 2-year disease trajectory in LADA patients, treatment with 
linagliptin may, at least, have attenuated the rate of decline in C-
peptide levels.” 
Kobayashi 1996 Intervention Insulin vs Glibenclamide (SU). 
 
 Primary Outcomes C-peptide - was significantly improved at 6 and 12 months after the 
initiation of insulin in the insulin group. However, in SU group 
decreased progressively. The differences in C-peptide response 
changes between the insulin group and the SU group show significant 
differences at 6, 12, 24, and 30 months. 
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Blood glucose - tended to decrease from the baseline value in the 
insulin group, whereas the value increased significantly from the 
baseline value in the SU group. 
ICA titers - disappeared in four of the five (80%) insulin group patients 
during the observation In the SU group, ICAs persisted in all patients. 
GADA titers - status remained unchanged. 
 
 Secondary Outcomes HbA1c - remained unchanged in the insulin group and increased in the 
SU group. 
 
 Additional Outcomes BMI - no changes in body weight were observed in either group. 
Adverse effects - there were no adverse effects observed or episodes 
of severe hypoglycemia during the study. 
 
 Limitations (as stated 
in the study) 
No limitations of the study were reported. 
 
 
 Conclusions (as 
stated in the study) 
“Subcutaneous small doses of insulin, resulting in a high rate of 
negative conversion of ICA and an improved serum C-peptide 
response, may be effective in preventing progressive β -cell failure in 
ICA patients with the clinical features of NIDDM.” 
Kobayashi 2002 Intervention Insulin vs SU. 
 
 Primary Outcomes Serum C-peptide response to OGTT - decreased progressively in the 
SU group and became significant at 24 and 36 months. In contrast, the 
Sigma C peptide values remained unchanged in the patients in the 
insulin group, and these values were significantly different from those 
of the SU group at 36 months. 
Blood glucose - Two-hour blood glucose values to OGTT in the SU 
group increased during a follow-up period and became significantly 
higher than those in the insulin group at three years. 
 
 Secondary Outcomes GADA titers - remained unchanged in both the insulin and the SU 
groups. 
No significative alterations were reported in levels of FPG, HbA1c, 
serum creatinine, and urinary microalbumin. 
 
 Additional Outcomes No additional outcomes were observed. 
 
 Limitations (as stated 
in the study) 
No limitations of the study were reported. 
 
 
 Conclusions (as 
stated in the study) 
“If administered in the early stage of SPIDDM, a small amount of 
insulin instead of sulphonylurea can intervene in or modulate 
progressive β-cell failure in SPIDDM.” 
L-Hallin 1999 Intervention Placebo with Insulin vs Insulin with SU. 
 
 Primary Outcomes Unclear. 
 
 Secondary Outcomes Unclear. 
 
 Additional Outcomes Phase I 
FPG - decreased after four months of combined SU and insulin 
treatment. 
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HbA1c - decreased from 9.65 ± 1.53% to 7.23 ± 1.09% after four 
months of combined SU and insulin treatment. 
FCP –concentrations were 15% lower than baseline values at the end 
of phase I. 
KITT - the insulin sensitivity index improvement by more than 30%.  
BMI - more than 90% of the patients gained weight during the 4 
months of combined therapy. 
 
Phase II 
FBG – at 3±4 weeks. At the end of the study, 60% of showed an 
increase in FBG of ≥40% at two consecutive visits in placebo + insulin 
group. 
HbA1c – in placebo + insulin group increased significantly during phase 
II. However, in glibenclamide + insulin group no changes were 
observed. 
FCP – showed no changes throughout in this phase of trial. 
Free P-insulin – showed no changes throughout the trial. 
KITT - the insulin sensitivity index decreased in of withdrawal of SU 
increased significantly during phase II. 
 
 Limitations (as stated 
in the study) 
No limitations of the study were reported. 
 
 
 Conclusions (as 
stated in the study) 
“Combining sulphonylurea and insulin is an effective therapy in a 
majority of patients with Type 2 diabetes. The present data suggest 
that patients who are GAD-antibody-positive are less likely to respond 
and that a long duration of diabetes does not exclude a beneficial 
effect of SU.” 
 
Li 2009 Intervention Insulin vs Insulin with 1- α hydroxyl-vitamin D3. 
 
 Primary Outcomes Unclear. 
 
 Secondary Outcomes Unclear. 
 
 Additional Outcomes FCP- stayed steady in the insulin plus vitamin D group, while FCP 
decreased in insulin-alone group during the 12-month intervention. 
PCP - remained stable in the insulin plus Vitamin D group, while in the 
insulin-alone group PCP levels showed a trend towards decline 
treatment. 
 
 Limitations (as stated 
in the study) 
“Small number of patients”; “we did not measure serum 1-α(OH)D3 
and 1.25(OH)2D3”. 
 Conclusions (as 
stated in the study) 
“Adding vitamin D3 to insulin therapy preserved β-cell function better 
than insulin therapy alone in patients with LADA.” 
 
Maruyama 2003 Intervention Insulin vs Glibenclamide (SU). 
 
 Primary Outcomes SCP and change in C-peptide response – the ƩCPR value in the SU 
group decreased progressively after a 48-month period. However, this 
value in the insulin group was unchanged. 
No differences in blood glucose were reported. 
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 Secondary Outcomes GADA titer – no patient with a low GADA titer progressed to IDDM in 
either group. Among the high GADA titer subjects, 9/14 in the SU 
group but only 2/16 in the Insulin group developed IDDM. 
No differences in HbA1c and BMI were reported. 
 
 Additional Outcomes No additional outcomes were observed. 
 
 Limitations (as stated 
in the study) 
No limitations of the study were reported. 
 
 
 Conclusions (as 
stated in the study) 
“Small doses of insulin effectively prevent β-cell failure in slowly 
progressive type 1 diabetes.” 
 
Maruyama 2008 Intervention Insulin vs Glibenclamide (SU). 
 
 Primary Outcomes SCP and change in C-peptide response - the C-peptide responses to 
OGTT progressively decreased in the SU group while, in the insulin 
group increased at 12 and decreased at 24 months, and the values 
remained unchanged for up to 60 months. 
 
 Secondary Outcomes HbA1c - at the end of the follow-up, in both groups, did not significantly 
differ from those at baseline. 
Blood glucose - the 2-h blood glucose levels were significantly 
increased at the completion of study in both groups.  
FBG - value at 60 months in the SU group was significantly increased 
compared with baseline whereas that in the insulin group was not. 
Insulin dependent state - thirteen (43%) and three (10%) patients in 
the SU and insulin groups, respectively, progressed to an insulin-
dependent state. 
GADA titers - at the completion of the study in the insulin group and 
the SU group were significantly decreased compared with baseline 
values however these values did not significantly differ between these 
two groups during the study. 
BMI – in the insulin and SU groups was significantly increased at the 
completion of the study. 
 
 Additional Outcomes No additional outcomes were observed. 
 
 Limitations (as stated 
in the study) 
No limitations of the study were reported. 
 
 
 Conclusions (as 
stated in the study) 
“Insulin intervention to preserve β-cell function is effective and safe 
for patients with SPIDDM or latent autoimmune diabetes in adults.” 
 
Palmer 2018 Intervention Rosiglitazone vs Glyburide. 
 
 Primary Outcomes FCP - decrease in groups of patients positive or negative for 
autoantibodies treated with rosiglitazone. 
SCP - decrease in groups of patients positive or negative for 
autoantibodies treated with rosiglitazone. 
 
 Secondary Outcomes ICA, IAA, IA-2A, and GAD antibodies - groups of patients positive or 
negative for autoantibodies treated with rosiglitazone had lower 
values. 
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 Additional Outcomes Serious adverse effects – in the rosiglitazone autoantibody positive 
group one patient died, while in the rosiglitazone autoantibody 
negative group one patient had atrial fibrillitation and another 
cholecystitis. In the glyburide autoantibody positive group, there was 
no serious adverse effect and in the glyburide autoantibody negative 
group, one patient had a heart attack while two had a stroke. 
Adverse effects - in the glyburide autoantibody positive and negative 
groups two patients showed hypoglycemia. 
 
 Limitations (as stated 
in the study) 
“Small numbers based on high drop out of participants.” 
 
 
 Conclusions (as 
stated in the study) 
“This study showed that the rosiglitazone treatment ameliorate or 
slow the underlying disease process in antibody positive type 2 
diabetes.” 
 
Pozzilli 2018 Intervention Dulaglutide vs Glargine (AWARD-2 and AWARD-4) or Dulaglutide vs 
Sitagliptin vs Placebo (AWARD-5). 
 
 Primary Outcomes HbA1c - in patients treated with dulaglutide, the HbA1c decreased at 
3, 6, and 12 months however greater reductions were observed in 
AWARD-4, particularly in GADA-negative populations. Compared with 
sitagliptin, greater decreases in HbA1c were observed during 
treatment with dulaglutide in GADA-positive and GADA-negative 
patients. 
 
 Secundary Outcomes FPG - reductions were observed in GADA-negative and GADA-positive 
patients in AWARD 2 and -5, while in AWARD-4, where all patients 
already had conventional insulin treatment at baseline, no reductions 
in FPG were detected during dulaglutide-treatment in GADA-negative 
or GADA-positive patients. 
HOMA-β - increased in GADA-positive and GADA-negative patients 
during treatment with dulaglutide (AWARD 2 and 4). 
HOMA-IR - there was little or no change in at 6 or 12 months in GADA-
positive and GADA-negative patients. 
Hypoglycemia - most occurred in AWARD-4. In AWARD-2 and AWARD- 
5, few GADA-positive patients reported hypoglycemia. 
 
 Additional Outcomes No additional outcomes were observed. 
 
 Limitations (as stated 
in the study) 
“Low patient numbers”; “retrospective nature of the analysis and lack 
of available data on C-peptide measurements”; “study was not set up 
to compare GADA-positive patients treated with dulaglutide versus 
other single anti-hyperglycemic therapies.”; “the outcome of our 
analyses resulted from combined antidiabetic treatments.” 
 
 Conclusions (as 
stated in the study) 
“Dulaglutide was an effective anti-hyperglycemic treatment in 
patients with LADA, including patients with high and low GADA titers.” 
 
Thunander 2011 Intervention Insulin vs OHA (metformin and/or SU). 
 
 Primary Outcomes Unclear. 
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 Secondary Outcomes Unclear. 
 
 Additional Outcomes HbA1c - the differences between the groups in absolute levels were 
not significant either at baseline or after 12, 24 or 36 months. 
C-peptide levels - decrease over 36 months without any significant 
difference between the groups. 
 
 Limitations (as stated 
in the study) 
No limitations of the study were reported. 
 
 
 Conclusions (as 
stated in the study 
“Early insulin treatment in LADA patients lead to better preservation 
of level of metabolic control, and it was safe and well tolerated.” 
 
Wang 2019 Intervention Insulin vs Sitagliptin. 
 
 Primary Outcomes Percentage of T-lymphocyte - the percentage of Treg to CD4+ T cells 
in the SITA group was significantly lower than that in the CONT group 
at baseline. The percentage of Th2 to CD4+ T cells was higher than that 
of the CONT group at 6 months and 12 months. At 12 months, the 
percentage of Th17 to CD4+ T cells was lower in the SITA group than 
that of the CONT group. 
Messenger ribonucleic acid expression - no significant differences 
could be found in the mRNA expression or transcription factors in the 
SITA group and CONT. 
 
 Secondary Outcomes HbA1c - no significant differences were present. 
GADA titer - no significant differences were present. 
FPG - after the 12-month visit, in the CONT group were significantly 
higher than baseline.  
C-peptide - no significant differences were present. 
PPG - after the 12-month visit, in the CONT group were significantly 
higher than baseline. 
 
 Additional Outcomes No additional outcomes were observed. 
 
 Limitations (as stated 
in the study) 
“Small sample size, different population and relatively short follow-up 
period.” 
 Conclusions (as 
stated in the study) 
“Sitagliptin altered the phenotype of T cells and downregulated the 
expression of T-BET and RORC in LADA patients, and ameliorated 
glycemic control in LADA patients.” 
 
Yang 2009 Intervention Insulin vs Insulin with Rosiglitazone, SU and Rosiglitazone. 
 
 Primary Outcomes FCP - there was no significant difference between SU group and RSG 
group. In INS + RSG group did not decrease until the 36th month. 
However, in INS group showed apparent decrease after the 6th 
month. 
PCP - were higher in RSG group compared with those in SU group after 
the 18th month. In INS + RSG group sustained, whereas in INS group 
were decreased after the 12th month. In INS + RSG group (after the 
12th month) were higher than those in INS group. 
HOMA2-%β - in SU group tended to decrease at 18 months, and lower 
than the baseline at follow-up; was lower in SU group than those in 
RSG group in the 24th month and the 36th month. 
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 Secondary Outcomes HbA1c - increased in RSG group but not in SUs group, at 3 years. In INS 
+ RSG group the value was lower than baseline at the first 12 months, 
at the same time daily insulin dose decreased. 
 
 Additional Outcomes Adverse effects - INS + RSG treatment was associated with an 
increased incidence of edema requiring diuretics compared with 
insulin. 
 
 Limitations (as stated 
in the study) 
No limitations of the study were reported. 
 
 
 Conclusions (as 
stated in the study) 
“Rosiglitazone combined with insulin wherever or not preserved β-cell 
function in LADA patients after 3 years.” 
 
Zhang 2020 Intervention Metformin with insulin vs Saxagliptin with Metformin with Insulin vs 
VitD3 with Saxagliptin with Metformin with Insulin. 
 
 Primary Outcomes FCP - no significant differences were observed in group A at 6 months 
and 12 months compared with baseline. At 12 months in group B were 
significantly lower than those at baseline, while in group C, at 12 
months were not significantly different from those at baseline. No 
significant differences were detected in three groups throughout the 
follow-up. 
PCP - no significant differences were observed in any of the groups. 
C-peptide index (CPI) - in group A were significantly reduced at 12 
months compared with baseline, while they showed no significant 
differences in either group B or group C at 6 months and 12 months. 
Moreover, decreased continually at 6 and 12 months in group A. In 
contrast, in group C continued to increase at 6 and 12 months. No 
significant differences were found during treatment in group B. 
 
 Secondary Outcomes FBG – no significant differences were observed among the three 
groups. 
PBG – no significant differences were observed among the three 
groups. 
HbA1c – no significant differences were observed among the three 
groups. 
GADA titres - in group C, the levels were decreased significantly at 12 
months compared with baseline. However, no changes were detected 
in group A or group B after 12 months of treatment. 
 
 Additional Outcomes No additional outcomes were observed. 
 
 Limitations (as stated 
in the study) 
“pilot study, so the sample size was small, and follow-up duration was 
relatively short”; “might not have sufficient power for studying the 
mechanism of the effect of vitamin D3 on LADA.” 
 
 Conclusions (as 
stated in the study) 
“Adding 2000 IU per day vitamin D3 to saxagliptin might preserve β-
cell function in patients with LADA.” 
 
Zhao 2014 Intervention Insulin with Sitagliptin vs Insulin without Sitagliptin. 
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 Primary Outcomes FCP and PCP - there were no significant differences in the levels of FCP 
and 2-hour CP in group A at 12 months compared with baseline. In 
group B, the level of FCP continually decreased from a baseline of 3, 6, 
9 and 12 months. The 2-hour C-peptide levels in group B continually 
decreased at 3, 6, 9 and 12 months.  The levels of 2-hour C-peptide in 
group A were significantly higher than those in group B at 12 months 
2-hour postprandial blood glucose - there were no significant 
differences between groups A and B.  
Blood glucose - no significant differences between groups A and B. 
 
 Secondary Outcomes BMI - there were no significant differences between groups A and B.  
GADA titers – there was no significant difference between group A and 
group B after 12 months of treatment. 
HbA1c - there were no significant differences between groups A and 
B.  
 
 Additional Outcomes Adverse effects - the incidence of drug-related adverse experiences 
including the incidence of hypoglycemia was low and similar between 
the two groups. 
 
 Limitations (as stated 
in the study) 
No limitations of the study were reported. 
 
 
 Conclusions (as 
stated in the study) 
“LADA patients treated with sitagliptin and insulin maintained β-cell 
function by comparison with insulin alone.” 
 
Zhou 2005 Intervention Insulin vs Insulin with Rosiglitazone. 
 
 Primary Outcomes Unclear. 
 
 Secondary Outcomes Unclear. 
 
 Additional Outcomes Insulin dose - were less in insulin + RSG group compared with that in 
insulin alone group. 
HbA1c - were less in insulin + RSG group compared with that in insulin 
alone groups. 
FCP and PCP - at 6 months observation, there were no significant 
changes for ΔCP and PCP levels in both groups.  At 12 months 
observation, both PCP and ΔCP levels in insulin + RSG group patients 
stayed steady. In contrast, PCP levels in insulin alone group decreased 
significantly, however ΔCP levels showed a decreasing trend but did 
not reach a statistical significance.   
At 18 months, PCP and ΔCP levels in insulin + RSG group patients still 
stayed steady, while in insulin alone group, PCP and ΔCP levels 
decreased more. 
 
 Limitations (as stated 
in the study) 
No limitations of the study were reported. 
 
 
 Conclusions (as 
stated in the study) 
“Rosiglitazone combined with insulin may preserve islet β-cell function 
in LADA patients.” 
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Appendix 7 | Risk of Bias of the Included Studies. The criteria were divided into 6 major categories: Selection 
bias, Reporting bias, Performance bias, Detection bias, Attrition bias, Other bias, and each of them was assigned 
the risk of bias, which could be high, low or unclear depending on the data that the study presented. 
Study Bias 
Reviewer 
assessment/Authors’ 
judgement 
Comments/Support for 
judgement 
Agardh 2005 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
Insufficient 
information: 
“A total of 47 patients 
was allocated to either 
one of four groups” 
Allocation 
concealment 
Some concerns 
Insufficient 
information: 
“A total of 47 patients 
was allocated to either 
one of four groups” 
Reportin
g bias 
Selective reporting Some concerns 
The study protocol is 
available but the 
study’s pre-specified 
(primary and 
secondary) outcomes 
of interest were not 
reported 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
Low risk 
“The trial was designed 
as a randomized, 
double blind, placebo-
controlled, group 
comparison, dose -
escalation study 
conducted in LADA 
patients” 
Detectio
n bias 
Blinding (outcome 
assessment) 
Low risk 
Probably done: “double 
blind” 
Attrition 
bias 
Incomplete outcome 
data 
Low risk 
No missing outcome 
data 
Other 
bias 
Other sources of 
bias 
High risk 
The study was support 
for Diamyd® 
Therapeutics and one 
of the authors is a 
member of Diamyd® 
Therapeutics 
Agardh 2009 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
Insufficient 
information: 
“Randomization was 
concealed by the 
clinical research 
organization 
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monitoring the study 
without any 
involvement by study 
investigators” 
Allocation 
concealment 
Low risk 
Insufficient 
information: 
 “Randomization was 
concealed by the 
clinical research 
organization 
monitoring the study 
without any 
involvement by study 
investigators.”; 
“Methods This Phase 2, 
placebo-controlled, 
dose-escalation clinical 
trial, which was 
randomized through a 
central office” 
Reportin
g bias 
Selective reporting Some concerns 
The study protocol is 
available but the 
study’s pre-specified 
(primary and 
secondary) outcomes 
of interest were not 
reported 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
Low risk 
“The trial was designed 
as a randomized, 
double-blind, placebo-
controlled, group 
comparison, dose-
escalation study 
conducted in GADA-
positive type 2 diabetic 
patients”; “Participants 
and caregivers were 
blinded to group 
assignments” 
Detectio
n bias 
Blinding (outcome 
assessment) 
Low risk 
“Participants and 
caregivers were 
blinded to group 
assignments”; “During 
the 5 years study 
period each patient 
was followed as an 
outpatient at regular 
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intervals, with a total of 
28 study visits” 
Attrition 
bias 
Incomplete outcome 
data 
Low risk 
No missing outcome 
data 
Other 
bias 
Other sources of 
bias 
High risk 
The study was support 
for Diamyd® 
Therapeutics and one 
of the authors is a 
member of Diamyd® 
Therapeutics 
Awata 2017 
Selectio
n bias 
Random sequence 
generation 
Low risk 
“The eligible patients, 
who were recruited 
from the collaborating 
hospitals or clinics, 
were all randomly 
assigned using a 
centralized internet 
web system”; “In the 
present open-label, 
randomized, controlled 
trial, 14 non-insulin-
requiring diabetic 
patients with glutamic 
acid decarboxylase 
autoantibodies (GADA) 
were randomly 
assigned to receive 
either sitagliptin (S 
group) or pioglitazone 
(P group)” 
Allocation 
concealment 
High risk 
“The eligible patients, 
who were recruited 
from the collaborating 
hospitals or clinics, 
were all randomly 
assigned using a 
centralized internet 
web system” 
Reportin
g bias 
Selective reporting Low risk No problem identified 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
High risk 
“All patients were 
randomized receive 
either sitagliptin or 
pioglitazone based on 
minimization adjusting 
for age, sex, HbA1c 
level, GADA titer and 
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metformin use before 
entry.” 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
“Notably, SU agents 
were never used. The 
patients in both groups 
were switched to an 
insulin injection 
regimen when the 
HbA1c levels became 
≥9.4% despite the 
above protocol of 
medication.” 
Attrition 
bias 
Incomplete outcome 
data 
Low risk 
No missing outcome 
data 
Other 
bias 
Other sources of 
bias 
Low risk 
“This work was funded 
via a grant from the 
Waksman Foundation 
of Japan, Inc. The 
funder had no role in 
any aspect of the study 
beyond funding.” 
Buzzetti 2016 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
“This study analyzed 
the efficacy and 
tolerability of 
saxagliptin in patients 
with type 2 diabetes 
classified as GADA-
positive (LADA) or 
GADA-negative from 
five randomized, 
placebo-controlled 
trials.”; “limited 
number of patients 
that were GADA- 
positive” 
Allocation 
concealment 
Some concerns 
“This post hoc analysis 
included data from five 
previously reported 
randomized, placebo-
controlled, 24-week 
phase 3 studies” 
Reportin
g bias 
Selective reporting Low risk No problem identified 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
Low risk 
“Data for patients 
receiving saxagliptin 
2.5, 5, and 10 mg/d 
were pooled from the 
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five studies and 
compared with data 
pooled for patients 
receiving placebo” 
Detectio
n bias 
Blinding (outcome 
assessment) 
Some concerns 
Lack of information on 
the 5 trials included in 
the study. 
Attrition 
bias 
Incomplete outcome 
data 
Low risk 
No missing outcome 
data 
Other 
bias 
Other sources of 
bias 
High risk 
The study was funded 
by one of the article 
authors 
Cabrera-Rode 
2002 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
Insufficient 
information: “Patients 
were randomly 
assigned to two 
treatment groups”; 
“Afterwards patients in 
each group were 
randomly assigned to 
two treatment groups” 
Allocation 
concealment 
High risk 
“They were categorized 
into two groups 
according to diabetes 
duration (up to 3 years 
and more than 3 years) 
to avoid the influence 
of this variable on 
antibodies titers and 
endogenous insulin 
production which 
deteriorate with 
disease progression.” 
Reportin
g bias 
Selective reporting High risk 
HbA1c was not 
reported however FBG 
was reported 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
High risk 
“We studied the 
presence of ICA among 
1000 individuals with 
type 2 diabetes. Thirty-
four type 2 diabetic 
patients were ICA+ 
persistent. Fourteen 
ICA+ persistent 
subjects with type 2 
diabetes and combined 
therapy (Insulin plus 
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glibenclamide) were 
selected from the 
above-mentioned ICA+ 
type 2 diabetic subjects 
to take part in this 
study.” 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
“Intermediate acting 
human insulin was 
injected 
subcutaneously once or 
twice daily in both 
groups throughout the 
study.” 
Attrition 
bias 
Incomplete outcome 
data 
High risk 
No adverse effects 
were mentioned 
Other 
bias 
Other sources of 
bias 
Low risk No problem identified 
Davis 2005 
Selectio
n bias 
Random sequence 
generation 
High risk 
“The 678 patients 
whose FPG values 
remained at or above 
15.0 mmol/l or who 
had hyperglycemic 
symptoms were 
allocated only to the 
more intensive glucose 
5102 control policy and 
randomized to 
sulphonylurea”; 
“Patient clinical 
characteristics and 
autoantibody status 
were determined at 
entry to the UK 
Prospective Diabetes 
Study (UKPDS) before 
randomization to 
different glucose 
control policies.”; 
“Baseline 
characteristics for the 
randomized patient 
groups did not differ by 
allocated therapy” 
Allocation 
concealment 
High risk 
“patient clinical 
characteristics and 
autoantibody status 
were determined at 
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entry to the study 
before randomization 
to different glucose 
control policies” 
Reportin
g bias 
Selective reporting High risk 
No record of mortality, 
C-peptide or intention 
to treat analysis 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
High risk 
“Patient clinical 
characteristics and 
autoantibody status 
were determined at 
entry to the UK 
Prospective Diabetes 
Study (UKPDS) before 
randomization to 
different glucose 
control policies.” 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
 
“The patients whose 
FPG values remained at 
or above 15.0 mmol/l 
or who had 
hyperglycemic 
symptoms were 
allocated only to the 
more intensive glucose 
control policy and 
randomized to 
sulphonylurea or 
insulin therapy” 
Attrition 
bias 
Incomplete outcome 
data 
High risk 
"C-peptide levels, 
HOMA2-%β or adverse 
effects weren't given." 
Other 
bias 
Other sources of 
bias 
High risk 
Commercial 
sponsorship gives 
potential for bias 
Hals 2019 
Selectio
n bias 
Random sequence 
generation 
Low risk 
“Participants were then 
randomized, non-
blinded, into two arms 
of add-on medications 
to metformin, using a 
centralized 
randomization 
database”; 
“Participants to be 
randomized after the 
run-in period were 
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examined by a doctor 
and a nurse.” 
Allocation 
concealment 
Low risk 
“The primary endpoint 
in the trial was β-cell 
function, evaluated 
using glucagon-
stimulated C-peptide 
tests (GSCTs) 
performed at baseline 
(ie, at randomization) 
and after 3, 9 and 21 
months.”;  
“Participants were then 
randomized, non-
blinded, into two arms 
of add-on medications 
to metformin, using a 
centralized 
randomization 
database at St Olavs 
University Hospital 
(Trondheim, Norway).” 
Reportin
g bias 
Selective reporting High risk 
“We did not correct for 
multiple test” 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
High risk 
“Participants were then 
randomized, non-
blinded, into two arms 
of add-on medications 
to metformin, using a 
centralized 
randomization” 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
Significance testing 
without these data 
carried forward did not 
change the study 
results. 
Attrition 
bias 
Incomplete outcome 
data 
High risk 
“Significance testing 
without these data 
carried forward did not 
change the study 
results.”  
Other 
bias 
Other sources of 
bias 
Some concerns 
“Parts of this study 
were presented in 
abstract form at the 
European 
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Association for the 
Study of Diabetes 
annual meeting.” 
Johansen 2014 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
“Exploratory results 
from a 2-year 
double-blind, 
randomized, controlled 
study.” 
Allocation 
concealment 
Low risk 
“Exploratory results 
from a 2-year 
double-blind, 
randomized, controlled 
study.” 
Reportin
g bias 
Selective reporting High risk 
The statistical analysis 
was not sent. 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
Low risk  “Double-blind study” 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
“GAD65-positive 
linagliptin patients with 
C-peptide 
measurements at 
weeks 28, 52, and 104 
compared with 
glimepiride-treated 
patients were 
slightly younger (mean 
age 59–62 vs. 63–68 
years) with lower C-
peptide levels (821–
944 vs. 1,326–1,425 
pmol/L), whereas 
HbA1c levels were 
similar.” 
Attrition 
bias 
Incomplete outcome 
data 
High risk 
No adverse effects was 
mentioned 
Other 
bias 
Other sources of 
bias 
High risk 
“The study was 
supported financially 
by Boehringer 
Ingelheim.” 
 
Kobayashi 
1996 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
“ Equal numbers of 
patients were 
randomly assigned to 
treatment with insulin 
or SU.” 
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Allocation 
concealment 
Some concerns 
“Equal numbers of 
patients were 
randomly assigned to 
treatment with insulin 
or SU.”  
Reportin
g bias 
Selective reporting Low risk No problem reported. 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
High risk 
Unblinded patients: 
“The patients were 
encouraged to 
document the dose of 
insulin or oral agent 
and to bring the data to 
ensure their 
compliance.” 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
"The criteria for 
determining failure of 
oral hypoglycemic 
agents included FBG 
becoming >12.2 
mmol/1 and/or 
an HbA1c value >10% 
with the maximal daily 
dose of glibenclamide 
(15 
mg). The frequency of 
the initial insulin dose 
was basically once a 
day in the morning. If 
the FBG level was >6.7 
mmol/1, additional 
insulin was 
given in the evening." 
Attrition 
bias 
Incomplete outcome 
data 
Low risk  
No missing outcomes 
data. 
Other 
bias 
Other sources of 
bias 
Low risk 
No problem identified. 
 
Kobayashi 
2002 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
“Patients were 
randomly assigned to 
one of two groups.” 
Allocation 
concealment 
Some concerns Insufficient information 
Reportin
g bias 
Selective reporting High risk Levels of FBG, HbA1c, 
serum creatinine, and 
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urinary microalbumin 
not given. 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
Some concerns 
“The study was a 
randomized, 
multicenter trial”; “One 
group received 
subcutaneous insulin 
injection (insulin 
group); the other 
received oral 
sulphonylurea (SU 
group)”  
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
"When FBG in the SU 
group patients increase 
to over 200 mg/dl 
and/or HbA1c 9% 
despite the maximum 
dose of glibenclamide 
(7.5 mg) and strict diet 
treatment, the mode of 
treatment in the SU 
group patients was 
changed to insulin. 
Even after this change 
of treatment from 
sulphonylurea to 
insulin in the SU group, 
the patients received 
annual 75-g OGTT.” 
Attrition 
bias 
Incomplete outcome 
data 
High risk 
The statistical analysis 
was not given and no 
adverse effects was 
mentioned 
Other 
bias 
Other sources of 
bias 
Low risk 
No problem identified. 
 
L-Hallin 1999 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
“Nine participating 
centers randomized 
175 patients (113 men, 
62 women) with a 
median age of 61 
(range 32±77) years 
and a diabetes duration 
of 9 (1±36) years.” 
Allocation 
concealment 
Some concerns Insufficient information 
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Reportin
g bias 
Selective reporting Some concerns 
The study protocol is 
available but the 
study’s pre-specified 
(primary and 
secondary) outcomes 
of interest were not 
reported 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
Low risk 
“while a double-blind 
study medication 
replaced the open 
glibenclamide.” 
Detectio
n bias 
Blinding (outcome 
assessment) 
Low risk 
“Both glibenclamide 
and placebo were 
provided in the same 
type of packaging and 
tablet counts were 
performed to assess 
compliance”; “Forty 
patients were 
randomized to 
continue with 
glibenclamide + insulin 
during the double-
blinded phase II; one 
patient in this group 
was excluded because 
of intercurrent medical 
problems”; “It was not 
possible to identify any 
clinical measurements 
that could reliably 
predict which patients 
were responders to the 
combined therapy.” 
Attrition 
bias 
Incomplete outcome 
data 
Low risk  
No missing outcomes 
data. 
Other 
bias 
Other sources of 
bias 
High risk 
"This study was 
supported by grants 
from Hoechst AG, 
Frankfurt am Main" 
Li 2009 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
Insufficient 
information:  
“In a prospective, 
randomized controlled 
parallel study, the 35 
patients were 
randomly assigned to 
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two different study 
groups” 
Allocation 
concealment 
Some concerns 
Insufficient 
information: 
“In a prospective, 
randomized controlled 
parallel study, the 35 
patients were 
randomly assigned to 
two different study 
groups” 
Reportin
g bias 
Selective reporting High risk 
HbA1c was not 
reported and 
"The study protocol is 
available but the 
study’s pre-specified 
(primary and 
secondary) outcomes 
of interest were not 
reported." 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
High risk 
Unblinded patients: 
 “Daily therapeutic data 
were recorded to 
ensure patient 
compliance.” 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
“The goal for glycemic 
control was fasting 
blood glucose <6.1 
mmol/L and 2-h 
postprandial blood 
glucose <8.0 mmol/L 
without hypoglycemia.” 
Attrition 
bias 
Incomplete outcome 
data 
Low risk  
No missing outcomes 
data. 
Other 
bias 
Other sources of 
bias 
Low risk No problems identified 
Maruyama 
2003 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
“The study was a 
randomized, 
multicenter 
prospective trial. 
Patients were randomly 
assigned to one of two 
groups.” 
Allocation 
concealment 
Some concerns 
“The study was a 
randomized, 
multicenter 
prospective trial. 
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Patients were randomly 
assigned to one of two 
groups.” 
Reportin
g bias 
Selective reporting High risk 
Blood glucose and 
HbA1c levels, and BMI 
were not given. 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
Some concerns 
Not clear if patients or 
investigators were 
blinded. 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
“When FPG in the SU 
group patients 
exceeded over 200 
mg/d Land/or HbA1c 
exceeded 9% despite 
the maximum dose of 
glibenclamide (7.5 mg) 
and strict dietary 
treatment, the mode of 
treatment in the SU 
group patients was 
changed to insulin.” 
Attrition 
bias 
Incomplete outcome 
data 
High risk  
No adverse effects was 
mentioned. 
Other 
bias 
Other sources of 
bias 
Low risk No problems identified 
Maruyama 
2008 
Selectio
n bias 
Random sequence 
generation 
Low risk 
“Eligible patients were 
randomly assigned 
using a centralized, 
masked-draw system 
to receive injections of 
insulin (insulin group) 
or oral SU (SU group)”; 
“One patient was lost 
between enrollment 
and entry, resulting in 
60 patients being 
randomly allocated to 
either the insulin or the 
SU group.” 
Allocation 
concealment 
Low risk 
“Eligible patients were 
randomly assigned 
using a centralized, 
masked-draw system 
to receive sc injections 
of insulin (insulin 
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group) or oral SU (SU 
group).”; “Insulin group 
were SPIDDM patients 
who were allocated to 
insulin treatment at 
entry, and the SU 
group included SPIDDM 
patients who were 
allocated to SU therapy 
at entry.” 
Reportin
g bias 
Selective reporting Some concerns 
“Those who had been 
switched from SU to 
insulin, were included 
in this analysis.” 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
High risk 
"Those assigned to the 
insulin group ceased 
using oral 
hypoglycemic agents 2 
d before starting insulin 
therapy." 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
“Follow-up 
assessments and 
endpoint levels of FBG 
and glycosylated 
hemoglobin (HbA1c) 
were measured at 
baseline and every 3 
months during the 
follow-up period”; “If 
this strategy did not 
achieve the target, NPH 
insulin was replaced 
with pre- mixed insulin 
(Novolin 30R; Novo 
Nordisk) twice daily 
plus a pre-meal 
regimen of regular 
insulin (Novolin R; 
Novo Nordisk), 
increasing the dose of 
insulin by 2 U.” 
Attrition 
bias 
Incomplete outcome 
data 
High risk 
No adverse effects 
were mentioned. 
Other 
bias 
Other sources of 
bias 
Low risk No problems identified. 
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Palmer 2018 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
“Patients were then 
randomized to either 
rosiglitazone or 
glyburide.” 
Allocation 
concealment 
High risk 
“Randomized and open 
label study “ 
Reportin
g bias 
Selective reporting High risk 
“If the patient and 
his/her private 
physician prefer, the 
treatment protocol was 
implemented by the 
patient's private 
physician.” 
“Patients unable to 
reach goal with 
monotherapy had 
metformin (initially) or 
acarbose (secondarily) 
added, as there is no 
evidence to suggest 
that either affect β-cell 
function.” 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
High risk  “Open label study.” 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
“If adequate control, 
HbA1c less than 7%, 
was not achieved on 
glyburide or 
rosiglitazone 
monotherapy, 
metformin was added 
and the dose gradually 
increased as needed 
and tolerated to a 
maximum of 1000 mg 
twice daily. If 
necessary, acarbose 
was also used up to a 
maximum dose of 100 
mg thrice daily as 
needed and tolerated.” 
Attrition 
bias 
Incomplete outcome 
data 
Low risk No missing outcomes 
data. 
Other 
bias 
Other sources of 
bias 
Low risk 
No problem identified. 
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Pozzilli 2018 
Selectio
n bias 
Random sequence 
generation 
Some concerns  
"A post-hoc analysis 
was performed using 
data from three 
randomized phase 3 
trials (AWARD-2, -4,-5; 
patients with GADA 
assessment) which 
were part of the 
dulaglutide clinical 
development program 
in T2D." 
Allocation 
concealment 
Some concerns 
"A post-hoc analysis 
was performed using 
data from three 
randomized phase 3 
trials (AWARD-2, -4,-5; 
patients with GADA 
assessment) which 
were part of the 
dulaglutide clinical 
development program 
in T2D." 
Reportin
g bias 
Selective reporting Low risk No problem identified 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
High risk 
"The only prospective 
study was small (N=30) 
and open label." 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
"The patients in the SU 
group were judged to 
have reached a stage of 
secondary failure of SU 
agents when FBG levels 
exceeded 200 mg/dl 
and/or HbA1c levels 
exceeded 9.0% despite 
the use of a maximum 
dose of glibenclamide 
(7.5 mg/d). Patients in 
the SU group were 
switched to a multiple 
insulin injection 
regimen when they 
reached the stage of 
secondary failure of SU 
agents." 
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Attrition 
bias 
Incomplete outcome 
data 
Low risk 
No missing outcomes 
data 
Other 
bias 
Other sources of 
bias 
Low risk 
No problem identified 
 
Thunander 
2011 
Selectio
n bias 
Random sequence 
generation 
High risk 
"The majority of the 
patients were 
randomized into two 
groups, in blocks of 
eight, by prepared 
closed envelopes kept 
at the two hospital 
policlinics. However 
complete strict 
randomization was not 
possible, as some 
patients refused 
randomization to 
possible insulin 
treatment before it was 
unavoidable." 
Allocation 
concealment 
High risk 
"However complete 
strict randomization 
was not possible, as 
some patients refused 
randomization to 
possible insulin 
treatment before it was 
unavoidable." 
Reportin
g bias 
Selective reporting Some concerns 
The study protocol is 
available but the 
study’s pre-specified 
(primary and 
secondary) outcomes 
of interest were not 
reported. 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
High risk 
"Some patients refused 
randomization to 
possible insulin 
treatment before it was 
unavoidable. They 
were referred to the 
control group." 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
"Glucagon-stimulation 
tests were performed 
at baseline and after 
12, 24 and 36 months 
during annual policlinic 
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visits at the two 
research clinics. After 
an overnight fast, C-
peptide was 
determined before and 
6 min after i.v. injection 
of 1 mg glucagon." 
Attrition 
bias 
Incomplete outcome 
data 
High risk 
Intention to treat was 
reported but no 
evidence that it was 
used. i.e. last result 
carried forward for 
those lost to follow-up, 
analysis within the 
insulin arm of those 
randomized to insulin 
but choosing to be 
treated with 
conventional 
medication. 
Other 
bias 
Other sources of 
bias 
Low risk 
 
No problem identified. 
 
Wang 2019 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
“A total of 40 LADA 
patients were recruited 
from December 2014 
to December 2016." 
Allocation 
concealment 
Some concerns 
 "The 40 patients 
enrolled in this study 
were randomized at a 
1:1 ratio to insulin with 
sitagliptin 
100 mg/day (SITA 
group; n = 20) or 
insulin without 
sitagliptin (CONT 
group; n = 20)." 
Reportin
g bias 
Selective reporting Low risk No problems identified. 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
Some concerns  Insufficient information 
Detectio
n bias 
Blinding (outcome 
assessment) 
Low risk 
"All 40 participants 
completed the 
treatment protocol and 
attended the visits at 
all three timepoints. 
 198 
Fasting blood samples 
were tested for 
hemoglobin A1c 
(HbA1c), GADA, fasting 
blood glucose and C-
peptide; 2-h 
postprandial blood 
samples were tested 
for postprandial blood 
glucose and C-peptide." 
Attrition 
bias 
Incomplete outcome 
data 
High risk 
 
No adverse effects 
were mentioned. 
 
Other 
bias 
Other sources of 
bias 
Low risk  No problem identified. 
 
Yang 2009 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
“Between September 
2001 and August 2003, 
149 GAD-Ab 
positive patients 
screened from 
consecutively 1580 
phenotypic 
type 2 diabetes were 
diagnosed as LADA. 
LADA patients 
(>25 years, n = 54) in 
the city of Changsha, 
China, were 
included in this 
prospective study.” 
“This study was a 
stratified, randomized, 
unblinded, controlled 
trial...” 
Allocation 
concealment 
High risk 
“This study was a 
stratified, randomized, 
unblinded, controlled 
trial...” 
“Then, those patients 
in 
oral hypoglycemic 
agents group were 
assigned to receive 
sulphonylureas (SUs 
group, n = 15) or 
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rosiglitazone 4 mg/d 
(RSG 
group, n = 15) 
therapy.” 
Reportin
g bias 
Selective reporting Some concerns 
The study protocol is 
available but the 
study’s pre-specified 
(primary and 
secondary) outcomes 
of interest were not 
reported 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
High risk 
“This study was a 
stratified, randomized, 
unblinded, controlled 
trial...” 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
“One 
patient in SUs group 
received insulin 
treatment and was 
excluded in the 1.5 
years.” 
 
Attrition 
bias 
Incomplete outcome 
data 
Low risk 
No missing outcomes 
data. 
Other 
bias 
Other sources of 
bias 
High risk 
"This study was 
supported by grants 
from Glaxo-SmithKline 
(China) Investment Co. 
Ltd.” 
Zhang 2020 
Selectio
n bias 
Random sequence 
generation 
Low risk 
"The trial was designed 
as a multi-center, 
randomized-controlled 
study conducted on 
LADA patients in more 
than 40 hospitals in 
China."; "A central 
randomization system 
was adopted, and the 
study population was 
stratified." 
Allocation 
concealment 
Low risk 
"A central 
randomization system 
was adopted, and the 
study population was 
stratified." "All patients 
were randomized into 
3 groups based on a 
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central randomization 
system." 
Reportin
g bias 
Selective reporting High risk 
“Analysis of 
covariance was 
employed to eliminate 
the influence of other 
three primary 
outcomes 
when comparing each 
primary outcome, or to 
eliminate the influence 
of 25(OH)D3 
levels at baseline when 
comparing 25(OH)D3 
levels among the three 
groups during 
the follow-up.” 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
Some concerns  
"Insufficient 
information" 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
"As most of the clinical 
trials reported, FCP and 
PCP levels were 
measured at baseline, 
6 and 12 months." 
Attrition 
bias 
Incomplete outcome 
data 
High risk 
No adverse effects 
were mentioned 
Other 
bias 
Other sources of 
bias 
Low risk No problem identified 
 
Zhao 2014 
Selectio
n bias 
Random sequence 
generation 
Low risk 
"The trial was designed 
as a single-center, 
randomized-controlled 
study conducted in 
LADA patients."; 
"Stratified 
randomization 
was performed by 
professional 
statisticians without 
involvement of the 
study investigators." 
Allocation 
concealment 
Low risk 
"Stratified 
randomization was 
performed by 
professional 
statisticians without 
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involvement of the 
study investigators."; 
"Thirty patients with 
adequate compliance 
during the run-in 
period had baseline 
assessments and were 
randomized in a 1:1 
ratio 
to insulin with 
sitagliptin 100 mg daily 
(group A, n =15) or 
without sitagliptin 
(group B, n = 15)." 
Reportin
g bias 
Selective reporting Low risk No problem identified. 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
Some concerns 
"Thirty patients with 
adequate compliance 
during the run-in 
period had baseline 
assessments and were 
randomized in a 1:1 
ratio to insulin with 
sitagliptin 100 mg daily 
(group A, n = 15) or 
without sitagliptin 
(group B, n =15)." 
Detectio
n bias 
Blinding (outcome 
assessment) 
Some concerns Insufficient information 
Attrition 
bias 
Incomplete outcome 
data 
Low risk 
No missing outcomes 
data. 
 
Other 
bias 
Other sources of 
bias 
High risk 
Commercial 
sponsorship gives 
potential for bias. 
Zhou 2005 
Selectio
n bias 
Random sequence 
generation 
Some concerns 
“This pilot study 
is a randomized, 
unblinded, controlled 
trial.” 
Allocation 
concealment 
Some concerns 
“This pilot study 
is a randomized, 
unblinded, controlled 
trial.” 
“All 23 patients were 
randomly assigned to 
two different 
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treatment regimes, 
with one group 
receiving insulin 
alone (insulin group, n 
= 12) and the other 
receiving 
rosiglitazone plus 
insulin (insulin + RSG 
group, n = 11).” 
Reportin
g bias 
Selective reporting Some concerns 
The study protocol is 
available but the 
study’s pre-specified 
(primary and 
secondary) outcomes 
of interest were not 
reported 
Perform
ance 
bias 
Blinding 
(participants and 
personnel) 
High risk 
This pilot study 
is a randomized, 
unblinded, controlled 
trial.” 
Detectio
n bias 
Blinding (outcome 
assessment) 
High risk 
“A 75-g oral glucose 
tolerance test (OGTT) 
was 
performed on all 
patients at entry and 
repeated every 
6 months for 
measurement of blood 
glucose, HbA1c, 
fasting C-peptide (FCP) 
and C-peptide after 2-h 
glucose 
load (PCP). Insulin and 
rosiglitazone dose were 
withheld 
on the day of OGTT.” 
Attrition 
bias 
Incomplete outcome 
data 
Low risk 
No missing outcome 
data 
Other 
bias 
Other sources of 
bias 
High risk 
Funded by grant from 
Glaxo-SmithKline 
Investment Co. 
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Appendix 8 | Summary Results of Risk of Bias Across Studies. Once the risk of bias summary table was done and imported into R Software, the summary results across 
studies were obtained. 
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Appendix 9 | Traffic Light Plot: Risk of Bias of the Included Studies. Once risk of bias summary table was 
done and imported into R software, the risk of bias in each domain for each study were obtained. 
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Appendix 10 | Funnel Plot: Insulin compared to Sulphonylureas 
Appendix 11 |Funnel Plot: Insulin compared to Sitagliptin 
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Appendix 12 | Forest Plot: Sensitive Analysis, Outcome: Mean Differences in HbA1c levels from baseline to 
endpoint in Insulin vs Sulphonylureas 
Appendix 13 | Forest Plot: Sensitive Analysis, Outcome: Mean Differences in HbA1c levels from baseline to 
endpoint in Insulin vs Sitagliptin 
